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Résumé 
La sclérose latérale amyotrophique (SLA) et la démence fronto-temporale (DFT) sont deux 
maladies qui constituent un continuum clinico-pathologique. La mutation de FUS, une protéine 
nucléaire à fonctions multiples, provoque des cas familaux de SLA, et ces mutations provoquent une 
redistribution sub-cellulaire de FUS, du noyau vers le cytoplasme. Certains cas de DFT présentent 
une telles distribution anormale en l’absence de mutations de FUS. Il n’est pas connu si la maladie 
est provoquée par une perte de la fonction nucléaire de FUS et/ou un gain de fonction 
cytoplasmique. 
Nous avons généré et caractérisé une lignée de souris exprimant une forme cytoplasmique de 
FUS (Fus-ΔNLS). La localisation exclusive de FUS dans le cytoplasme provoque la mort des 
motoneurones via un gain de fonction dans les motoneurones eux-mêmes. Une localisation 
cytoplasmique partielle de FUS est suffisante pour développer un phénotype de la SLA et de DFT.  
Les mécanismes élucidés permettront de comprendre les bases des SLA/DFT et de  
 
Mots-clés : SLA/DFT, FUS, cytoplasmique localisation, gain de fonction 
 
 
 
 
Résumé en anglais 
Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTLD) are now considered 
as a unique clinicopathological spectrum referred to as ALS/FTLD. Cytoplasmic aggregation of the 
physiologically nuclear FUS protein is a hallmark feature of a subset of ALS/FTLD. It remains 
unknonwn whether the critical pathogenic event relies on a loss of FUS normal nuclear functions, a 
toxic gain of function of FUS in the cytoplasm, or a combination of both.  
To answer this question we have generated a conditional mouse model expressing truncated 
FUS without nuclear localization signal - FusΔNLS. Our data showed that complete cytoplasmic 
mislocalization of truncated FUS protein within spinal motor neurons is a major determinant of motor 
neuron degeneration via toxic gain of function. A partial mislocalization of truncated FUS protein was 
sufficient to trigger key features of ALS and of FTLD.These studies allowed the elucidation of 
mechanisms underlying FUS role in ALS/FTLD, and will hopefully lead to development of therapies 
for these devastating diseases. 
 
Key words: ALS/FTLD, FUS, cytoplasmic mislocalization, toxic gain of function 
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FOREWORD 
  
 The general topic of my PhD work was the understanding of the molecular mechanisms of 
amyotrophic lateral sclerosis (ALS). During these last 3 years, I pursued two major 
objectives. 
First, I sought to understand the consequences of loss of function of ALS8/VAPB, a 
gene that has been reported as mutated in a few familial ALS cases. When I arrived in the 
laboratory, it had already been shown that VAPB knock-out mice did not develop ALS, but 
showed a mild rotarod defects. I went further into the analysis of these mice and showed that 
they developed abnormal muscle response to fasting (Han et al, 2013, PLOS Genet). In 
collaboration with Dr Niels Decher, we also showed that VAPB knock-out mice suffered from 
heart defects (manuscript in preparation). While the analysis of VAPB knock-out mice led to 
interesting insights into the physiological function of VAPB, we concluded from our work that 
the loss of function of VAPB has likely little relevance to ALS. I have also participated in 
another study investigating a role of the hypothalamus in ALS (manuscript submitted). I 
included these papers in the Annex of the manuscript. 
A second objective was initiated in parallel to understand the mechanisms of ALS 
mediated by FUS mutations. FUS mutations are a much more frequent cause of familial ALS 
than VAPB mutations, and lead to typical ALS. In the present manuscript, I describe our two 
step analysis of a novel knock-in model of FUS-ALS, with a first study focusing on the 
phenotype of homozygous mice (Publication N°1), and a second study in preparation 
describing the early characterization of heterozygous knock-in mice (Publication N°2). 
INTRODUCTION 
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INTRODUCTION 
Neurodegenerative diseases are a group of diverse disorders characterized by progressive 
loss of specific populations of neurons. In the vast majority of cases, etiology is unknown. 
Although, these diseases affect different neuronal populations, lead to widely different clinical 
manifestations, and are characterized by disparate pathological findings, they share a common 
characteristic, the presence of misfolded and aggregated proteins in and/or around neurons. 
Over the past few years, several clinical, genetic (molecular), and neuropathological features 
have been recognized as shared by different neurodegenerative diseases. As a typical example, 
an important scientific interest has been driven toward the DNA/RNA-binding protein FUS (fused 
in sarcoma). This growing interest in FUS arose after the discovery of variants in the FUS gene 
causing or contributing to multiple neurodegenerative diseases, including amyotrophic lateral 
sclerosis (ALS), rare forms of frontotemporal lobar degeneration (FTLD), polyglutamine diseases 
as well as essential tremor (ET). Additionally, abnormal aggregation of FUS protein has been 
reported in postmortem material of patients suffering from these neurodegenerative diseases in 
the absence of somatic FUS mutations. These findings suggest an important role of FUS in the 
pathogenesis of these diseases. 
Although several lines of evidence indicate that cytoplasmic mislocalization of FUS, is a key 
event in disease pathogenesis, definitive in vivo evidence is lacking. The respective 
contributions of gain vs. loss of function, as well as the cell types in which the critical pathogenic 
events occur are still undefined. 
More generally, the links between FUS dysregulation and pathophysiological processes 
leading to neurodegeneration in ALS/FTD are poorly understood.  
Despite worldwide efforts in the research field, current understanding of the normal function 
of FUS, and its role in the pathology of ALS, FTLD and other neurodegenerative diseases, are 
still insufficient. Further understanding of the underlying pathogenic mechanisms of these FUS-
related disorders might lead to improvements in the treatment and prevention of such disorders. 
In this introduction, I will first describe ALS and FTLD as the major diseases involving FUS. I 
will then present the structure and physiological functions of FUS. The pathology of FUS, and 
the effects of FUS mutations, will be detailed to discuss the currently existing models of FUS 
diseases. 
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I. ALS AND FTLD: clinical, genetic and pathological link  
ALS and FTLD were traditionally considered as two completely different neurological 
disorders with discordant clinical features. Over the years, however, several observations have 
suggested that there is a link connecting these disorders. Multiple lines of emerging evidence 
showed that these disorders share mutual clinical, pathological and genetic features and led to 
establishment of ALS/FTLD disease spectrum. 
 
A. Clinical presentations  
1. Amyotrophic lateral sclerosis (ALS) 
Classical concept – a single disease vs. new concept – heterogeneous syndrome 
Amyotrophic lateral sclerosis (ALS) is the most frequent adult onset degenerative 
disease of the motor neuron (motor neuron disease) with an incidence of 2.6/100 000.It is 
characterized by progressive loss of cortical-upper (UMN) and spinal-lower (LMN) motor 
neurons (1–3).The name describes the key features of the disease: muscle wasting 
(amyotrophic) due to the degeneration of the lower motor neurons and their axons and 
degenerationof the upper motor neurons and their corticospinal axonal tracts (lateral sclerosis) 
(4). Clinically, gradual loss of motor neurons leads to muscle weakness, fasciculation, spasticity 
and paralysis with a devastatingly rapid disease progression and respiratory failure as the cause 
of death for most patients (Figure 1) (3). Disease onset, generally in adulthood, peaks at 60–70 
years of age. Half of the affected individuals die within 3-5 years. The genetics of ALS comprises 
only 5-10% of cases due to identified genetic mutations while nearly 90-95% remains of 
unknown origin. Regardless of the genetics, ubiquitin-positive inclusions are found in dying 
motor neuronsin almost all ALS cases. More than a century after Jean-Martin Charcot first 
description of the disease in 1869, and in spite of many efforts towards the elucidation its 
etiology and the search for a treatment for ALS remains an incurable disease of unknown origin. 
One possible reason for this failure could be due to the fact that for a long period, ALS 
has been identified as a single nosological entity, characterized by a pattern of progressive 
motor neuron degeneration.Textbook neurology addresses ALS as a degenerative disease that 
selectively affects upper and lower motor neurons– a description which suggests that the 
clinical presentation of ALS is very homogenous. This may explain why the disease was 
expected to have a single cause, a single pathogenesis and a single phenotype. However, with 
growing knowledge of profound clinical, neuropathological and now genetic heterogeneity, the 
concept of ALS as one disease appears increasingly unsustainable.  
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1.1. Phenotypic heterogeneity: from motor neuron disease to neurodegenerative 
disease 
Clinical examination usually reveals atrophy and weakness of muscles, fasciculation, 
hyperreflexia and often a mild to severe hypertonia. Clinicians designate weakness, muscle 
atrophy and fasciculation as lower motor neuron signs, whereas hyperreflexia and 
hypertoniaindicate upper motor neuron involvement (Figure 1). 
Figure 1. Different patterns of MN involvement in ALS 
 
Schematic representation of LMN (red) and UMN (blue) degeneration with clinical signs (red and 
blue boxes) in ALS 
 
The evidence of both upper and lower motor neuron involvement is required for the 
diagnosis of ALS, and have been incorporated in the so-called revised El Escorial criteriaor the 
newer Awaji criteria (Table 1) (5). Using these criteria ALS itself can be classified as definite, 
probable or possible. 
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Table 1. Diagnostic criteria for amyotrophic lateral sclerosis (ALS) derived from the revised El 
Escorial and Awaji criteria
 
Reproduced from Costa et al., J. Arch. Neurol.,2012. 
 
In spite of the precise clinical description of ALS, there is a considerable variability in its 
phenotypic expressions, with regard to the site and age of onset, the rate of progression, 
disease duration and clinical presentation, and the presence and degree of cognitive 
dysfunction. Among other parameters, phenotypic heterogeneity arises due to pattern of motor 
neuron involvement and extent of extra-motor involvement. 
 
1.1.1. Multiple  sites of onset 
There are several classification systems in place for ALS. The first one relies on the site 
of onset of the disease : spinal, bulbar or respiratory (Figure 2) (6). Most of the patients 
present first with asymmetric and painless weakness in a limb, which is referred as spinal-onset 
ALS. In contrast, about 20% of patients present first with weakness in bulbar muscle causing, 
dysarthria, dysphagia and tongue fasciculations. Finally 3–5% of patients present first with a 
respiratory onset, characterized by orthopnea or dyspnea (7). Compared to spinal-onset 
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patients, with bulbar- and respiratory-onset patients have a worse prognosis and a decreased 
disease duration and long term survival (7), reviewed in(6). 
Figure 2. Site of onset in ALS 
 
Red indicates LMN involvement, blue indicates UMN involvement. Darker shading indicates 
more-severe involvement. 
(a) In spinal-onset ALS, patchy UMN and LMN involvement is observed in all limbs. 
(b) In bulbar-onset ALS, UMN and LMN involvement is observed in the bulbar muscles.  
(c) In  spinal-onset ALS, UMN and LMN involvement is observed in the respiratory muscles 
Reproduced from : Swinnen & Robberecht, Nat. Rev.Neurol., 2014. 
 
1.1.2. Variability in age of onset 
The age of clinical onset of ALS is usually between the fourth or sixth decade of life. 
However, onset at almost any age has been described. Juvenile ALS is rare and defined as ALS 
with age at onset before 25 years, and the course of progression is generally slower than in 
other forms of ALS. Onset after 80 years is associated with a particularly faster progression (8). 
Biological onset of the disease is unknown. In rodent models of ALS, which admittedly are 
overexpression models, abnormalities are present as early as embryonic development (9–11). 
Nevertheless, these animals develop no clinical abnormalities until adulthood. Thus, biologically, 
the disease may start early in life and become clinically apparent much later. 
1.1.3. Diversity of disease progression and survival 
The range of disease progression is wide. Although median survival in ALS is 
generally around 3 years from diagnosis, variability in survival is remarkable with some patients 
die within months after onset and others surviving for more than two decades (Figure 3). Less 
than 20% of patients survive over 5 years from the disease onset (10). Long survival is seen 
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more frequently in patients with juvenile ALS and upper motor neuron-predominant ALS (8). 
Large differences in survival and age at disease onset exist even between individuals from a 
same family, in whom ALS is caused by the same mutation, suggesting that other factors may 
modify the phenotype (12).  
Figure 3. Variability of disease progression in ALS 
 
Reproduced from: Swinnen & Robberecht, Nat. Rev.Neurol., 2014. 
 
1.1.4. Heterogenous clinical presentation 
Neurodegeneration of motor neuron 
Depending on the overall pattern of upper or lower motor neuron involvement and the 
degree of asymmetry, first clinical presentation could vary in between two opposite extremes 
(Figure 4). On the one hand, patients in whom only the lower motor neurons are initially found 
affected, usually asymmetrically, are classified as progressive muscular atrophy (PMA). On the 
other hand, if only evidence of upper motor neuron degeneration is initially found, often 
symmetrically, a diagnosis of primary lateral sclerosis (PLS) is made. Both PMA and PLS 
progress over time to ALS in a significant proportion of patients (about 5% in each case). The 
main reason for distinguishing these phenotypes is the difference in prognosis. The patients with 
PMA fare slightly better than those with clinical evidence of both lower and upper motor neuron 
involvement while patients with PLS survive longer than both (13). 
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Further to this, a causal primacy of lower motor neuron over upper motor neuron 
degeneration remains an issue of debate. Many of the initial pathological changes in rodent 
models of ALS occur in the lower motor neurons, supporting a dying-back view of pathogenesis 
(14). However, ALS can also be viewed primarily as a disease of the upper motor neurons, 
which connect monosynaptically, only in humans and not rodents, with anterior horn cells. This 
is supported by the clinical observation that the oculomotor, abducens, and Onuf's motor nuclei, 
which all lack direct cortical motor neuron connections, are strikingly resistant to degeneration 
(15). 
Figure 4. ALS, pattern of motor neuron involvement. 
 
Red indicates LMN involvement, blue indicates UMN involvement. Darker shading indicates 
more-severe involvement. PMA (isolated LMN involvement) and PLS (isolated UMN 
involvement) constitute the ends of a spectrum of LMN and UMN involvement; intermediate 
phenotypes are considered to be different expressions of ALS 
PMA- In progressive muscular atrophy, LMNs in arms and legs are involved, often proximally. 
PLS- In primary lateral sclerosis, UMNs of arms and legs are primarily involved, but later in the 
disease, discrete LMN involvement can be detected. 
Reproduced from :Swinnen & Robberecht, Nat. Rev.Neurol., 2014. 
 
Neurodegeneration of extramotor neurons 
ALS phenotypic variability becomes more apparent when it combines different motor and 
extramotor involvement. In some patients, neurons in the prefrontal and temporal cortexare 
affected. This leads to cognitive and/or behavioural problems. ALS patients with mild 
behavioural dysfunction are classified as having ALS with behavioural impairment (ALSbi), 
whereas patients with mild executive and language dysfunction are said to have ALS with 
cognitive impairment (ALSci). In total, around 30% of ALS (16). However, in about 15% of ALS 
cases, patients who meet the Neary criteria for frontotemporal dementia (FTD), the main 
symptom of frontotemporal lobe degeneration (FTLD) are considered to have ALS-FTLD (17). 
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On the other hand, up to 50% of patients with a diagnosis of FTLD have some motor neuron 
involvement and are said to have FTLD–MND (16,17). Of note, 15% of FTLD patients show 
signs of motor neuron degeneration that meet criteria for ALS and are classified as ALS–FTLD 
(Figure 5) (17). This suggests that ALS and FTLD are at the ends of a same disease spectrum.  
Although, there are extremes of relatively isolated involvement of each of these 
compartments PLS, PMA and FTLD, all of these overlap with classic ALS on post-mortem 
neuropathological examination, by showing protein inclusions. 
Figure 5. ALS, a spectrum disorder. 
 
ALS and FTD constitute the ends of a spectrum of motor neuron and frontotemporal neuron 
involvement. This spectrum includes patients with ALS who express isolated ALSci or ALSbi, 
and patients with ALS who meet the Neary criteria for FTLD and are, thus, diagnosed with ALS–
FTLD. Some patients with FTLD have insufficient motor neuron involvement for a diagnosis of 
ALS, and are classified as FTLD–MND 
Reproduced from :Swinnen & Robberecht, Nat. Rev.Neurol., 2014. 
 
Following examples of extramotor involvement comes from research that has been done 
in our laboratory. In ALS, spasticity is traditionally thought to be the result of degeneration of the 
upper motor neurons (18,19), although degeneration of other neuronal types, in particular 
serotonergic neurons, might also represent a cause of spasticity (20). A pathological study in 
ALS patients as well as in mice confirmed hypothesis that degeneration of serotonergic neurons 
could at least in part underlie spasticity (20). It was observed in patients that central serotonergic 
neurons suffer from a degenerative process with prominent neuritic degeneration, and 
sometimes loss of cell bodies. More recently, serotonergic degeneration has been observedin a 
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mouse model of ALS, further confirming the data from patients (H. Eloussini et al, Unpublished 
data). Another ongoing study from our laboratory, suggests that hypothalamic pro-
opiomelanocortin neurons (POMC) are lost in different ALS animal models (SOD1 G86R, TDP43 
A315T, FUSΔNLS mice). The decrease of POMC caused abnormal food intake behavior, and 
could be implicated in ALS hypermetabolism problems, frequently observed in patients (P. 
Vercruysse et al, manuscript submitted). 
 
2. Frontotemporal lobar degeneration (FTLD) 
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease first described by 
Arnold Pick in 1892, originally called Pick's disease. This initial description reported upon a 
patient with progressive aphasia and anterior temporal lobar atrophy (21). FTLD encompasses a 
group of heterogeneous diseases characterized by relatively selective atrophy of the frontal 
and temporal lobes, (Figure 6) sometimes bilateral. Atrophy is due to progressive 
degeneration of neurons particularly in the superficial layers of the frontotemporal cortex and in 
the dentate gyrus of the hippocampus (21). 
(21)(21)FTLD is the second most common cause of early onset dementia, after Alzheimer's 
disease (22) and occurs with an incidence of 3.5–4.1/100 000 per year in individuals under 65 
(23) and accounts for 20% of young onset dementia cases (24). 
The term FTLD is often used to describe pathological conditions that are clinically 
predominantly or commonly presented by frontotemporal dementia (FTD). It is a syndrome that 
is characterized by progressive alteration in behaviour, language, sociability and personality, 
with relative preservation of memory at early disease stages (25,26). Signs and symptoms 
typically manifest in late adulthood, more commonly between the ages of 55 and 65, 
approximately equally affecting men and women.The median survival from the onset of 
symptoms is 6–11 years, independent of age at onset or gender (27). 
For FTLD, a stronger genetic contribution, compared to ALS, is reflected by the higher 
percentage (up to 30-50%) of patients with a familial history, while etiology of the rest remains 
unknown. 
Like in other neurodegenerative diseases, detailed neuropathological studies have elicited 
proteinopathies defined by ubiquitin positive inclusions and/or aggregates (28–31). 
Currently, there is no cure for FTLD, but there are treatments that help alleviate symptoms. 
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Figure 6. Brain atrophy in patients with FTLD 
 
Reproduced from: Presentation for RNA Virtual Institute VH-VI-510 reevaluation: Dysmetabolism 
in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Berlin, 201 
 
2.1. Phenotypic heterogeneity  
FTD is traditionally difficult to diagnose due to the heterogeneity of the associated 
symptoms. Clinical subtypes of FTD include the behavioural variant (bvFTD) and two forms of 
primary progressive aphasia (PPA): progressive nonfluent aphasia (PNFA) and semantic 
dementia (SD) (32). Signs and symptoms are classified into three groups based on the functions 
of the frontal and temporal lobes (33): 
The behavioural variant frontotemporal dementia (bvFTD) is characterized by changes 
in social behaviour and conduct, with loss of social awareness and poor impulse control (24), 
such as disinhibition, apathy, loss of empathy, or stereotypic behavior, leading to a loss of social 
competence (26,34). When executive functions are impaired, patients become unable to perform 
skills that require complex planning or sequencing. 
Semantic dementia (SD) is characterized by the loss of semantic understanding, 
conceptual knowledge resulting in impaired word comprehension, although speech remains 
fluent and grammatically faultless (24). Concomitant development of anomia is frequent (26). 
Progressive nonfluent aphasia (PNFA) is characterized by progressive difficulties in 
speech production and grammatical error-making, with relatively preserved language 
comprehension (24). Apraxia of speech (AOS) or orofacial apraxia is frequently accompanying 
the aphasia (34). 
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At least in the initial stages of FTD, the following abilities are preserved: perception, 
spatial skills, memory and praxis (24). In the later stages of the disease, patients tend to struggle 
with binge eating and present compulsive behaviors  including overeating, stuffing oneself with 
food, changes in food habits (35).  
Recent studies over several years have developed new criteria for the diagnosis of 
behavioral variant frontotemporal dementia (bvFTD). Six distinct clinical features have been 
identified as symptoms of bvFTD (36). 
1. Disinhibition 
2. Apathy/Inertia 
3. Loss of Sympathy/Empathy 
4. Perseverative/compulsive behaviors 
5. Hyperorality 
6. Dysexecutive neuropsychological profile 
Of the six features, three must be present in a patient to diagnose one with possible 
bvFTD. 
bvFTD accounts for more than 50 % of the FTLD cases, while PNFA and SD correspond 
each to 25 % of the cases (37). Overlap between the clinical syndromes of bvFTD, PNFA and 
SD can occur during the progression of the disease and clinical distinction between them is often 
complicated in advanced disease stages. 
The comorbidity of behavioural alterations, cognitive impairment or dementia with ALS 
has been noticed since the early 20th century (38). Additionally, FTD is often associated with an 
extrapyramidal movement disorder (parkinsonism or corticobasal syndrome) (32). 
 
3. Clinical link among ALS and FTLD   
The clinical overlap between ALS and FTLD is now well established and increasingly 
recognized. As already noted above 30-50% of ALS patients show at least some executive 
function deficits, and 15% meet the clinical criteria for FTLD(16,17,32); likewise, up to 50% of 
FTLD patients present with some forms of motor neuron dysfunction and 15% meet criteria of 
ALS (16,17,32). However, before the recent genetic revolution in ALS and FTLD, the 
background of this clinical overlap was completely ignored (Figure 7). 
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Figure 7. ALS-FTLD clinical overlap  
 
Reproduced from :Presentation for RNA Virtual Institute VH-VI-510 reevaluation: Dysmetablism 
in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Berlin, 2015. 
ALS with behavioral impairment (ALSbi), ALS with cognitive impairment (ALSci). 
 
B. Molecular basis  
1. Heterogenous molecular basis of ALS: 
The increasingly blurred boundary between sporadic to familial forms 
There are three recognized forms of ALS: sporadic, familial and the endemic ALS–
Parkinson dementia syndromes of Guam and the Kii peninsula (39). 
Most ALS cases, about 90-95 % (40) are isolated in nature, and are referred to as 
“sporadic” ALS (sALS) with unknown etiology. A subset of ALS cases (remaining 5-10%) is 
inheritedand referred to as “familial” ALS (fALS). Most of  the inherited cases rely on an 
autosomal dominant way, but autosomal recessive and X-linked forms also exist (41). 
It is believed however that fALS incidence is underestimated due to flaws in patient 
history and reduced genetic penetrance of certain mutations. FALS is clinically indistinguishable 
from sporadic cases (sALS), except the mean age of onset for fALS occurs about 10 years 
earlier. 
The early substrate for ALS is likely to involve genetic, developmental, and 
environmental factors. For most apparently sporadic cases, multiple genetic factors with small 
individual effects might in part affect development and maturation of the nervous system. This 
process might result in a motor system architecture that is more permissive to pathological 
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changes later in life, for example. Environmental triggers might then operate on an already 
primed system (Figure 8). Head injuries, cigarette smoking, exposure to toxic substances (e.g. 
heavy metals, pesticides) and other including diet (42,43) have all been linked to detrimental 
effects on the human body, however only recently these factors have been associated with sALS 
(44).One of the most cited environmental risk factor is physical activity. An active sports-oriented 
life stile has been associated with ALS patients (45) and increased incidence amongst 
professional athletes has also been reported (46). 
As with other neurodegenerative diseases, given the genetic predisposition and the 
proper environmental conditions, the probability of developing familial or sporadic form of ALS 
increases with age (Figure 8) (47). Gender has been documented to be a factor in the likelihood 
of developing ALS, with male:female ratio of 1.5:1 (47). 
Figure 8. Early supstrat of ALS – factors to consider in aethiology of ALS 
 
As seen in several other neurodegenerative diseases, ALS is believed to occur due to a 
convergence of factors: genetic variation in genes, late disease onset age, in the 50s, indicates 
that the risk of getting ALS increases with age and several environmental factors are known to 
increase the risk of getting this disease: head trauma, smoking and exposure to diets rich in 
heavy metals.  
 
The most significant advances in understanding of the etiology of neurodegenerative 
disorders come from the identification of disease-causing genes. For almost two decades, only 
one gene was known to have a role in ALS pathogenesis, superoxide dismutase 1 (SOD1). 
Today, the pace of gene discovery has greatly accelerated, fuelled in large part by advances in 
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new technologies like genome wide associated studies (GWAS), whole-exome (WES) and 
whole-genome sequencing (WGS) in relation to previous linkage gene analysis (Figure 9). 
Figure 9. Progress of genetic findings related to ALS etiology and pathogenesis 
 
Mendelian ALS genes are shown, with the sizes of the circles indicating the relative contribution 
of each gene toward the explanation of ALS cases. The effect of TBK1 is likely to expand, as 
indicated by the dashed circle outline, in the near future as additional studies emerge. 
Reproduced from :Bettencourt & Houlden.Nat. Neurosci., 2015. 
 
Mutations in almost 40 genes have been identified to be implicated in or associated with 
ALS pathogenesis (48). In the last 3 years alone, six new ALS genes have been discovered 
(40). In parallel this indicates ALS as genetically heterogenous disease. Mutations of all these 
genes account for 68% of fALS and surprisingly 11% of sALS patients (Figure 10) (40), while 
the rest of the cases remain of unknown cause. Among these, the most common ones, 
representing over 50% of the fALS cases (4), are found in the four major genes encoding 
superoxide dismutase 1 (SOD1; ~20%) (49), fused in sarcoma (FUS; 1-5%) (50,51) and trans-
active response (TAR) DNA-binding protein TDP-43 (TARDBP; 1-5%) (52). Recently, a 
hexanucleotide repeat expansion (GGGGCC)n in the C9ORF72 gene was identified as the most 
frequent cause of fALS (~40%) (53,54). 
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Figure 10. Frequency distribution of genes involved insALS and fALS. Blurred line between 
sALS and fALS 
 
Reproduced from : Renton, Chio & Traynor. Nat. Neurosci.,2014. 
 
A rapid advance in knowledge of the genetic architecture of ALS, reveals missing links 
between the genetic subtypes with clinical subtypes and pathological phenotypes. Despite 
the fact that each new genetic discovery is broadening the phenotype associated with the clinical 
entity we know as ALS, it also underlies multiple common points which are nowadays emerging 
themes: 1) genetic convergence that unifies the etiology, 2) a final common pathway of 
diverse proposed pathogenic mechanisms, 3) an oligogenic rather then monogenic nature of 
disease, and 4) overlapping phenotypes of the disease spectrum. 
The early studies of the C9ORF72 hexanucleotide repeat expansion suggest that it is 
also present in a sizeable minority of apparently sALS cases (53,54) outlining the genetic 
convergence between fALS and sALS. Likewise, mutations of the other genes SOD1 (49),FUS 
(50,51), TARDBP (52), optineurin (OPTN) (55) and newly discovered TANK-binding kinase 
1(TBK1) (56,57) are as well detectable in a small but significant proportion of the 90–95% of 
sALS reporting no family history (Figure 10). All together, the current macrogenetic landscape in 
ALS, highlights the increasingly blurred boundary between familial and apparently 
sporadic disease. 
 
2.  Heterogenous molecular basis of FTLD: 
Given this variability in phenotype, it is not surprising that the molecular basis of FTLD is 
also heterogeneous. Unlike ALS cases, about 30-50% of patients have a familial history of 
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disease, and referred to as “familial” FTLD (fFTLD). When considering clinical FTLD subtypes, 
family history is most prominent in bvFTD (45%), especially when concomitant symptoms of 
MND are present (60%), while SD appeared to be the least hereditary FTLD subtype (<20%) 
(58). Otherwise, the remaining cases are with unknown etiology and are referred to as “sporadic” 
FTLD (sFTLD). Combinations of genetic variants and environmental factors are likely to be 
responsible for the disease in the majority of patients with sporadic FTLD. 
In the FTLD, disease causative mutations were identified in 9 genes and represent 30-
50% of fFTLD with two major genes firstly described: the microtubule-associated protein tau 
(MAPT) (59) and the progranulin (PGRN) (60). Together, they account for 10%–20% of FTLD 
(Figure 11). 
In the past few years, remarkable advances have been made in the molecular genetics 
of FTLD. Today, the genetic causes responsible for the majority of autosomal dominant cases 
have been determined (61). 
Figure 11. Frequency distribution of genes involved in fFTLD 
 
Data taken from: Ling, Polymenidou and Cleveland. Neuron., 2013. 
 
3. Genes linked to ALS and FTLD: 
In this chapter causative genes linked to ALS and FTLD are presented divided in three 
groups (Table 2): 
Pure ALS genes – found only associated with classical ALS and characterized by 
predominantly motor phenotype. 
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Overlapping genes – involved in ALS and overlapping with other diseases, 
characterized by the presence of overlapping motor and extramotor phenotypes and and with 
particular emphasis on genes found in both diseases ALS-FTLD. 
Pure FTLD genes – found only associated with cognitive and behavioral phenotype – 
FTD   
Table 2. Genes linked to ALS and FTLD  
 
Reproduced from : Ling , Polymenidou and Cleveland. Neuron., 2013. 
AD: autosomal dominant, AR: autosomal recessive, POAG: Primary open angle glaucoma, PDB: 
Paget′s disease of the bone, IBM: inclusion body myositis. 
 
3.1. Pure ALS genes 
3.1.1. Superoxidedismutase 1 (SOD1) 
SOD1 mutations were found to cause familial ALS in 1993, representing the first 
demonstration that linkage analysis could successfully pinpoint the underlying genetic cause of a 
rare neurodegenerative disease (49). 
There are now more than 160 recorded mutations in this 153 amino-acid protein, mostly 
missense, all apparently resulting in fALS (20%) or sALS (1-2%) (40). 
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Considerable phenotypic heterogeneity occurs across the various SOD1mutations. For 
instance, the SOD1 A4V mutation can induce very aggressive disease while long survival has 
been reported in association with the SOD1 D90A mutation (40). In general, patients have 
almost exclusively lower motor neuron signs and almost never bulbar onset of disease (62). 
Although, cognitive impairment is not a prominent feature of SOD1 disease, patients with D90A 
manifest FTLD at the later stages of the disease (63). 
SOD1 main physiological function is to protect cells from oxidative damage by 
metabolizing superoxide radicals (64).The molecular basis of the toxicity of mutant SOD1 is 
multifactorial. Because SOD1 detoxifies superoxide anion, it is likely that mutant SOD1 
provokes oxidative stress (65). Whatever the molecular underpinnings of its cytotoxicity, 
SOD1 can disrupt a wide set of cellular functions. While a complete recounting of these 
pathways is beyond the scope of this manuscript, some of the adverse effects include: 
provocation of cellular hyperexcitability (66), disruption of mitochondrial function (67), induction 
of the unfolded protein response (UPR) and endoplasmic reticulum (ER) stress (68), impairment 
of molecular motors and axonal transport (69), and early disruption of the neuromuscular 
synaptic structures (70). 
Whatever the pathway is, it ends with misfolded proteins, having toxic effects on the 
cell's degradation machinery, impairing its two major components: the proteasomal pathway and 
the autophagy, and triggering its deposition in inclusion bodies within spinal motor neurons 
(71). Mutant SOD1 also spontaneously forms oligomers (72) as well as visible aggregates (73). 
Neuropathologically, ALS patients with SOD1 mutation show loss of spinal cord neurons 
but while there is immunopositivity for ubiquitin and p62 inclusions in the spinal neurons and 
glia cells, there is usually negativity for TDP-43 (74).The protein appears to gain a novel, toxic 
function that leads to motor neuron degeneration (75). 
The SOD1 mutations discovery in ALS led directly to the development of the SOD1 
transgenic mouse (76). Though important in elucidating the cellular mechanisms by which 
mutationof this gene predispose to motor neuron degeneration, the use of this model to select 
agents for human trials has been increasingly called into question (77). 
 
3.2. Overlapping genes 
3.2.1. TAR DNA-binding protein (TARDBP) 
In  2006 the protein TDP-43 was identified by Neumann and colleagues as major 
component of the ubiquitin-positive neuronal inclusions that are the pathological hallmarks 
of both ALS and frontotemporal dementia FTLD (28).This finding provided strong evidence that 
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FTLD and ALS are closely related conditions with overlapping molecular pathogenesis. 
Importantly, in 2008 it was shown that mutations in TARDBP caused a fraction of familial is 
causative gene mutated in ALS cases (52). 
This presented a landmark event in our understanding of both diseases pathogenesis.  
There have now been more than 40 mutations found in TARDBP accounting for ~4% of 
fALS cases and a smaller percentage of sALS cases and rare FTLD (78). Most are missense 
mutations, but there are a few deletion mutations that give rise to a protein truncated at the very 
C-terminal (79). 
Bulbar involvement was originally reported more frequently than might be expected, but 
assimilation of all published phenotypes suggests that the proportion is about the same as for all 
ALS. Phenotype is usually ALS with or without FTLD but only rarely isolated FTLD (78). 
Under normal conditions, TDP-43 is located in the nucleus, where it is involved as all 
DNA/RNA binding proteins in multiple steps of RNA metabolism (80). The data imply that TDP-
43 causes pathogenesis in a two-step manner. The first step involves the exit of TDP-43 from 
the nucleus and the second step involves the irreversible formation of stress granule-based 
aggregates. Disease-associated mutations cause a shift of TDP-43 location from nucleus to 
cytoplasm and increase its aggregation propensity (81), but it is uncertain whether these 
changes are sufficient to initiate this vicious circle in vivo. TDP-43–mediated toxicity may reflect 
either loss of its function in the nucleus, an acquired adverse effect of its pathological 
presence in the cytoplasm (gain-of-function), or both. Indeed, in a recently developed mouse 
model, the expression of mutant TDP-43 induced a phenotype even without formation of 
aggregates or abnormal processing of the cytoplasmic mutant protein and with no loss of TDP-
43 from the nucleus which suggested a toxic gain of function (82). In line with this are findings 
from the very recent study that, by comparing the pathological changes in TDP-43WTxQ331K (with 
cytoplasmic aggregation and nuclear clearing) and TDP-43Q331K mice (with only cytoplasmic 
aggregation)  showed that the loss of nuclear TDP-43 may accelerate, but it was not essential 
for the disease. Whereas cytoplasmic aggregation of TDP-43 seen in aged TDP-43Q331K and 
TDP-43WTxQ331K mice, was sufficient to cause neurodegeneration (83). Thus, while nuclear 
clearance of TDP-43 may accelerate disease it does not appear to be essential to cause 
neurodegeneration and loss of nuclear TDP-43 function may not be a primary or disease-critical 
event. 
Neuropathology in cases of ALS with TARDBP mutations tends to reveal features similar 
to those of sALS, with neuronal loss and gliosis in the anterior horns of the spinal cord, and 
pallor of the corticospinal tracts. Immunohistochemically, there are TDP-43 positive 
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cytoplasmic inclusions in upper and lower motor neurons, but also in other regions of the 
central nervous system including frontal and temporal cortex (84). In the brain, cytoplasmic TDP-
43 undergoes secondary modifications such as hyperphosphorylation, ubiquitylation and 
processing into smaller fragments (28). 
The discovery of the central role of TDP-43 in ALS pathogenesis has highlighted the 
importance of RNA processing. Additional support for this hypothesis comes from the discovery 
of FUS, another RNA-binding protein. 
 
3.2.2. Fused in sarcoma (FUS) 
In 2009, shortly after the identification of TDP-43, a second RNA-binding protein 
functionally homologous and structurally comparable with TDP-43, FUS was linked to familial 
ALS (50,51). FUS is discussed in more details afterwards (see below). 
 
3.2.3. Hexanucleotide repeat expansion in C9ORF72 
In 2011, a duo of teams made the discovery of a massive hexanucleotide repeat 
expansion in C9ORF72 as the cause of ALS and FTLD. The distinctive mutation in this gene is 
an expansion of an intronichexanucleotide GGGGCC (G4C2) repeat motif (53,54). Normally 
present in 30 or fewer copies, in C9ORF72-associated ALS, the repeat domain expands to 
encompass hundreds of tandem repeats (85). The expanded segment is transmitted as a 
dominant trait. Intriguingly, in several patients with C9ORF72 mutations, a second mutation has 
been found in another gene (TARDBP, for example) (86). The biological significance of this 
finding is unknown, but it suggests that in some families, ALS may be oligogenic in etiology 
(87). 
It has reinvigorated the ALS and FTLD research field for a variety of reasons. First, the 
pathogenic expansion accounts for a remarkable percentage of both fALS (~37%) and familial 
FTLD (~21%) and genetically explains the majority of the overlap of these two disparate 
clinical syndromes (88). Second, the repeat expansion has been found to account for ~6% of 
apparently sALS cases and 6% of patients with supposed sFTLD (53,54,88). 
C9ORF72 linked diseases clinically present with a widely variable phenotype including 
ALS or FTLD-ALS or FTLD (53). Bulbar onset is frequent in C9ORF72-associated ALS, as is 
frontotemporal involvement, which is usually of the behavioural variant, but patients with 
primary progressive aphasia (PPA) have been described (53,54,89–92). 
The normal function of the presumably cytoplasmic protein C9ORF72 is unknown. 
However, it has recently been demonstrated that C9ORF72 regulates endosomal trafficking and 
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colocalizes with Rab proteins that are implicated in autophagy and endocytic transport. 
C9ORF72 also colocalizes with ubiquilin-2 and microtubule-associated protein light chain 3 
(LC3) positive vesicles, and co-migrates with lysosome-stained vesicles in neuronal cell lines, 
providing further evidence that C9ORF72 regulates autophagy (93). 
How repeat expansions in C9ORF72 cause ALS remains to be elucidated. In the ALS 
patients with a C9ORF72 expansion that have been studied, the levels of C9ORF72 mRNA were 
reduced by 50% (53), suggesting that the expanded allele does not generate mature mRNA. 
Thus, the C9ORF72 expansion may result ina loss-of-function. The expanded hexanucleotide 
repeats form nuclear RNA foci in neurons in the frontal cortex and spinal cord in patients with 
C9ORF72 mutations (53). Pre-mRNA containing the expansion may thus exert a deleterious 
gain-of-function effect.These two mechanisms (haplo-insufficiency versus gain-of-function) 
are not mutually exclusive and do not exclude other mechanisms for the repeat expansion to 
cause fALS. 
Neuropathologically, patients with ALS who carry C9ORF72 hexanucleotide expansions 
present with typical features such as TDP-43-positive inclusions within the remaining motor 
neurons, as well as in the cortex and the hippocampus (91). Interestingly, two recent reports 
have indeed identified dipeptide repeat (DPR) proteins, which are most likely generated 
through RAN translation from expanded G4C2 RNA, within aggregates of patients with 
C9ORF72 expansion-associated ALS and/or FTLD (94,95). The pathogenic significance of these 
DPR proteins remains to be demonstrated, but a study in Drosophila suggested that the DPR 
proteins could represent, by themselves the toxic agents (96). 
 
3.2.4. Valosin-containing protein (VCP) 
In the same year than C9ORF72, mutations in the valosin-containing protein (VCP) gene 
responsible for 1–2% of fALS cases were also reported (97). This is important given that these 
mutations provide another genetic link between motor neuron degeneration and FTLD, where 
VCP mutations are rare and represent less than 1 % of the fFTLD cases (most frequently bvFTD 
and SD) (98). 
Today, 17 different mutations have been identified, and underlie an unusual clinical 
syndrome characterized by FTLD, inclusion body myopathy and Paget's disease of the bone 
(IBMPFD) (99). The existence of inclusion body myopathy in these patients was similarly 
interesting because it demonstrated that mutations in a single gene could result in pathology on 
both sides of the neuromuscular junction. This has given rise to the concept of multisystem 
proteinopathy, in which multiple tissues are affected. 
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Physiologically, VCP interacts with a large number of ubiquitinated proteins to enable 
degradation or recycling and functions in multiple protein clearance pathways, including 
extracting misfolded proteins from the ER and sorting of endosomal proteins for proper 
trafficking. Depletion of VCP leads to accumulation of immature autophagosomes, similar to 
what is observed upon expression of IBMFD-linked mutations (100), suggesting that VCP is 
required for proper autophagy. Most intriguingly, TDP-43 is apparently mislocalized to the 
cytosol upon VCP-mediated autophagic dysfunction (100). 
FTLD patients with a VCP mutation have TDP-43-positive inclusions (98).  
The best supported hypotheses of the disease mechanism of VCP mutations are 
disturbed ubiquitin–proteasome mediated protein degradation, autophagy, or both (101). 
 
3.2.5. Ubiquilin 2 (UBQLN2) 
In 2011, missense mutations in UBQLN2, located on the short arm of chromosome X, 
were initially identified in autosomal dominant ALS (41). Nevertheless, ubiquilin 2 pathology has 
been observed in ALS patients who do not carry mutations in the gene. 
Although, isolated ALS was the predominant phenotype, occasional patients had 
concomitant symptoms of FTLD with abnormalities in both behaviour and executive functions; 
however, none of these patients presented with FTLD alone. 
Ubiquilin 2 is a member of the ubiquilin family, with unknown exact function. It has been 
implicated in ubiquitinated proteins degradation via both ubiquitin-proteasome system (UPS) and 
autophagy, in G-protein coupled receptor endocytosis , and may be an important component of 
the final common pathway mediating motor neuron degeneration (41). 
In human spinal cord autopsy material of UBQLN2 ALS mutation carriers, inclusions 
were positive for UBQLN2, ubiquitin, p62, TDP-43, FUS and OPTN but not SOD1 (41,102). In 
cases with ALS-FTLD with or without UBQLN2 mutations, UBQLN2-positive inclusions are found 
in the hippocampus which are absent in ALS cases without dementia indicating that UBQLN2 
aggregation and neurodegeneration are linked (41). Inclusions in spinal cord tissue from sALS 
and fALS patients with unknown mutations or mutations in SOD1, TDP-43 or FUS also stain 
positive for UBQLN2 (41,102). 
 
3.2.6. Charged multivesicular body protein 2B (CHMP2B) 
A mutation in the gene encoding charged multivesicular body protein 2B (CHMP2B), was 
found in a large Danish FTLD pedigree at chromosome 3 (103,104). Mutations affect the C-
terminal end of the protein due to aberrant splicing.  
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CHMP2B encodes a protein with functions in the endosomal–lysosomal and the 
autophagic protein degradation pathway.  
Ubiquitin-immunoreactive inclusions do not stain for tau, TDP-43 or FUS 
antibodies (105) (106). 
 
3.2.7. Optineurin (OPTN) 
OPTN autosomal recessive mutations were described in a few ALS families in 2010 (55). 
This has become interesting because of the intriguing phenotypic pleiotropy associated with 
such mutations. Indeed, the OPTN locus has been previously implicated in Paget's disease of 
bone (107). Dominant missense, recessive deletion and nonsense mutations of OPTN have 
been identified in both patients with fALS and with sALS. 
Physiologically, OPTN functions as an inhibitor of NFκB-signaling (108), acts as an 
autophagy receptor(109) and participates in the regulation of vesicular trafficking and 
maintenance of the Golgi apparatus(110). 
In sALS cases, OPTN is present in cytoplasmic inclusions and colocalizes with 
ubiquitin, TDP-43, and possibly FUS (108,111–113). 
 
3.2.8. Sequestosome 1 (SQSTM1) 
SQSTM1 encodes p62 protein and mutations in this gene are known to cause Paget's 
disease of bone (114). A candidate gene screening approach identified missense and deletion 
variants in ~1% of in familial and sporadic ALS patients (115–117). 
Similar to ubiquilin, p62 has been shown to interact with polyubiquitinated proteins (118) 
and with LC3, allowing p62 to target polyubiquitinated proteins to the proteasome or autophagy. 
Therefore, both p62 and ubiquilin-2 link the ubiquitin-proteasome and autophagy pathways. 
p62-positive inclusions have also been reported as deposited in neurons and glia of a 
wide array of other neurodegenerative diseases (91). While the way these ALS-associated 
variants in p62 contribute to pathogenesis has not been established, autophagy/proteasome 
disturbance seems likely to play a role. 
 
3.2.9. Other genes 
Mutations in several other genes have been reported as rare causes of ALS or ALS-like 
syndromes. In 2014, whole-exome sequencing led to the identification of one mutation in the 
gene coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) in two 
families presenting with ALS/FTLD (119). 
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A large collaborative effort in 2015, by Cirulli et al., involving researchers from more than 
two dozen laboratories, recently led to the identification of a genome-wide association between 
rare, non-benign variants in TANK-binding kinase 1 (TBK1) and ALS (56). Most importantly, 
mutation in familial cases of ALS were recently identified in the TBK1 gene (57). Notably, the 
new ALS gene (TBK1) converges, together with previously known ALS genes (such as OPTN 
and SQSTM1) on autophagy pathway (56,57). 
 
3.3. Pure FTLD genes  
Two causal genes firstly identified: the microtubule-associated protein tau (MAPT) (59) 
and the progranulin (PGRN) (60) together account for 10%–20% of FTLD  cases (22). 
 
3.3.1.  Microtubule-associatedprotein TAU (MAPT) 
In 1998, mutations in the MAPT gene located on chromosome 17 were identified in a 
number of families with FTLD and parkinsonism (59). Since then, 44 different MAPT mutations 
have been reported, accounting for 5–20% of cases of familial FTLD (120).  
MAPT encode the four microtubule-binding domains of TAU. In normal brain, the tau 
protein occurs as six isoforms of which three contain three microtubule-binding domains (3R 
TAU) and three contain four microtubule-binding domains (4R TAU). A substantial number of 
missense mutations affecting the splicing of exon 10 result in aberrant ratios of 3R and 4R TAU. 
Consequently, the binding of TAU to tubulin is impaired either due to an increased expression of 
4R tau relative to 3R TAU isoforms, or due to the altered binding properties of the mutant TAU 
protein (120). In addition, coding MAPT mutations increase the tendency of TAU to form 
neurotoxic aggregates that are pathological characterictic of the more then 40% of FTLD 
cases (121). 
FTLD with tau-positive inclusions is mainly associated with bvFTD. However, forms of 
PPA are also reported. Symptoms of associated motor neuron diseases are rare. On average, 
FTLD-TAU is characterized by the earliest onset age in the FTLD syndromes (38). 
 
3.3.2. Progranulin (PGRN) 
A major breakthrough occurred in 2006 when the progranulin (PGRN) gene was 
identified as the second FTLD-related located gene on the same chromosome 17 (60). Indeed, 
PGRN mutations account for an even larger proportion of FTLD families than do mutations in 
MAPT(120). To date, 69 different PGRN mutations have been reported (122) distributed across 
29 
 
the complete coding region and splice sites of the gene. They are loss-of-function mutations 
leading to reduced functional protein and resulting in haplo-insufficiency (123). 
The characteristic pathological inclusions were tau-negative, ubiquitin-positive. It is 
now known that these inclusions are TDP43-positive. 
Despite the fact that haplo-insufficiency is the common disease mechanism in all patients 
carrying a PGRNmutation, the associated clinical phenotype is variable, including bvFTD and 
PNFA(124). Parkinsonism symptoms are often observed, but motor neuron symptoms are rare 
(125). 
 
4. Genetic link among ALS and FTLD  
The description of mutations for several genes that are common to both ALS and FTLD 
provided a genetic link between them. Around six-seven genes that have been identified since 
nowadays represent a strong genetic proof of the continuum between these two pathologies 
(Figure 12). 
The genetic link between ALS and FTLD was first established when TARDBP was found 
to be mutated in both diseases (52). This first gene was rapidly followed by a second one, FUS 
(50,51). A third, notable example was the identification of a hexanucleotide expansion in the 
C9ORF72 gene, among both ALS and FTLD cases (53,54,126).The average mutation 
frequencies reported in European populations are 37% for fALS, 6% for sALS, 21% for fFTLD, 
and 6% for sFTLD patients, which make C9ORF72 the strongest genetic link between these two 
diseases (61). Importantly, all these genes are involved in multiple steps of RNA metabolism 
(4). 
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Figure 12. ALS-FTLD genes 
 
ALS-FTLD genes plotted to show phenotype, year of discovery and importance gauged by 
research outputs. The X axis is a score representing the involvement of each gene in ALS or 
FTLD. The Y axis represents year of mutation identification. The circle size represents the level 
of research on each gene.   
Reproduced from: Al-Chalabi A et al., Acta Neuropathol.,2012  
 
ALS, ALS/FTLD and/or FTLD causing mutations were also identified in genes involved in 
protein clearance pathways or in maintaining proper protein homeostasis, including 
ubiquilin-2 (UBQLN2) (41), vasolin-containing protein (VCP) (97,99), vesicle-associated 
membrane protein-associated protein B (VAPB) (127), p62/sequestosome (SQSTM1) (115–
117), optineurin (OPTN) (55), and charged multivesicular body protein 2B (CHMP2) (103,104). 
Interestingly, these genes are associated with two major categories of cellular function: 
protein homeostasis and RNA metabolism. Together with the toxic protein aggregation that 
represent a classical pathological hallmark of both ALS and FTLD, these convergent genetic 
findings indicate that protein and RNA metabolisms are key cellular pathways systematically 
impaired in both diseases (Figure 13). 
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Figure 13. ALS-FTLD genetic overlap and converging underlying cellular pathways 
 
Taken from: Presentation for RNA Virtual Institute VH-VI-510 reevaluation: Dysmetablism in 
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Berlin, 2015 
 
C. Pathological characteristics 
1. Pathological overlap between ALS and FTLD   
Along with neuronal degeneration, neuronal insoluble protein 
deposits/inclusions/aggregates are a histopathological hallmark of several neurodegenerative 
disorders. Inclusions are mostly cytoplasmic (NCI, neuronal cytoplasmic inclusions) and less 
frequently with nuclear localisation (NII, neuronal intranuclear inclusions). However, the role 
played by inclusions in neurodegenerative pathogenesis remains enigmatic and the published 
data are currently not sufficient to conclude if aggregation is directly responsible for 
neurodegeneration. 
Hence, ALS and FTLD are neuropathologically characterized by accumulation of 
ubiquitin-positive protein inclusions in affected cells of the central nervous system (neurons 
and glia) (29,128). For instance, p62 positive aggregates are systematically found in inclusions 
(129). In ALS patients, inclusions are not restricted to the spinal cord but also present in other 
brain regions such as the frontal and temporal cortices, hippocampus and cerebellum (130). As 
well, FTLD patients have inclusion detected outside brain,  in the brainstem and spinal cord 
(131). 
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Recent advances in the identification of the exact protein composition of the inclusion 
further supported the clinical ALS/FTLD continuum by a pathological overlap. 
A last shared pathological feature is activation of immune system and signs of 
neuroinflammation. 
In all, pathological links between ALS and FTLD include three main 
characteristics: protein inclusions, neuronal degeneration and neuroinflamation. 
 
1.1. Protein deposits/inclusions/aggregates in ALS and FTLD   
The presence of protein aggregates in and around affected neurons is a hallmark of ALS 
and FTLD. It is remarkable that the proteins encoded by genes linked to ALS/FTD (TARDBP, 
FUS, CHMP2B, VCP, UBQLN2 and MAPT) are almost all present in protein aggregates in a 
large proportion of sporadic patients indicating a more widespread role for their abnormal 
localization in  disease pathogenesis. 
Following the identification of SOD1 aggregates in SOD1-ALS patients, a greatest 
breakthrough was finding that TDP-43 is the major ubiquitinated protein in inclusions in both ALS 
and FTLD diseases (28). Mutations in TARDBP are unique to ALS and are not found in other 
neurodegenerative disorders (52,84) with the exception of a small number of FTLD cases (132–
137). TDP-43 positive inclusions are found in almost all sALS patients (non-mutated TDP-43) 
and in the vast majority of fALS patients with associated genes TARDBP, VCP, C9ORF72, 
UBQL2, OPTN, but not in SOD1 and FUS related fALS (74,138) (Table 3). FTLD with TDP-43 
aggregates includes sporadic and genetic forms, with mutations having been identified in PGRN, 
VCP and TARDBP, along with the C9ORF72 repeat expansion and UBIQLN2 (139,140). Before 
TDP-43 was discovered this the most common subtype of the disease, was known as FTLD with 
ubiquitinated inclusions (28). Furthermore, the distribution of the TDP-43-positive aggregates is 
disease-specific: they are present in spinal cord motor neurons, hippocampal and frontal cortex 
neurons and glial cells in ALS, and have a more widespread distribution in the brain of FTLD 
patients (141). 
Pathological modifications of TDP-43 in these disorders include a redistribution of the 
protein from the nucleus to the cytoplasm in cells with inclusions, as well as 
hyperphosphorylation, ubiquitination and N-terminal truncation of the protein (28). 
In all, based on these findings, ALS and FTLD with TDP-43 positive inclusions are now 
grouped as TDP-43 proteinopathies (ALS-TDP and FTLD-TDP) according to the major 
deposited protein within inclusion (Table 3). On the basis of the morphology and anatomical 
distribution of TDP-43 pathology, four distinct FTLD-TDP subtypes have been identified (142), 
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supported by genetic and clinical correlations (Table 3), as well as distinct biochemical 
properties of TDP-43 in the different subtypes (28). 
More recently, FUS was found as accumulating in remaining TAU/TDP-43-negative, rare 
ALS and FTLD subtypes (29,50,51). Indeed, the identification of mutated FUS within ubiquitin-
positive neuronal cytoplasmic inclusions (NCI) in a portion of ALS cases led to the reexamination 
of other neurological diseases with NCI of unknown origin.  Pathological examination of post-
mortem tissue of FUS mutation carriers showed predominant degeneration of lower motor 
neurons with FUS-positive cytoplasmic  inclusions and a normal distribution of TDP-43, thereby 
distinguishing them from other ALS cases (50,51). The precise pattern of FUS-immunoreactivity 
in ALS cases without FUS mutations is still unclear. Some studies report that FUS is not present 
in sALS patients and SOD1 fALS (29,50,143), while others show FUS-positive inclusions with 
signals for TDP-43, p62 and ubiquitin in all sALS and fALS cases, except for SOD1 mutation 
carriers (113,144). 
Subsequently, abnormal FUS was detected within inclusion bodies in neuronal cytoplasm 
NCI and nucleus NII, as well as glial inclusions, in several uncommon forms of frontotemporal 
lobar degeneration (FTLD) (29,145–147). These rare subsets of FTLD, previously referred to as 
atypical FTLD with ubiquitinated inclusions (aFTLD-U), neuronal intermediate filament inclusion 
disease (NIFID) and basophilic inclusion body disease (BIBD) (29,145–147). However, in 
contrast to ALS, FTLD patients with FUS inclusions only rarely harbor genetic alterations in FUS 
(148). Interestingly, FUS-positive inclusions in FTLD cases are immunoreactive for Ewing RNA-
binding protein (EWSR1), and TATA-binding protein-associated factor 15 (TAF-15), two other 
members (along with FUS as third) of the FET family of RNA binding proteins, and for 
transportin-1, while inclusionsin ALS cases with FUS mutations do not stain for these 
proteins(149,150). 
Biochemical analyses show that mutant FUS protein itself is not ubiquitinated, 
hyperphosphorylated or cleaved (29). However, FUS is enriched in the insoluble fraction of 
FTLD brains (29). Deposited FUS is arginine methylated in ALS, but not in FTLD (151). 
Furthermore, nuclear clearing of FUS is not as evident as observed for TDP-43 (29). 
ALS and FTLD that share FUS aggregation as common pathological feature and a 
presumed underlying disease mechanism have now been grouped together as the FUS 
proteinopathies. The two major clinical and pathological types are known as FTLD with FUS 
pathology (FTLD-FUS) and ALS with FUS pathology (ALS-FUS). This nomenclature is 
analogous to the classification that has been developed for the TDP-43 proteinopathies (Table 
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3). FTLD-FUS is additionally divided in three subtypes corresponding to previously known rare 
subsets of FTLD: aFTLD-U, NIFID and BIBD. 
Subsequent confirmation that FUS is present in the pathological inclusions in most of the 
FTLD patients without TDP-43-containing inclusions has led to a proposed reclassification of 
ALS and FTLD based on the main protein component of inclusion (30,31) (Table 3). 
Table 3. Pathological and clinical features of ALS and FTLD subtypes 
 
New molecular classification of FTLD and ALS. FTLD and ALS are divided into different 
neuropathological subtypes based on the disease-signifying deposited protein in pathological 
inclusions and genetic defects associated with a certain pathological and clinical subtype. 
*clinical features present in some, but not all, pathological subtypes. #Rare case reports of 
patients with clinical FTLD, but no description of pathology, ALS, amyotrophic lateral sclerosis; 
BIBD, basophilic body disease; CBD, corticobasal degeneration; DPR, dipeptide repeat proteins; 
FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; LMN, lower motor 
neuron; MSTD, multiple system taupathy with dementia; NIFID, neuronal intermediate filament 
inclusion disease; PNFA, progressive non fluent aphasia,;SD, semantic dementia; Ub, ubiquitin 
inclusions; UMN, upper motor neurons; UPS, ubiquitin proteasome system. 
Reproduced from Dormann D & Haass C Mol. Cell. Neurosci. 2013. and Reproduced from 
Deng, H. et al., Nat. Rev. Neurol.2014 
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Although, the majority of inclusions from cases with the C9ORF72 intronic expansion 
stain positive for TDP-43 (with exception of rare TDP43-negative but ubiquitin and p62-positive), 
neurons also develop another type of inclusions. Cytoplasmic aggregates composed of dipeptide 
repeat proteins (DPR) encoded by the intronic hexanucleotide repeats that are produced through 
non-canonical, repeat-associatednon-ATG–mediated (RAN-mediated) translation. These 
atypical peptides reflect translation of amino acids from all possible reading frames of the G4C2 
expanded domains (94,95). These are now classified accordingly to ALS-DPR and FTLD-DPR 
representing DPR proteinopathies. 
Other proteins could be found co-aggregated with the main ones in both diseases. In 
cases ofALS-FTLD, with or without UBQLN2 mutations, UBQLN2-positive inclusions are found 
in the hippocampus. These inclusionsare absent from pureALS cases (i.e. without dementia), 
which indicates that UBQLN2 aggregation and neurodegeneration are linked (41,102). In cases 
with ALS-FTLD with or without UBQLN2 mutations, UBQLN2-positive inclusions are found in the 
hippocampus which are absent in ALS cases without dementia indicating that UBQLN2 
aggregation and neurodegeneration are linked (41). Inclusions in spinal cord tissue from sALS 
and fALS patients with unknown mutations or mutations in SOD1, TARDBP or FUS also stain 
positive for UBQLN2(41,102). 
In all, TDP-43 and FUS are the major components of pathological inclusions 
observed in almost 100% of ALS and over 50% of FTLD patients. In the remaining TDP-43 
and FUS negative inclusions found in ALS cases, SOD1 positive inclusions were detected 
in less than 2% (ALS-SOD1). In less than 50% inclusions identified in FTLD cases that 
were negative for both proteins, the main component was TAU protein encoded by 
corresponding MAPT gene (FTLD-TAU), or proteins of ubiquitin-proteasome system 
named FTLD-UPS (around 1%) (Figure 14). 
Figure 14. Pathological protein inclusions in ALS and FTLD, according to the major 
misaccumulatedprotein. Inclusions of TDP-43 and FUS/TLS in ALS and FTD reflect the 
pathological overlap of ALS and FTD 
 
Reproduced from : Ling , Polymenidou and Cleveland. Neuron., 2013. 
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When all inclusions negative for TDP-43 and FUS are substracted from ALS and FTLD 
cases, the distribution looks then like presented in Figure 15. 
Figure 15. Frequency of TDP-43 and FUS pathological protein inclusions in ALS and FTLD 
 
Reproduced from: Presentation for RNA Virtual Institute VH-VI-510 reevaluation: Dysmetablism 
in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Berlin, 2015 
 
Altogether, linking the different types of protein aggregates to specific genetic alterations 
uncovered the converging cellular pathological processes affected in both ALS and FTLD. 
 
1.1.1. Common cellular pathomechanisms among ALS and FTLD  protheinopathies: from 
proteinopathy  to ribonucleopathy 
The consistent presence of ubiquitin and p62 in ALS and FTLD aggregates regardless of 
the main deposited protein, implicated a role of the protein quality control system in ALS and 
FTLD pathophysiology. Ubiquitin proteasome system (UPS) and the autophagy-lysosome 
system function to monitor protein quality and protect cells from dysfunctional, misfolded or 
denatured proteins, by degradation. 
Ubiquitination marks proteins for degradation and p62 is an important participant in 
autophagy (152) (Figure 16). It has been already postulated that ubiquitinated proteins form 
aggregates when dysfunctional protein levels exceed cell protein capacity for clearance. As 
previously mentioned and in line with this, mutations in genes encoding autophagy regulators 
have been associated with ALS and FTLD: VCP, p62, CHMP2B and UBQLN2 (41,97,103,115–
117). This fact further underlined the notion that proteasomal degradation might play a 
causative role in ALS and FTLD pathogenesis and reinforced the notion that ALS/FTLD is 
a ‘proteinopathy’. 
Meanwhile, many genes linked to ALS and FTLD were found to encode for DNA/RNA 
binding proteins and/or to influence RNA metabolism. Indeed, in addition to already known TDP-
43, FUS and C9ORF72,mutations in several other RBPs were recently identified, in particular 
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TAF15 (153) and EWSR1(154), two proteins from the same family as FUS, and some that are 
less closely related RBPs such as ataxin 1, ataxin 2, hnRNPA2B1, hnRNPA1, matrin-3 and 
CREST(155–159). Consequently, the aberrant RNA metabolism was proposed as crucial in the 
pathogenesis (reviewed in(160)) (Figure 16). 
Under physiological conditions, these DNA/RNA-binding proteins are largely nuclear, and 
a fraction of the mere known to also translocate to the cytoplasm. Disease-associated mutations 
are either located in highly unstructured protein domains with prion-like properties, resulting in a 
higher propensity to aggregate (155), or in the vicinity of the nuclear localization signal (NLS) 
impairing nuclear import of the mutant protein, with concomitant sequestration of the 
endogenous wild-type protein into cytoplasmic aggregates, often leaving the nucleus entirely 
depleted of the affected protein (161). 
Altogether, these findings highlight that errors in RNA metabolism may be central 
to ALS and FTLD pathogenesis. 
These insights shifted the focus from ‘ALS/FTLD as a proteinopathy’ to ‘ALS/FTLD as 
a ribonucleopathy’(162). 
However, these two pathways are not mutually exclusive. Indeed, the failure to maintain 
proper protein and RNA homeostasis drives a feed-forward cycle that leads to perturbation of 
many aspects of protein and RNA functions (Figure 16). This became clear when it was 
discovered that both TDP-43 and FUS regulates expression of genes involved in protein 
clearance.  For instance FUS binds to the mRNAs encoded by genes like OPTN (163,164), 
UBIQUILIN-2 (164,165), and VCP (163–165). As for TDP-43, it affects the mRNAs levels of 
CHMP2B, OPTN, VAPB, and VCP (4,166) (Figure 16). 
Thus far, altered RNA granule formation, self-aggregating properties of prion-like 
domains and dysfunction of the protein quality control system, have been suggested to 
contribute to protein aggregation in ALS and FTLD. 
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Figure 16. Common cellular pathomechanisms among ALS and FTLD  protheinopathies 
 
(1) TDP-43 is a DNA- and RNA-binding protein involved in RNA processing. Natively folded 
TDP-43, shown in the nucleus, regulates RNA splicing. As a nucleocytoplasmic shuttling protein, 
TDP-43 is also involved in cytoplasmic RNA processing including the stress granule response 
and RNA transport. (2) C9ORF72 mutation causes the sequestration of RNA-binding proteins, 
which impairs RNA processing. C9ORF72-mediated ALS also manifests with accumulation and 
aggregation of TDP-43. (3) MATR3, hnRNPA1 and hnRNPA2B1 mutations also impair RNA 
processing and induce TDP-43 proteinopathy, likely through direct binding interactions with 
TDP-43 which influence its folding and function. (4)FUS mutations are thought to cause ALS, 
independent of TDP-43 proteinopathy, via impaired processing of transcripts that may be 
common to those targeted by TDP-43. (5) Mislocalization of excess TDP-43 to the cytoplasm 
can be promoted by (6) TARDBP mutations and (7) environmental stressors, both of which also 
promote (8) TDP-43 fragmentation. (9) Cleaved and mislocalized TDP-43 species are prone to 
misfolding and aggregation, which is associated with the addition of phosphorylation and 
ubiquitin chains. (10) The ubiquitin proteasome system (UPS) and autophagy ordinarily serve to 
maintain TDP-43 homeostasis; however, in ALS these protein degradation systems fail to 
prevent the accumulation of TDP-43, thus favoring the formation of large protein complexes 
called aggresomes. (11) Mutations in VCP, UBQLN2, andSQSTM1 can impair protein 
degradation. (12) Aberrant RNA processing, and particularly stress granule formation, may 
promote the aggregation of TDP-43. (13) Conversely, TDP-43 misfolding and aggregation 
impairs RNA processing function, and sequesters TDP-43 in a dominant-negative fashion. 
Strategies that prevent TDP-43 misfolding and/or enhance clearance of pathological TDP-43 
have the potential to prevent RNA processing deficits and pathogenesis in the majority of ALS 
cases. P = phosphorylation; Ub4 = tetra-ubiquitin chain 
Reproduced from : Scotter, Chen & Shaw. Neurotherapeutics., 2015 
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1.2. Degeneration of neurons in ALS and FTLD 
Motor neuron death was the first histopathological phenomenon described in ALS and 
FTLD. To date, the disease mechanisms behind this neurodegeneration remain unknown. While 
for a long period motor neuron death has been considered as an intrinsic neuronal process, it is 
now accepted that other cells are involved including astrocytes and microglia and skeletal 
muscle cells (167–172). 
The role of astrocytes in ALS has been shown using in vitro co-cultures of healthy motor 
neurons with astrocytes from either transgenic ALS mouse models (167) or from patients 
bearing a SOD1 mutations (168). Astrocytes expressing mutant SOD1 induced motor neuron 
death via the secretion of toxic factors. This showed that the toxicity of astrocytes in  ALS is a 
general process that is not specific  to the expression of a mutant SOD1 gene. 
Furthermore, the muscle tissue appears as a player in the pathology (169).This 
hypothesis is supported by the fact that the muscle exerts a direct influence on the neurons from 
which it receives innervation (170). More specifically, muscle hypermetabolism is sufficient to 
induce a partial denervation and motor neuron disease (171). Muscle-specific expression of a 
double mutant of SOD1 (G37R and G93A),or of the wild human SOD1, is sufficient to trigger 
muscle atrophy, degradation of the neuromuscular junction (NMJ), axonopathy and 
degeneration of the motoneurons (MN) (172). 
In FTLD, the massive atrophy of frontal and temporal lobes suggests a massive loss of 
neurons and/or glial cells. Only one type of degenerative neurons in FTLD have been identified: 
the Von Economo neurons (VE neurons). VE neurons are large bipolar neurons present in the 
layer V of the anterior cingulate cortex, and representing approximately 5% of the neurons in this 
area (173). Although, the function is not precisely known, their location suggests a role in 
complex social interactions. This selective degeneration of VE neurons has been recently 
described in a small group of patients with sFTLD and having a type of FTLD-TAU 
histopathology or FTLD-U. The authors showed a loss of 74% VE neurons compared to control 
subjects (174). The loss of VEN neurons in FTLD patients has been confirmed in two other 
studies and seems to occur in early stages of FTLD, suggesting that these neurons are among 
the neuronal population targeted by the disease (175,176). 
 
1.3. Neuroinflammation in ALS and FTLD  
Neuroinflammation is characterized by the activation of glial cells astrocytes and 
microglia, the release inflammatory factors such as cytokines and the infiltration of immune cells 
into the cerebrospinal fluid (CSF) upon blood brain barrier injury. 
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Microglias are the principal inflammatory cells of the central nervous system (CNS) and 
are considered as the macrophages of CNS. Their activationis defined as a proliferation, a 
change in morphology, and an increased capacity of phagocytosis (177). 
Astrocytes have a supporting role in the physiology of neurons, especially in the 
formation and the maintenance of synapses, the recycling of neurotransmitters and the energy 
intake (reviewed in (178)). Under condition of neuroinflammation, the activation of astrocytes 
results in their proliferation, their migration to an injured area and the overexpression of the Glial 
Fibrillary Acidic Protein (GFAP). 
The presence of neuroinflammation in ALS was demonstrated by revealing the presence 
of activated astrocytes in the brain (179), and in the spinal cord of patients (180). Because these 
studies were conducted on post mortem tissues from patients that had reached the final stage of 
the disease, it was not possible, at the time, to determine whetherthe observed 
neuroinflammation was a consequence of the death of motor neurons or whether it had actively 
participated to the neurodegeneration process. 
On the opposite, the ALS transgenic models indicates an active role of astrocytes and 
microglia in neurodegeneration. Firstly, overexpression of GFAP has been reported in the spinal 
cord of G93A SOD1 mice prior to motor neurons death (181). Second, a couple of studies 
elegantly showed that the targeted decrease of conditional SOD1 G37R expression either in 
microglia, or in astrocytes, was sufficient to increase mutant mice survival (182,183). Thus, 
expression of the mutant gene in these two cell populations affects disease onset and 
progession. 
Neuroinflammation was also highlighted in FTLD. The presence of activated microglia 
and astrocytes was reported in the brains of patients (184,185). It was published that astrocytic 
activation in the frontal cortex is positively correlated with the level of atrophy and that microglial 
activation in the white matter  is present from the early stages of the disease (186). Another 
study confirmed that astrocytic activation is present at stages that proceed pathology, before the 
massive neurodegeneration (187). More generally, an increase in pro and anti-inflammatory 
cytokines was demonstrated in the CSF of FTLD patients (188). These studies suggest an 
important role of glial activation and inflammation in the disease. However, they did not show 
whether neuroinflammation is beneficial or detrimental to neurons. Alongside to astrocytic 
activation, several studies showed degeneration of astrocytes in the brain of FTLD patients 
(189). 
The role of microglia and astrocytes in the FTLD has also been studied in animal models. 
Neuroinflammation has been observed in many transgenic FTLD models, including those based 
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on the mapping expression TDP-43 (190), MAPT (191), CHMP2B (192), PGRN (193) and FUS 
(194–198). Yoshiyama et al. showed that microglial activation appears early in the pathology in a 
mouse model of FTLD based on the expression of tau P301S. They also showed that 
immunosuppression in this model is beneficial for the survival of neurons. Furthermore, a study 
published in 2005 showed that a conditional overexpression of MAPT in astrocytes induced the 
accumulation of hyperphosphorylated and ubiquitinated TAU in these, accompanying the 
neurodegeneration (199). These studies therefore indicate involvement of astrocytes in 
neurodegeneration at least in the FTLD positive TAU inclusions. Conversely, another study 
using a model based on PGRN inhibition showed that the behavioural impairment observed in 
these mice was independent of astrocyte activation and inflammation (200). 
Altogether ALS and FTLD are now considered as two extremes of a clinic-
pathological disease spectrum commonly referred to as ALS/FTLD and set forth FUS as 
one of the important common key player between both diseases. 
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II. FUS – A MULTIFUNCTIONAL RNA/DNA BINDING PROTEIN 
A. FUS structure and physiological role 
FUS was identified about 20 years ago as a fusion oncogene in human myxoid 
liposarcomas, hence its name (FUSed in sarcoma) (201). FUS is also known as Translocated in 
liposarcoma (TLS). Mutations in FUS  were reported to cause ALS in 2009, and deposition of 
FUS in pathological protein inclusions in ALS cases carrying FUS mutations was also observed 
(50,51). Immediately after these initial genetic pathological discoveries linking FUS to ALS, FUS 
inclusions were also found in the brains of a subset of FTLD patients despite the absence of 
FUS mutations in these patients (29,146,202). 
 
1.  Gene structure of FUS 
The FUS gene is located on chromosome 16 and contains 15 exons encoding a 
multidomain protein consisting of 526 amino acids (Figure 17). It belongs to a group of 
DNA/RNA binding proteins that share typical structures, including a N-terminal transcriptional 
activation domain (QGSY, 165 amino acids), adjacent to a glycine rich region (RGG1), followed 
by RNA recognition motif region (RRM, 86 amino acids). This RRM contains a nuclear export 
signal (NES) of eleven amino acids, located near by the N-terminal end. In C-terminal, a 31 
amino acid-zinc finger domain (ZnF) is found embedded in between two glycine rich regions 
(RGG2 and RGG3) creating a 130 amino acids-domain. The last 19 C-terminal amino acids of 
FUS delineate an atypical nuclear localization signal, containing proline and tyrosine residues 
(PY-NLS, later referred to as NLS) (203,204) (Figure 17). 
At least one specific role for each protein domain of FUS has been documented. The N-
terminal QGSY-rich domain functions as a potent transcriptional activation domain (205,206). 
This specific role as transcriptional activator has been well described since FUS was recognized 
to have an oncogenic properties .In addition, the QGSY-rich domain is directly implicated in the 
aggregation of FUS in vitro (207,208), and this has been linked to its prion-like features 
(209).(207,208)(207,208) The three glycine rich regions (RGG), together with the RNA recognition 
motif (RRM) and the zinc finger domain (ZnF) are required for nucleic acid binding (210,211). 
However, the way FUS binds to nucleic acids and the amino acids involved in this process still 
remain to be determined. Yet, different in vitro studies suggested that the RGG2-ZnF-RGG3 
domain is most likely the major RNA binding domain and has a preference for GU-rich 
sequences (212,213). 
Although, FUS predominantly resides within the nucleus, it constantly shuttles between 
the nucleus and the cytoplasm. FUS nuclear import is mediated by the binding of this PY-NLS 
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(204) to the nuclear import receptor Transportin (also known as Karyopherinβ2) (151,203) 
(Figure17). 
Figure 17. FUS gene structure :schematic representation of the FUS transcript and its specific 
domains 
 
FUS has 526 amino acids and contains several conserved domains: SYGQ, RGG, RRM, E, NLS 
and ZnF. Numbers under the protein line indicate the boundaries of each domain. The putative 
prion domain of FUS comprises amino acids 1–239 and 391–407. E, nuclear export signal; NLS, 
nuclear localization signal; RGG, Arg–Gly–Gly-rich motifs; RRM, RNA-recognition motif; QGSY, 
Ser–Tyr–Gly–Gln; ZnF, zinc-finger motif 
Reproduced from Deng, H. et al., Nat. Rev. Neurol.2014 
 
2. Physiological role of FUS  
FUS is ubiquitously expressed during embryogenesis, but its expression is rapidly 
downregulated in the peripheral organs during postnatal development. FUS remains expressed 
at significant levels in neurons throughout the lifetime, suggesting that FUS may exert important 
functions in the central nervous system (214). 
FUS protein has been now recognized to play a role in a number of critical cellular 
functions. These include nuclear functions, such as DNA repair and maintaining of genomic 
integrity, regulation of transcription, and pre-mRNA processing, as well as cytoplasmic functions 
such as RNA transport, local translation, microRNA biosynthesis as well as multiple protein-
protein interactions. These different functions are detailed below. 
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2.1. DNA repair 
DNA repair is defined as the processes by which a cell identifies and corrects damage to 
the DNA molecules that encode its genome. Many proteins were shown to be involved in DNA 
damage response, repair and protection (215). 
FUS binds to denatured single-stranded DNA and promotes its annealing to 
complementary single stranded DNA and D-loop formation (216) (Figure 18, a). Moreover, FUS 
is also phosphorylated by ATM following the induction of double strand breaks and is involved in 
regulation of gene expression induced by DNA damage (217,218). FUS does not only take part 
to DNA damage response has also a pivotal role in neuronal DNA repair via its direct interaction 
with the histone deacetylase 1 (HDAC1) (218). 
Consistent with a major role in genomic stability, Fus knockout mice show genomic 
instability as well as enhanced radiation sensitivity (219–221). 
Defects in DNA repair have been extensively linked to neurodegenerative diseases 
(218). Together, these emerging findings suggest that FUS plays an important role in the 
preservation of genomic integrity trough DNA repair mechanism, which could be affected 
by disease associated FUS mutations. 
 
2.2. Transcriptional regulation and gene expression 
Transcriptional regulation is the means by which a cell regulates the synthesis of RNA 
from the DNA matrix, thereby controlling gene expression. The regulation of transcription is a 
vital process in all living organisms and is orchestrated by transcription factors and other 
accessory proteins working in concert to finely tune the nature and the amounts of RNA being 
produced through a variety of mechanisms.  
The N-terminal QGSY-rich domain of FUS functions as a potent transcriptional activation 
domain in oncogenic fusion proteins (205,206), suggesting a fundamental role in transcription 
initiation and/or elongation. Indeed, several studies identified an interaction of the FUS protein 
with integral components of the transcriptional pre-initiation complex (PIC), including RNA 
polymerase II and the TFIID complex (Figure 18, b,c) (222,223). FUS has been reported as 
acting as co-regulator, by modulating the transcription of target genes through association with 
nuclear hormone receptors and gene-specific transcription factors (such as Spi-1/PU.1, NF-κB 
and Runx2) (224–226). In addition, by binding to non-coding RNAs,and by inhibiting the acetyl-
transferase activities of CREB-binding protein (CREB) and p300, FUS interferes with 
transcriptional repression of cyclin D1 and RNA polymerase III (227,228). FUS also 
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associates with TBP and TFIIIB to repress transcription of small structural and catalytic RNAs by 
RNAP III (227). 
Last, FUS is able to bind to the promoter region of several genes transcribed by RNA 
polymerase II to regulate their expression (229). Indeed, a recent study identified potential FUS-
response elements of many target genes, indicative of transcriptional activation or repression 
directly by FUS (229). Additionally, FUS and protein arginine methyl transferases (PRMT1) 
synergistically coactivate transcription initiation at the survivin promoter (230). The extent of FUS 
targets remains to be identified, and is likely to be different from one cell type to another. 
Thus, FUS strongly affects expression of specific target genes, that remain to be 
fully identified.This suggests that critical patterns of gene expression could be changed 
upon FUS mutations, contributing to the FUS related pathology. 
 
2.3. mRNA Splicing 
Splicing is a modification of the nascent pre-messenger RNA (pre-mRNA) transcript in 
which introns are removed from the pre-mRNA, leading to the generation of a mature mRNA 
consisting exclusively of exons. For nuclear encoded genes, splicing takes place within the 
nucleus after or concurrently with transcription. Splicing is needed for the messenger RNA 
(mRNA) before it can be used to produce a correct protein through translation. Splicing is 
performed by a large complex of small nuclear ribonucleoproteins (snRNPs) called spliceosome. 
FUS has been identified as part of the spliceosome machinery with a role in splicing 
regulation of pre-mRNA by three independent proteomic studies (231–233) (Figure 18, d, e). 
Recently, it was shown that FUS directly associates with several components of the 
spliceosomal complex, among which SMN protein was the major partner (234,235). As well, 
FUS was required for the formation of nuclear gems, substructures that are involved in the final 
stages of snRNP modification and assembly (234,235). 
The identification of RNAs bound to FUS is a first step to understand the role of FUS in 
RNA splicing. Using crosslinking and immunoprecipitation (CLIP) followed by high-throughput 
sequencing or RNA immunoprecipitation (RIP) and then by microarray analysis, several groups 
published global RNA targets of FUS (163–165,236,237). These studies reveal that FUS binds 
to several thousand different pre-mRNAs, preferentially to long introns and less frequently to 
exons and 3′UTRs. Full length FUS was bound to mRNAs introns 70% of the time, while mutant 
FUS only interacted with the intronic regions 13% of the time, and with 3′ UTRs 61% of the time. 
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RIP-chip analysis, showed that the mature mRNA targets or “targetome” of FUS in the 
cytoplasmic compartment of the motor neuron-like cells are related to general cellular activities, 
including DNA repair, cell cycle, and RNA processing (163). 
Furthermore, FUS also regulates its own expression by alternative splicing of exon 7 and 
nonsense-mediated decay (238). 
In all, these findings suggest that splicing alterations in response to FUS 
mutations may be relevant and possibly contribute to neurodegeneration. 
 
2.4. RNA biogenesis and processing 
FUS is a component of the large Drosha complex, an RNase III enzyme that is required 
for microRNA biogenesis (239) (Figure 18, f). FUS might stimulate microRNA biogenesis by 
facilitating co-transcriptional Drosha recruitment. In one suggested paradigm, processing of 
specific miRNA families requires interaction with RNA-binding proteins (240). FUS is recruited to 
chromatin at sites of their transcription and binds the corresponding pre-microRNAs. Moreover, 
FUS depletion leads to decreased Drosha levels at the same chromatin loci and to a reduced 
microRNA biogenesis. Many of microRNA species modulated by FUS depletion are involved in 
neuronal function, differentiation and synaptogenesis. 
A possible link between FUS mutations and altered neuronal microRNA biogenesis 
in neurodegeneration was suggested (241). However, the precise function of FUS in these 
cellular processes is still poorly characterized.  
 
2.5. RNA transport and local translation 
A function of FUS in RNA transport was first suggested by the observation that FUS 
shuttles between the nucleus and cytoplasm while bound to RNA (211). In addition, complexes 
of FUS and mRNA is translocate to neuronal dendrites and spines in response to neuronal 
activity. Dendritic transport of FUS seems to depend both on microtubules and actin filaments 
(Figure 18, g,h,i) (211,242). This  process seems to be essential for local protein synthesis 
(local translation) (Figure 18, i) and synaptic plasticity (243). As noted above, RNA 
immunoprecipitation (RIP) followed by microarray analysis identified several hundred cytosolic 
mRNA targets of FUS in the motor neuron-like cell line NSC-34 (163). 
Whether FUS mutations impact RNA transport remain to be determined by further 
studies. 
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2.6. Protein interactions  
A number of direct protein-protein interactions are required for FUS functions in RNA 
metabolism, including SMN (234,235), HDAC1 (218) or PRMT1 (244) and have been detailed 
earlier. 
Figure 18. FUS displays diverse physiological roles 
 
 (a) FUS has DNA homologous pairing activity and is important for the repair of DNA double 
strand breaks. (b) FUS interacts with the transcriptional pre-initiation complex (e.g. RNA pol II 
and the TFIID complex) and with gene-specific transcription factors. (c) FUS also directly binds 
to specific DNA sequences in the promoter region of certain target gene. (d)FUS affects 
alternative splicing by interacting with intronic regions near splice sites and subsequently 
recruiting the spliceosome or other splicing factors, such as hnRNPs or SR proteins, to the 
nascent pre-mRNA. (e) FUS interacts with both the transcriptional machinery and the splicing 
machinery and therefore has been proposed to couple transcription to splicing. (f) FUS is a 
component of the large Drosha complex, an RNase III enzyme that is required for microRNA 
biogenesis (g) FUS shuttles between the nucleus and cytoplasm and thus might play a role in 
mRNA export. From the cytoplasm FUS, is imported back to nucleus via TRANSPORTIN (h) In 
neurons, FUS is involved in the transport of specific mRNAs, to dendrites and dendritic spinesvia 
an associationwith actin or microtubules. (i) This may regulate local translational of localized 
mRNAs and may be important for synaptic function. (j) FUS is involved in stress granule 
formation, however it is still not clear if it is physiological function. Yellow color represents FUS 
subcellular localization which is predominantly nuclear.  
Reproduced from Dormann D & Haass C Mol. Cell. Neurosci. 2013. 
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In general, an important issue in understanding the FUS pathogenic mechanisms 
in neurodegeneration is to get detailed insight of FUS physiological role. Of outmost 
importance is to define the full set of transcripts that are directly bound and post-
transcriptionally regulated by FUS in association with splicing, in particular in neuronal 
cells. 
 
B. Neurodegenerative disorders with FUS pathology 
Alongside with involvement in ALS and FTLD, immunostaining for FUS revealed intense 
reactivity in some other neurological diseases like in Huntington's diseaseas well as 
spinocerebellar ataxias 1 and 3, and neuronal intranuclear inclusion body disease (245–247). 
 
1. FUS mutations related to FUS proteinopathies - ALS-FUS / FTLD-FUS  
At the time of writing more than 50 mutations in the Fus gene have been identified in ALS 
and very rarely in FTLD (Figure 19). This gene accounts for a small percentage of fALS cases 
(~4%), and fFTLD cases (~1%), and it is also found in sALS cases (~1%). 
The majority of ALS-linked mutations of FUS are clustered in or around the nuclear 
localisation signal (NLS). By causing the disruption of the binding of FUS protein to transportin, 
these mutations prevent the nuclear import of FUS and result in the cytoplasmic accumulation of 
the mutant FUS (203,248,249). Along with these dominantly inherited missense mutations, 
several truncating or frameshift mutations of FUS have been identified in ALS that result in the 
complete deletion of the NLS (250).The inheritance pattern of these mutations is autosomal 
dominant, except in one family of Cape Verdean origin, FUSH517Q, which seems to display a 
recessive pattern (50) (Figure 19). Recently, a second mutation in a homozygous state was 
identified, a single base deletion in the FUS gene (FUSc.1486delG) leading to a frameshift and a 
premature codon termination (251). 
Reports of FUS mutations in patients with clinical FTLD are rare, and only four FUS 
mutations have so far been identified in patients with ALS/FTLD or in their families. Two patients 
with FUS mutations (p.R521H, and p.G156E) had ALS with FTLD features (252,253), and a two 
additional mutations (p.G206S and p.R521C) were identified in families affected by ALS/FTLD 
(254). One patient with a p.M254V mutation and another patient with a p.P106L mutation 
presented with FTLD without motor neuron signs (255). However, no autopsy data or functional 
analyses from mutation carriers were available to confirm FUS pathology in any of these patients 
with FTLD. Until now, no FUS mutations have been found in any patient with pathologically 
confirmed FTLD-FUS (29,144). 
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Although, ALS is the most common phenotype observed upon FUS mutation, ALS-
FTLD or FTLD alone also occur. 
Amongst the ALS-FUS patients, the proportion of bulbar and spinal onsets are similar to 
that of typical ALS. An aggressive phenotype is associated with FUSP525L, 
FUSc.1554−1557delACAG, FUSG478LfsX23 and, to a lesser degree, FUSR495X. Of note all 
these mutations are located in the NLS, affect patients in the first or second decade of life and 
are fatal after half of a year (143,256,257).The newly described homozygous frameshift deletion 
in FUS (p.Gly496Glyfs*31) was observed in a male patient with an upper limb onset at 39 years 
(251). His family history was negative for ALS or other neurodegenerative disorders. The patient 
died 12 months after the disease onset because of a rapidly worsening respiratory failure. This 
FUS mutation causes a frameshift in the 3′ end of the gene, coding for the NLS, which once 
again confirms that the NLS of FUS represents a mutational hot-spot in ALS patients. This 
further corroborates the link between mutations leading to NLS deletion and aggressive ALS 
phenotype. 
Although, clinical presentation is widely variable, patients with the FTLD-FUS usually 
develop a rapidly evolving FTD syndrome, mostly bvFTD, sometimes in combination with 
motor neuron symptoms (258). 
Histologically, brain and spinal cord tissue from patients with FUS mutations showed 
severe motor neuron loss in the spinal cord, and to a lesser extent in the brain stem. Mild to 
moderate upper motor neuron loss was seen in the motor cortex. FUS-immunoreactive 
cytoplasmic inclusions, ubiquitin- and p62-positive were  found in spinal cord of FUS patients 
(50,51). 
Pathologically, FTLD-FUS was characterized by severe, usually asymmetric atrophy of 
the frontotemporal cortex in patients. As already mentioned, an accumulation of FUS protein in 
inclusions was associated with this clinicopathological type of FTLD (29,145–147)(Table 3, 
Figure 19). FUS-immunoreactive cytoplasmic inclusions are usually ubiquitin- and p62-
positive (29,128,256). However, FUS protein itself is not ubiquitinated, hyperphosphorylated or 
cleaved, yet insoluble (29). FUS immunohistochemistry also shows normal nuclear levels in 
many neurons and glial cells(29). It is important to repeat that inclusions in a subset of sporadic 
FTLD-FUS casesare immunoreactive for the full-length FUS protein, together with TAF15, 
EWSR1and transportin-1 (149,150). 
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Figure 19. Schematic representation of the FUS gene mutations identified in patients with 
neurodegenerative diseases 
 
*
The pathogenicity of many mutations identified in patients with FTLD still needs to be validated. 
‡
Mutations identified in patients with ALS and FTLD, or in their families. 
§
Mutations identified in 
patients with ALS, and in those with essential tremor. 
||
Mutations identified in patients with 
essential tremor. 
¶
Mutations identified in patients with ALS, and in those with both ALS and 
FTLD. Abbreviations: ALS, amyotrophic lateral sclerosis; E, nuclear export signal; FTLD, 
frontotemporal lobar degeneration; NLS, nuclear localization signal; RGG, Arg–Gly–Gly-rich 
motifs; RRM, RNA-recognition motif; SYGQ, Ser–Tyr–Gly–Gln; ZnF, zinc-finger motif 
Reproducedfrom Deng, H. et al. Nat. Rev. Neurol.2014 
 
2. Similarities and differences related to FUS proteinopathies - ALS-FUS/FTLD-FUS  
Although, FUS accumulation is the common denominator of ALS-FUS and FTLD-FUS, 
significant genetic and pathological differences have been observed for ALS-FUS and FTLD-
FUS. 
 First, ALS-FUS was always associated with a genetic defect in the FUS gene (50,51), 
while FTLD-FUS was only rarely associated with FUS mutations (29,252–255,259,260). 
Second, ALS-FUS was characterized by the selective deposition of FUS, while FTLD-
FUS showed co-accumulation together with TAF15, EWSR1 and their nuclear import receptor 
Transportin (149,150) reviewed in (262). In all FTLD-FUS subtypes, FUS-positive pathology was 
also labeled for TAF15 and EWRS1 and cells with inclusions showed a reduction in the normal 
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nuclear staining of all FET proteins. In contrast, in cases of ALS-FUS, TAF15 and EWSR1 
remained localized to the nucleus and did not label FUS-positive inclusions (149,150). 
Third, in ALS-FUS, deposited FUS was methylated on arginine residues, but not in 
FTLD-FUS (151,262). 
Together, these findings strongly suggest that neurodegeneration is directly related to 
the subcellular redistribution of FUS rather than only due to mutations. 
 
3. Possible mechanisms of FUS toxicity - Loss vs gain of function 
A two-hit model, which is similar to the one mentioned above for TDP-43, has been 
proposed to underlie FUS toxicity (203,248). The first step involves the exit of FUS from the 
nucleus and the second step involves the irreversible formation of stress granule-based 
inclusions. Indeed, most mutations in FUS disrupt nuclear import and cause a cytoplasmic 
mislocalization of FUS. It seems that nuclear import defect is a key event in ALS pathogenesis, 
since mutations that cause a very severe nuclear import block (e.g. P525L) are characterized by 
an unusually early disease onset and rapid disease progression (203,248) (Figure 19). 
FUS–mediated toxicity could either rely on a reduced ability of FUS to perform its normal 
nuclear functions referred to as loss of function, or on a toxic gain of function of FUS in the 
cytoplasm - an acquired adverse effect of its pathological presence in the cytoplasm. 
As ALS caused by mutated FUS is most often inherited in an autosomal dominant 
manner, it suggests that the toxicity is the result of a gain-of-function for FUS. However, if 
mutated FUS has lost a function or if mutated FUS is binding to DNA, RNA, or protein and 
abrogating their normal functions, then a loss of function would be indicated. The third 
possibility is a combination of these two mechanisms. 
However, it is currently unknown whether mutant FUS causes toxicity owing to a toxic 
gain-of-function mechanism, a loss-of-function mechanism or both.  
Current evidence suggest that FUS-induced pathology could arise from one of the 
following aspects. 
 
3.1. Alteration of gene expression and splicing 
Gene expression andsplicing alteration may be involved in FUS toxicity (Figure 20, a-f). 
As already mentioned above several groups published results for the global RNA targets of FUS 
(163–165,236,237). 
ALS-associated FUS mutants expressed in HEK 293 cell lines bind to very different RNA 
targets compared to wild type FUS (165). It was shown that mRNAs for endoplasmic reticulum 
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and ubiquitin proteasome-related target gene categories were overrepresented in transcripts 
bound by mutant FUS proteins with cytosolic mislocalization (165). In a motor neuron-like cell 
line, FUS has been preferentially bound to cytoplasmic mRNAs that are involved in the ubiquitin-
proteasome pathway, in particular the cullin-RING E3 ubiquitin ligases (163). As well as, other 
studies confirmed that FUS binds to the mRNAs encoding genes responsable for protein 
clearance and  involved in ALS and/or FTLD: OPTN (163,164), UBIQUILIN-2 (42),and VCP 
(42,44).  
The role of FUS in splicing has also been shown by performing loss of function studies. 
Indeed, shRNA-mediated knockdown of FUS in primary mouse neurons revealed 78 FUS-
responsive exons (236), while a similar number of splicing changes were detected in embryonic 
brains of Fus knockout mice (237). Last, antisense oligonucleotide-mediated depletion of FUS in 
adult mouse brain or in embryonic brains of Fus knockout mice found splicing changes in >300 
genes (164).  
Interestingly, a common finding from different groups was that FUS-regulated splicing 
events are essential for neuronal integrity and function. For instance, one neuronal gene whose 
splicing was consistently altered by the loss of FUS in all three studies is the microtubule 
associated protein TAU (encoded by MAPT, known to be one of the major genes mutated in 
FTLD). This is in accordance with a results published by Orozco and colleagues (263) that 
showed that in the absence of FUS, inclusions of Tau exons 3 and 10 increase in Tau mRNA 
leading to a shift in TAU isoform in an analogous manner like in TAU mutations associated with 
FTLD (59). 
Altogether, the evidence strongly suggests that FUS mutations alter gene 
expression and splicing. The underlying mechanisms of FUS toxicity might be either 
nuclear loss of function of FUS or toxic gain of function of FUS mutants. 
 
3.2. Defective stress granule and protein aggregation 
Stress granules are dense cytosolic ribonucleoprotein (RNP) complexes that negatively 
control mRNA translation in condition of cellular insults. Stress granules might help to protect 
RNAs from harmful conditions, thus their appearance under stress (264). Environmental stress 
triggers a series of signals, which early on involve phosphorylation of eukaryotic translation 
initiation factor eIF2α, then downstream-prion-like aggregation of the proteinTIA-1 leads to the 
formation of stress granules. 
Localization of mutant FUS in stress granules, has been recently and widely 
demonstrated suggesting a new pathological mechanism of  FUS (161,212,249,265–267) 
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(Figure 20, j). Moreover co-deposition of stress granule marker proteins with FUS is a common 
finding in ALS-FUS and FTLD-FUS supporting a role for stress granules in their pathogenesis 
(203). 
Some authors proposed an interesting hypothesis whereby cytoplasmic mislocalization 
under cellular stress induces FUS incorporation  into stress granules together with several RNA-
binding proteins and RNA molecules. This physiologic reaction might lead to irreversible 
aggregates due to defects in stress granule disassembly that occurr : upon chronic cellular 
stress or with aging (as a second hits), or facilitated by disease causing FUS mutations (203).  
In all, mutated FUS by gaining toxic function eventually could lead trough stress 
granule to irreversible pathological aggregation or cytoplasmic aggregates may 
sequester normal FUS (268), disrupt RNA processing and initiate motor neuron 
degeneration trough FUS loss of function. 
 
3.3. Prion-like properties 
A prion is a protein that can fold in multiple, structurally distinct ways, at least one of 
which is transmissible to other prion proteins. It is this form of replication that leads to disease 
that is similar to viral infection. While several yeast proteins have been identified as having 
prionogenic properties, the first prion protein was discovered in mammals and is referred to as 
the major prion protein (PrP). While PrP is considered the only mammalian prion, prion-like 
domains have been found in a variety of other mammalian proteins. Some of these proteins 
have been implicated in the ontogeny of age-related degenerative disorders such as ALS, FTLD, 
Alzheimer's disease, and Huntington's disease (269). This has given rise to the 'prion paradigm', 
where otherwise harmless proteins can be converted to a pathogenic form by a small number of 
misfolded, nucleating proteins (270). 
By scouring the human genome with an algorithm designed to detect RNA-binding 
proteins harboring a canonical RNA recognition motif (RRM) and a putative prion domains FUS 
and TDP-43, were rank as 1stand 10th among RRM-bearing prion candidates (270). Afterwards, 
it was proposed that misfolded FUS propagating from cell to cell in a prion-like fashion, might be 
involved in neurodegeneration (270,271).The FUS prion-like domains are located in the N-
terminal QGSY region of the protein (residues 1–239) and in the C-terminal RGG2 domain 
(residues 391–407) and both are required for FUS misfolding, aggregation and toxicity 
(208,209). 
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Despite this hypothesis is tempting it is not known yet how FUS mutations affect 
these prion-like properties as well how that contribute to the disease, through loss or 
gain of function. 
 
3.4. Post-translational modifications of FUS 
A major post-translational modification of FUS protein is methylation on arginin residues 
(R216, R218, R242 and R394), catalyzed by individual protein arginine methyl transferases 
(PRMT), in particuar PRMT1 (151,272). More important, FUS arginine methylation affects 
nuclear–cytoplasmic localization of FUS (151,272). One study showed that chemical or genetic 
inhibition of arginine methylation restored nuclear import of ALS-associated FUS mutants in 
HeLa cells or primary hippocampal neurons (151). Also, depletion of PRMT1 in mouse 
embryonic fibroblasts by gene knockout, or in human HEK293 cells by siRNA knockdown, 
diminished the ability of ALS-linked FUS mutants to localize to the cytoplasm. In murine spinal 
cord motor neurons, after shRNA-mediated PRMT1 knockdown ALS-linked FUS mutants were 
sequestered in the nucleus and cytoplasmic inclusions were reduced (272). Interestingly, only 
the inclusions seen in patients with ALS-FUS contain methylated FUS, whereas FUS aggregates 
in patients with FTLD-FUS are not methylated (151,262). 
In all, these findings suggest that arginine methylation might be important in FUS 
pathogenesis, further elucidation is however necessary. 
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Figure 20. Possible mechanisms of FUS toxicity 
 
 
(a-f) Mutation of Fus (represented with red star) might alter gene expression and/or splicing, as 
well as RNA microbiogenesis  (red dashed boxes), (g-i) Transport of specific mRNAsand local 
translational of localized mRNAs and may be disrupted by Fus mutations, j) Cytoplasmic 
mislocalization of mutated FUS protein, followed by cellular stress, might contributes to the 
transformation of stress granule to cytoplasmic aggregates that may sequester FUS  or other 
proteins and disrupt RNA processingk) Possible cell to cell spread (not yet tested for FUS) of 
prion-like aggregates may underlie (contribute to) disease spreading from a focal initiation, 
l)Post-translational modificiation could contribute to Fus toxicity (yet, it is still unknown how 
precisely). 
Yellow color represents FUS subcellular localization which is mostly mislocalized to cytoplasm if 
mutated due to impaired nuclear import by TRANSPORTIN.  
Reproduced from Dormann D & Haass C Mol. Cell. Neurosci. 2013. 
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C. Animal models of FUS related protheinopathies ALS/FTLD – remaining questions  
A key question in the field is how mutations in FUS cause neurodegeneration in ALS or 
FTLD. Different pathogenic mechanisms for FUS mutants including toxic gain-of-function, loss-
of-function, or a combination of effects have been hypothesized. Indeed, does the disease arise 
from a lack of normal FUS or some new, toxic action by the mutant protein? As in the case of 
TDP-43, either a gain of toxic properties or a loss of function owing to sequestration of these 
proteins in aggregates is plausible. 
Worldwide research effort is focus in answering this crucial question by generating 
different animal model. 
 
1. Non-rodent models 
Experiments in yeast (273,274), drosophila (275–279) and C. elegans (280,281) support 
the concept that cytoplasmic accumulation of FUS is toxic. 
A study conducted in yeast found that overexpression of human wild type WT FUS is 
toxic (273). In an independent study, ectopic expression of human full length FUS or ALS mutant 
FUSR524S and FUSP525L in yeast cells led to the formation of FUS punctate immunoreactive 
aggregates and dose-dependent cytotoxicity. Expression of N-terminal fragments or the C-
terminal fragment was sufficient for aggregate formation but did not cause any cytotoxicity (274). 
Taken together, these yeast models suggest that overexpression of either WT or 
mutant FUS is toxic in yeast cells, both N-terminal and C-terminal sequences are required 
for aggregation and cytoplasmic localization of FUS. 
Neuron-specific overexpression of full length FUS in Drosophila resulted in a dose-
dependent decrease in life span, and an impaired locomotor phenotype (276). Ectopic 
expression of either WT or mutant FUS in the motor neurons caused age dependent and 
progressive neurodegeneration such as axonal loss and functional defects including locomotive 
defects and tail lifting phenotypes. Yet, mutant FUS caused more toxicity as compared to WT 
FUS, suggesting that ALS-linked mutations of FUS acquired toxic gain of functions (277). By 
deleting the nuclear export signal (NES) FUS is trapped inside the nucleus. Deletion of the 
nuclear export signal strongly suppressed mutant FUS toxicity, suggesting that the cytoplasmic 
localization of FUS is a necessary step in causing the toxicity (275). In contrast, Xia et al. 
reported that FUS toxicity in Drosophila requires nuclear localization (278). 
Taken together, these studies demonstrate that, in Drosophila, the expression of 
mutant FUS is more toxic than that of WT FUS. 
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However, a recent study brought new insights in the problematic of FUS toxicity. 
Storkebaum et al., introduced cell-type-specific endogenous gene inactivation of cabeza (caz) 
(the Drosophila ortolog of human FUS). Neuron-selective caz inactivation was performed under 
temporal control; during development and in adult stage. Inactivation during development 
resulted in failure of pharate adult flies to eclose from the pupal case, and adult escapers 
displayed motor performance defects and reduced life span. Remarkably, selective caz 
inactivation in adult neurons did not affect motor performance and life span, indicating that 
neuronal caz is required during development, but not for maintenance of adult neuronal function. 
Together, these findings indicate that loss of neuronal caz function during 
development is necessary and sufficient to induce adult motor performance defects and 
shorten life span while later in life (partial) loss of neuronal FUS function may not be 
sufficient to cause adult motor neuron degeneration(279). 
Recently, a C.elegans model was generated by expressing WT or mutant FUS with ALS 
linked mutations using a pan neuronal promoter (280). Mutant FUS was predominantly localized 
in the cytoplasm and formed cytoplasmic aggregates as seen in human patients, while WT FUS 
was localized exclusively in the nucleus. The degree of cytoplasmic mislocalization of mutant 
FUS was correlated with the type of FUS mutations and the degree of neurodegenerative 
phenotypes seen in human ALS patients. Animals expressing mutant FUS demonstrated 
progressive motor defect and had a shorter life span as compared to WT FUS-expressing 
animals. Interestingly animals expressing WT FUS also showed motor defect, but that remained 
mild, suggesting that the mutant protein is more toxic than the wild type one (280). Transgenic 
worms expressing mutant FUS displayed adult-onset, age-dependent loss of motility, 
progressive paralysis and neuronal degeneration that was distinct from wild type alleles. 
Additionally, mutant FUS proteins are highly insoluble while wild type proteins remain soluble 
suggesting that protein misfolding may contribute to toxicity (281). 
In summary, these findings suggest that ALS-linked mutations in FUS cause 
neuronal dysfunction via a dominant gain-of-function mechanism and that mutant FUS 
aggregates lead to neurotoxicity in C. elegans. 
 
2. Rodent models 
2.1. FUS knockout and knockdown models  
So far three independent FUS knockout mouse models have been generated 
(219,220,234). Two independent groups reported FUS knockout (KO) mouse models long 
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before the identification of ALS-linked mutations in FUS but did not analyze their neurological 
phenotype. 
Back in 2000, Kuroda et al., developed the first FUS knockout model, the TLS–/– mice 
(hence its other name TLS for translated in liposarcoma), by disrupting the FUS gene in 
embryonic stem cells. In these mice, the coding region was interrupted inside the exon 8 
(immediately upstream of the RNA recognition motif) by a promoterless insertion cassette that 
created an allele encoding a truncated TLS–NEO fusion protein. Cells derived from the TLS–/– 
animals express no intact TLS protein, yet the TLS–NEO fusion protein encoded by the targeted 
allele is expressed at very low levels. HomozygousTLS–/–, male mice were completely sterile 
while females were less fertile. Mice exhibited increased sensitivity to ionizing irradiation that 
was consistent with a role for FUS in homologous DNA recombination, nowadays widely proven. 
More important, on the inbred 129svev background, rare mutant animals were alive at weaning, 
but none reached adulthood. The survival of TLS–/– animals of partially outbred background 
(with equal contribution of genes from the 129svev and CD1 strains) was virtually unimpaired. 
Other than their reduced size, the mutant animals appeared developmentally normal. The 
authors did not examine the neuronal phenotype and, to my knowledge, these mice were not 
further studied. Information about any phenotype related to ALS or FTD, at least in the surviving 
outbred mice, are lacking (220). 
Around the same time, Hicks et al., succeeded in making FUS knockouts. In their Fus–/– 
mice, the U3NeoSV1 gene-trap retrovirus was integrated into a region of genomic DNA 
homologous to exon 12 of human FUS. In this case, the provirus disrupted exon 12 of Fus, 
resulting in a null mutation and subsequently in the loss of wild-type Fus expression. Although, 
low levels of truncated Fus protein was also present, the authors claimed that it was unlikely to 
retain wild-type activity because the truncation removed essential domains that bind nucleic 
acids. Mice homozygous for the Fus mutation failed to suckle, and died within 16 hours of birth, 
only one Fus–/– mouse survived 2.5 days. Newborn Fus–/– mice were typically the smallest in 
the litter, otherwise, Fus–/– mice appeared to develop normally and histological examination of 
serial sections confirmed normal structure and development of all major organs and tissues 
(except smaller thymus gland). Interestingly, the Fus–/– mice demonstrated a reduction in the 
number of white blood cells. Furthermore, a majority of animals showed chromosomal 
abnormalities. These homozygous FUS-null mice died too soon to look for signs of an aging 
disease (219). 
In 2013, a third knockout model was published by Yamanaka et al., which were obtained by 
inserting b-Gal-neo cassette in between exons 2 and 3 of FUS gene (234).  
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FUS knockout mice were used to assess the importance of FUS for spliceosome integrity and 
gem formation. Their findings indicated that loss of FUS altered these processes, and suggested 
one more possible cellular mechanism for FUS loss of function. However, no other data 
regarding the phenotype of these mice are available. 
These findings describe physiological functions for FUS in a mouse model and 
indicate that FUS is essential for development and viability of neonatal animals, for the 
maintenance of genomic stability, DNA repair and splicing. 
 Results from these models, as well as potential remaining truncated FUS protein, 
have made it unclear whether FUS loss of function is required for ALS/FTLD pathology. 
A paper in April 2015, by Kino and Nukina (221), partially solved the problem. Authors 
started their experiments with Hicks’ black-6 animals that were missing just one copy of the Fus 
gene. To shuffle the background genotype, Kino out bred them to another strain – white ICR 
mice.The heterozygous offsprings were then intercrossed to obtain total Fus knockouts with a 
hodgepodge of black-6/ICR genomes. Unlike the original Hicks homozygotes, these mixed-
background knockout pups survived more than a day, but they could not compete with their Fus-
positive littermates for milk. When those robust siblings were removed from the cages, the Fus 
knockouts survived to adulthood and did not present anymotor phenotype. At a rotating rod – a 
common challenge for ALS mouse models, the knockouts performed same as their control 
littermates. At 90 weeks, Kino collected their spinal cords, and observed that the knockouts had 
similar numbers of motor neurons than controls. Mice missing the Fus gene lived to nearly two 
years with no signs of motor neuron disease. The authors concluded that the lack of motor 
neuron deficits suggests that FUS gain of function rather then FUS loss of function is the main 
pathophysiology in ALS. 
However, as evident by their small size and difficulty scrambling for milk after birth, the 
knock-out mice were not entirely normal. Homozygous knockout mice did not manifest ALS-like 
phenotype; instead they showed distinct behavioral and histological alterations. Compared to 
control mice, knockout mice were unusually active, they roved their cages more frequently, and 
spent more time exploring open and lighted areas. Thus, Fus knock-out mice developed some 
kind of hyperactivity disorder and reduction in anxiety-like behavior, as speculated by the 
authors. Their brains looked grossly normal, but some developed vacuoles in the hippocampus 
(221). 
This observation was strengthened by a group studying the consequences of FUS 
depletion. Udagawa et al., evaluated in vivo consequences of FUS depletion on synaptic 
functions. To this end, adeno-associated viruses (AAVs) expressing a shRNA targeting FUS 
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were stereotaxically injected into the mouse hippocampus. This area was chosen because the 
hippocampus is one of the most degenerated brain regions in FTLD/ALS patients and is involved 
in multiple aspects of behavior including learning and memory, emotions, anxiety, hyperactivity 
and social interactions. FUS knockdown mice interacted with the unfamiliar wild type intruder 
mouse as long as control mice did. The interaction time of the control mice gradually decreased 
over the course of four sessions. However, FUS knockdown mice interacted with the intruder to 
a similar extent over the four sessions, indicating that the FUS knockdown animals were 
deficient in social behavior. Thus, hippocampal FUS depletion caused a novelty-induced 
hyperactivity which might be responsible for social impairment, and could be reminiscent of 
typical FTLD symptoms (282). 
Altogether, these results suggest that that deficiency of FUS leads to behavioral and 
pathological abnormalities that might be relevant to neurodegenerative disorders, 
including FTLD. This suggests at least some contribution of FUS loss-of-function to 
neurodegenerative disorders. 
 
The major characteristic of FUS knockout and knockdown models are summarized in the 
Annex (Table 4) . 
 
2.2. Models with overexpression of wild type or mutant FUS 
Currently several rodent models stably overexpressing wild type FUS or expressing  
ALS-linked mutations in FUS have been published (194–198,283) (Table 5). 
To study the consequences of mutation in the FUS gene, transgenic rats ubiquitinously 
expressing the human FUS gene, with or without mutation, were generated  (195). Transgenic  
lines expressing  the human FUS, under tight control by Doxycycline (Dox) at substantial levels, 
were crossed with a CAG-tTA transgenic line to produce double transgenic offspring that 
expressed human FUS transgene in the absence of Dox. Breeding female rats were given Dox 
in their drinking water until delivery such that expression of the FUS  transgenes was recovered 
postnatally, after Dox withdrawal. Overexpression of a mutant FUS (FUSR521C substitution) 
induced progressive paralysis resembling ALS. Mutant FUS transgenic rats developed a 
progressive paralysis secondary to severe axonopathy of otherwise preserved spinal motor 
neurons, an atrophy of the skeletal muscles, and displayed a substantial loss of neurons in the 
cortex and hippocampus. Within neuronal cells FUSR521C subcellular distribution was affected 
to a minimal extent and was accompanied by FUS-negative ubiquitin-positive aggregates. Glial 
reaction was observed in the brain and spinal cord (195).  
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While transgenic rats that overexpressed the wild-type human FUS (WTFUS) were 
asymptomatic at young ages, they showed a deficit in spatial learning and memory and a 
significant loss of cortical and hippocampal neurons at advanced ages. Immunoreactivity to 
human FUS was detected in the brain and spinal cord where FUS mainly resided in the nucleus, 
but was also diffusely located in the cytoplasm. WT FUS rats accumulated ubiquitin; however 
FUS did not co-localize with ubiquitin (195). 
These results suggest that mutant FUS is more toxic to neurons than normal FUS 
and that increased expression of normal FUS is sufficient to induce neurodegeneration 
(195). 
Transgenic mice overexpressing wild-type human FUS (WTFUS), under the control of 
the mouse prion protein (PrP), central nervous system promoter developed an aggressive age- 
and dose- dependent phenotype with an early onset tremor followed by progressive hind limb 
paralysis and death by 12 weeks in homozygous animals. Large motor neurons were lost from 
the spinal cord accompanied by neurophysiological evidence of denervation and focal muscle 
atrophy. Surviving motor neurons in the spinal cord had greatly increased nuclear and 
cytoplasmic expression of FUS, with globular and skein-like FUS-positive and ubiquitin-negative 
inclusions. This was associated with astroglial and microglial reactivity. In the brain of the 
transgenic mice FUS inclusions together with diffuse cytoplasmic staining were also detected in 
the neurons without apparent neuronal loss and little astroglial or microglial activation. The 
increased expression of human FUS however was associated with a down-regulation of 
endogenous murine Fus in transgenic animals. Hemizygous FUS overexpressing mice showed 
no evidence of a motor phenotype or pathology after two years of age (196). 
Although, this phenotype recapitulates many behavioural and pathological 
aspects of ALS-FUS, deciphering if FUS overexpression is toxic in nucleus or in 
cytoplasm is hardly possible. Loss of endogenous murine Fus further complicates our 
understanding of the mechanism. Nevertheless, neurodegeneration observed in both 
mice and rats transgenic models somehow demonstrate that FUS overexpression per se 
is pathogenic. Both models support a toxic gain of function due to the accumulation of 
FUS rather than a loss of nuclear function. 
To investigate how FUS mutations lead to neurodegeneration, a technique called 
somatic brain transgenesis (SBT) was utilized to overexpress either WTFUS, FUS R521C, or 
FUS Δ14 throughout the brain, with the highest levels in the cerebral cortex and the 
hippocampus, and no detectable glial expression. SBT uses recombinant adeno-associated 
virus (rAAV) through bilateral intracerebroventricular injection to express a cDNA predominantly 
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in neurons beginning a few weeks after birth. Expression of both FUS mutants led to increased 
FUS protein in the neuronal cytoplasm, to the degree which correlated with the severity of the 
mutation as reflected by disease onset in humans. Despite increased cytoplasmic levels of 
FUSR521C, no obvious inclusions or aggregates of FUS were observed in mice injected with 
WTFUS or FUSR521C. Only, mice expressing the most aggressive mutation, FUSΔ14, showed 
histological features of human FUS proteinopathies, including insoluble FUS protein, basophilic 
and eosinophilic neuronal cytoplasmic inclusions, and presence of other pathologic markers, 
including ubiquitin, p62/SQSTM1, α-internexin, and the polyadenylate-binding protein 1 (PABP-
1). Any evidence of TDP-43 redistribution from the nucleus to the cytoplasm or presence of 
TDP-43 within inclusions in WTFUS, FUSR521C and FUSΔ14 mice was not find. Astrocytosis or 
microglial activation were absent. These mice were sacrificed at 3 months of age and untill then 
no motor or other behavioural phenotype relevant for ALS or FTLD was observed (283). 
However, results obtained for truncated form FUSΔ14 support the hypothesis that 
cytoplasmic FUS is toxic. The finding that FUSΔ14 expression can reproduce many 
pathologic features observed in subtypes of FTLD and ALS patients provides additional 
evidence that these diseases may share common mechanisms  
To examine FUS in the pathogenesis of FTLD, a rat model expressing human FUS with 
pathogenic mutation restrictedly in the neurons of the forebrain was developed. To induce 
expression Camk2a-tTA transgenic rat line were crossed with mutant FUS transgenic rats 
carring TRE-FUS-R521C. In the double-transgenic rats, expression of the mutant human FUS 
was observed only in the neurons, but not in the glia. This novel rat model showed progressive 
loss of neurons particularly in the superficial layers II and III of the frontal cortex accompanied 
with severe loss of neurites and dendritic spines. Accordingly, reactive microglia and astrocytes 
were first detected in the layers II and III of frontal cortex. Mislocalization of the FUS to the 
cytoplasm and ubiquitin aggregates developed primarily in the neurons of the entorhinal cortex 
of the temporal lobe. Intriguingly, aggregated ubiquitin was not colocalized with mutant FUS, but 
neurons with ubiquitin aggregates were deprived of endogenous TDP-43. Overexpression of 
mutant FUS in the forebrain neurons impaired rats’ spatial memory, which was detected by 
Barnes maze assay. By the age of 18 weeks most of the rats had difficulty in locating the 
escaping hole in the Barnes maze and reached disease end-stages (194). 
This mouse model shows that overexpression of mutated human FUS restricted to 
the rat forebrain and accompanied by the cytoplasmic mislocalization of FUS reproduces 
some bahavioural and histological charactheristic consistent with the findings in the 
FTLD patients. 
63 
 
However, from the aforementioned models it appears extremely hard to achieve 
aggregation in models with expression of full-length FUS or FUS lacking functional NLS like 
FUSR521C. 
To overcome these limitations and to answer the question whether FUS aggregation is 
sufficient to cause pathological changes typical for FUSopathies, Shelkovnikova et al., 
generated a new mouse model expressing a fragment of human FUS1–359 cDNA cloned into 
Thy-1 promoter. The truncated human protein FUS1–359 lacked RNA binding site, NLS and was 
highly aggregate-prone. In the central nervous system of hemizygous FUS1–359 transgenic 
mice, the truncated human protein was expressed in spinal cord, brainstem and cortex at a 
lower level than the endogenous mouse FUS protein. These animals abruptly developed a 
severe neurological phenotype early in their life. A typical motor dysfunction pattern included gait 
impairment caused by asymmetrical paresis and eventual complete paralysis of limbs, atrophy 
and denervation of the musle. Multiple FUS-positive inclusions were revealed primarily in the 
lower motor neuron cell bodies and axons. Unexpectedly, nuclear localization and aggregation 
of FUS variants completely lacking the C-terminal NLS were observed in a significant number of 
mouse neurons. Similar inclusions were observed in other neurons including upper motor 
neurons in the motor cortex. Only a fraction of FUS-positive inclusions was ubiquitinated, and in 
some cells, non-overlapping FUS and ubiquitin inclusions were present. In the late stage of the 
disease profound neuroinflammation was seen (198). 
This study produce the first direct in vivo evidence that aggregation of FUS protein 
can per se trigger ALS like FUSopathy with severe damage to susceptible neurons. 
However, because the truncated form of FUS was able to seed aggregation of normal FUS 
protein, secondary loss of function, along with direct toxicity induced by the aggregates, 
might play a role in the development of the neurodegenerative changes in the nervous 
system. 
Another study provided insight into how gain-of-function of FUS mutations affected 
critical neuronal functions. Transgenic mice expressing FLAG-tagged FUS-R521C mutant 
proteins using the Syrian hamster prion promoter, exhibited postnatal lethality and early onset 
motor behavioral deficits characterized by gait and motor coordination defects. The majority of 
the mice showed growth retardation, spastic paraplegia, severe muscle wasting and 
denervation. Loss of spinal cord motor neurons was progressive, age-dependent while cortical 
motor neurons were spared. Prominent  microgliosis and modest astrogliosis was found. 
FUSR521C mutant protein was predominantly nuclear but also found in the cytoplasm. 
Interestingly, in FUSR521C transgenic mice the distribution of endogenous FUS was affected. A 
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reduction of FUS was observed in neuronal nuclei, as well as in punctate structures that 
resembled synapse at the nerve terminals within spinal cord and sensorimotor cortex (197). 
Mutant FUSR521C proteins failed to interact with histone deacetylase 1 (HDAC1) and 
prevented the normal interaction of the remaining endogenous FUS with HDAC1. Consequently, 
FUSR521C mice exhibited evidence of DNA damage in selective genetic loci, followed by 
severe dendritic and synaptic defects in spinal motor neurons and cortical neurons. The results 
suggested that the dendritic defects in FUSR521C motor neurons most likely preceded neuron 
loss and could contribute to spinal motor neuron degeneration in FUSR521C mice. DNA 
damage was not widespread in FUSR521C mice, but can be detected in 5′noncoding exons of 
the Bdnf gene in both spinal cord and brain. Indeed, these results identified BDNF as target of 
FUSR521C–associated DNA damage and RNA splicing defects in mice. RNA-seq analyses of 
FUSR521C spinal cords revealed additional transcription and splicing defects in genes that 
regulate dendritic growth and synaptic functions (197). 
Together, these results indicate that mutant FUSR521C protein present abnormal 
gain-of-function properties in protein-protein and protein-RNA interactions that 
contribute to the severe defects restricted to neurons.  
The major characteristic of transgenic models with overexpression of wild type or mutant 
FUS are summarized in the Annex (Table 5). 
 
2.3. Summary of current results in available Fus models 
- Models of Fus knockout show early lethality in inbred strains (219,220) 
- Mixed-background  knockout mice survive birth to adulthood but do not manifest ALS-like 
phenotype (221) 
- FUS knockout as well hippocampal FUS knockdown leads to behavioural phenotypes 
related to typical FTLD symptoms (221,282) 
- Two out of three existing models show potential remaining of truncated FUS protein 
(219,220) 
- There is no available Fus conditional knockout mouse model. 
- Transgenic models with overexpression of wild type or mutant FUS in general 
recapitulates some features of ALS (195–198) and FTLD (194,283), however it is unclear 
whether the phenotypes were caused by overexpression per se or were specific to the 
FUS mutation. 
- Transgenic FUS expression leads to downregulation of endogenous FUS (196,197). 
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- Transgenic models show both nuclear and cytoplasmic FUS staining (194–198,283). All 
models failed to achieve total nuclear clearance with complete cytoplasmic 
mislocalization of FUS. 
- It is unclear to which extent the observed pathology is due to FUS loss of function or 
FUS gain of function. 
 
Therefore no clear picture has yet emerged on whether mutated FUS is more toxic 
than similar levels of wild type FUS. Similarly, it is unclear whether the phenotypes were 
caused by the overexpression per se or were specific to the FUS mutation. 
There have been several major hurdles indiscriminating the pathophysiological effects. 
First, models with ALS-associated mutations failed to achieve complete loss of nuclear import 
and total nuclear clearance of FUS (194–198,283). Despite showing FUS inclusions in the 
cytoplasm to varying degrees a substantial FUS nuclear staining as well as nuclear 
aggregations were present (195,198). Second, since FUS protein levels are very tightly 
regulated by an auto-regulatory mechanism involving alternative splicing of exon 7 (238), 
transgenic FUS expression leads to downregulation of endogenous Fus as a consequence, 
(196,197), making the interpretation of results even more complicated. 
In all, results from initial in vivo models of ALS-FUS have been inconsistent and the 
mechanisms remain unresolved. Thus, the debate between loss-of-function and gain-of-function 
hypotheses for FUS is not settled. Better mechanistic insights and animal models are crucial for 
a better understanding of the underlying mechanism(s). Transgenic  models overexpressing 
FUS may not adequately mimic the human FUS-opathies from a genetic point of view, and more 
sophisticated genetic approaches may be required. For example, knock-in animal models, where 
expression is upon the control of the endogenous FUS promoter, would therefore represent a 
better option to study the FUS pathology, and to determine the nature of FUS mutations. 
Furthermore, given the diversity of FUS functions, the generation of animal models of 
FUS-opathies fully recapitulating the human pathology and phenotype remains quite 
challenging. Thus, in order to address the spectrum of possible pathomechanisms in 
genetic and sporadic FUS-opathies (toxic gain of mutated FUS in nucleus; toxic gain of 
increased cytoplasmic FUS; loss of nuclear and/or cytoplasmic functions due to FUS 
mutations) comparative analysis of distinct model systems are necessary. 
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III. STATE OF ART - AIMS OF THE THESIS  
Although several lines of evidence indicate that cytoplasmic mislocalization of FUS, is a key 
event in disease pathogenesis, definitive in vivo evidence is lacking. The respective 
contributions of gain vs. loss of function, as well as the cell types in which the critical pathogenic 
events occur are still undefined. 
More generally, the links between FUS dysregulation and pathophysiological processes 
leading to neurodegeneration in ALS/FTD are poorly understood.  
 
We hypothesize that there are at least three ways in which aberrant subcellular distribution 
of FUS could impact on neurons leading to disease: 
 
1) Loss of function. The loss of FUS DNA/RNA processing properties may prevent the 
production of some “RNA X” or “Protein Y” that is required for proper regulation of 
neuronal function and survival. This could be a possible mechanism not only for nuclear 
but also for cytoplasmic function  
2) Gain of function. In addition to its RNA-binding domains, FUS also contains glycine-
rich protein-protein interactiondomains. Their presence in the cytoplasm could lead to 
“RNA X” dysregulation or/and misfolding of “Protein Y” via direct interaction at the protein 
level or through indirect biochemical pathways involving these proteins.This could be a 
possible mechanism not only for cytoplasmic but also for nuclear gain of function. 
3) A combination of gain and loss of function resulting from the mislocalization. 
 We postulated that FUS related diseases develop cell autonomously through a two-step 
pathogenic pathway. First, in vulnerable neurons, loss of nuclear import of FUS and cytoplasmic 
mislocalization leads to toxic functions, potentially involving aggregation, upon the action of 
modifierssuch asaging. Second, this culminates in neuronal death and the subsequent 
development of symptoms (Figure 21). If these pathogenic events appear in the LMN and UMN 
motor neurons, motor neuron disease resembling ALS will develop while, if the events occur in 
the neurons of frontal cortex, the resulting disease will be FTLD.  
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Figure 21.Working hypotesis 
 
Schematically represented working hypothesis that FUS diseases originate from a cell-
autonomous defect in nuclear import. This defect, upon the action of modifyers, like ageing, will 
lead to neuronal death. In this model, loss of nuclear import of FUS in LMN and UMN motor 
neurons, will cause ALS, while when same defect occure in the neurons of frontal cortex, the 
disease will mostly be FTLD. 
 
 If this working model stands true, then the following assumptions should also stand true: 
- Cytoplasmic mislocalization of FUS in motor neurons should be both necessary and 
sufficient to drive motor neuron loss. 
- Cytoplasmic mislocalization of FUS in frontal cortex should be both necessary and 
sufficient to drive neuronal loss and cortical atrophy 
- Aging should precipitate ALS and/or FTLD upon cytoplasmic FUS mislocalization, even 
partially 
 The goal of my PhD work was to test experimentally these assumptions. 
 Based on the previous working model, we derived four questions to be addressed: 
1) Does complete cytoplasmic mislocalization of FUS recapitulate ALS and/or FTLD in 
mice? 
LMN + UMN FRONTAL CORTEX
FTDALS
DEFECTIVE NUCLEAR IMPORT 
AND CYTOPLASMIC MISLOCALISATION
AGING ?
AGING ? AND/OR
POSSIBLE AGGREGATTON ?
DEGENERATION
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2) Is complete cytoplasmic mislocalization of FUS in selected neuronal types necessary 
to trigger the disease? 
3) Does partial cytoplasmic mislocalization of FUS recapitulate ALS and/or FTLD in 
mice? 
4) Is partial cytoplasmic mislocalization of FUS in selected neuronal types necessary to 
trigger the disease? 
The answers to these questions relied on the generation and characterization of relevant 
animal models to overcome the drawbacks detected in the currently existing animal models. In 
particular we generateda conditional knock-in mouse model to overcome well-known problems 
regarding transgenic models. 
RESULTS 
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I. PUBLICATION N⁰1 
(Manuscript submitted) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
A. Summary –publication N⁰1 
To investigate the in vivo consequences of altered FUS localization, we generated a 
conditional mouse model Fus∆NLS, with targeted ablation of the whole PY-NLS, encoded by 
the last exon (exon 15) of the Fus gene, as occurs in ALS-associated truncating mutations of 
FUS. Complete deletion of NLS led toeither complete (homozygous) or partial (heterozygous) 
cytoplasmic mislocalization depending on the number of mutant alleles (Figure 22). These mice 
have been be extensively characterized for neurodegeneration related phenotypes as well as 
for consequences of FUS subcellular redistribution. 
Figure 22. New knock-in mouse model- Fus∆NLS 
 
Schematically represented subcellular localization of truncated FUS in our novel knock-in mouse 
modelFus∆NLS inhomozygous animalsFus
ΔNLS/ΔNLS
.Yellow color representstruncated FUS subcellular 
localization which is entirely mislocalized to cytoplasm upon complete block of nuclear import by 
TRANSPORTIN, due to NLS deletion. 
 
In addition, we performed parallel and comparative analysis of phenotype characteristics 
and pathological changes in between our FUS knock-in model and a new FUS knockout mouse 
model. These mice were generated by our collaborator Erik Storkebaum (Munster, Germany). 
As this new model is a represent of loss of FUS function we were able to decipher the 
respective contributions of FUS gain vs. loss of function (Figure 23). 
Moreover, here, we determined if genomewide RNA processing alterations associated 
with FUS truncation reflected loss or toxic gain of the FUS protein function. To this purpose we 
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used a combination of approaches linked to high-throughput sequencing. Expression and 
splicing changes were determined by RNA-seq and RASL-seq, respectively, in both Fus 
models. RNA profiles were defined by using two complementary methods linked to high-
throughputsequencing for unbiased identification of RNA expression and splicing changes: 
strand-specificRNA-seq (284) and RNA-directed oligo Annealing, Selection, and Ligation or 
RASL-seq (285). 
Figure 23. Comparative analysis of distinct models 
 
Schematically represented subcellular localization of FUS in wild type animals Fus
+/+
, in two other models 
we introduced here homozygous ∆NLSFus
ΔNLS/ΔNLS
and homozygous knockout  animals Fus
-/-
 . Yellow 
color represents FUS subcellular localization which is normally distributed in Fus
+/+
 ,entirely mislocalized 
to cytoplasm in Fus
ΔNLS/ΔNLS
and completely absent Fus
-/-
. 
More importantly, our genetic strategy allows us to restore the expression of the full-length 
protein, in a cell-, tissue- or region- specific manner upon crossing with chosen CRE-expressing 
mouse lines. 
Since one of our aims was to determine whether selected neuronal types were amajor site 
of toxicity for FUS truncation, we took advantage of the conditionality of our Fus∆NLS model, to 
restore wild type FUS expression in the spinal motor neurons and check whether this genetic 
manipulation rescues the phenotype. To do this, we cross-bred Fus∆NLS mice with mice 
expressing the CRE recombinase from the ChATlocus, active in cholinergic neurons among 
which are the spinal motor neurons. 
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The cross-breeding was achieved through a two step breeding strategy (Figure 24). 
Figure 24. Cross-breeding strategy 
 
Schematically represented cross–breeding strategy. We crossed heterozygous Fus∆NLSmice with ChAT 
CRE mice to obtain heterozygous Fus
ΔNLS/+
/ChAT-CRE mice. The resulting F1 generation was 
intercrossed to generate F2 homozygous Fus
ΔNLS/ΔNLS
/ChAT-CRE mice. 
 
In the litters of these F2 generations, we will checked for phenotypical and pathological 
phenotypes between mice with or without ChAT transgene (Figure 25). 
Figure 25. Comparative analysis of Fus∆NLS mice with or without ChAT transgene 
 
Schematically represented FUS subcellular localization inneuronal cell expressing ChAT and all other 
cell.Yellow color represents FUS subcellular localization in neuronal cells and violet in all other cells. FUS 
is normally distributed in Fus
+/+
, entirely mislocalized to cytoplasm in Fus
ΔNLS/ΔNLS
in both cell types. 
Whereas in Fus
ΔNLS/ΔNLS
/ChAT-CRE normal nuclear FUS localization is restored in neuronal but not in 
other cells. 
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Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor 
neuron loss 
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Abstract 
FUS is an RNA-binding protein involved in amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD). Cytoplasmic FUS-containing aggregates are often associated with concomitant loss of 
nuclear FUS. Whether loss of nuclear FUS function, gain of a cytoplasmic function, or a combination of 
both lead to neurodegeneration remains elusive. To address this question, we generated knock-in mice 
expressing mislocalized cytoplasmic FUS and complete FUS knock-out mice. Both mouse models display 
similar perinatal lethality with respiratory insufficiency, reduced body weight and length, and largely 
similar alterations in gene expression and mRNA splicing patterns, indicating that mislocalized FUS 
results in loss of its normal function. However, FUS knock-in mice, but not FUS knock-out mice, display 
reduced motor neuron numbers at birth, associated with enhanced motor neuron apoptosis, which can be 
rescued by cell-specific CRE-mediated expression of wild-type FUS within motor neurons. Together, our 
findings indicate that cytoplasmic FUS mislocalization not only leads to nuclear loss of function, but also 
triggers motor neuron death through a toxic gain of function within motor neurons. 
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Introduction 
Mutations in several aggregation-prone RNA binding proteins (RBPs) are increasingly linked to 
various neurodegenerative diseases. Such mutations constitute a major cause of amyotrophic lateral 
sclerosis (ALS), the most frequent adult-onset motor neuron disease, with mutations in TDP-43 (Gitcho et 
al, 2008; Kabashi et al, 2008; Sreedharan et al, 2008) and FUS (Kwiatkowski et al, 2009; Vance et al, 
2009) accounting each for about 5% of familial ALS cases. Even in absence of mutations, abnormal 
cytoplasmic inclusions of TDP-43 represent a pathological hallmark of sporadic ALS, non-SOD1 familial 
ALS and frontotemporal dementia (FTD) (Neumann et al, 2009; Neumann et al, 2006), a 
neurodegenerative condition characterized by behavioral and language deficits. Similarly, compromised 
FUS nuclear localization and cytoplasmic FUS aggregates are found in ALS patients carrying FUS 
mutations, as well as in a subset of FTD patients without TDP-43 pathology (Mackenzie et al, 2010). 
Consistent with a central role of RNA processing misregulation in ALS and FTD pathogenesis, mutations 
in several other RBPs were recently identified, in particular TAF15 and EWSR1, two proteins from the 
same family as FUS (Couthouis et al, 2012; Couthouis et al, 2011), and other less closely related RBPs 
such as ataxin 2 (Elden et al, 2010), hnRNPA2B1 (Kim et al, 2013), hnRNPA1 (Kim et al, 2013) and 
matrin-3 (Johnson et al, 2014).  
Disease-associated mutations in RBPs typically disrupt the normal nuclear localization of mutant 
proteins, with concomitant sequestration of the endogenous wild-type protein into cytoplasmic aggregates 
(Neumann et al, 2006; Vance et al, 2013). Mutations are either located in highly unstructured prion-like 
protein domains, resulting in a higher propensity to aggregate (Kim et al, 2013), or in the vicinity of the 
nuclear localization signal (NLS), impairing nuclear import of the protein. For instance, the NLS of FUS 
is an atypical PY-NLS (Dormann et al, 2010) located at the C-terminus of the protein that represents a 
mutational hot-spot in ALS patients. Along with missense mutations, several truncating or frameshift 
mutations deleting the FUS NLS have been identified in ALS patients (Supplementary Fig. 1), and are 
often associated with juvenile onset and rapid disease progression (Baumer et al, 2010; Calvo et al, 2014; 
Deng et al, 2014; Waibel et al, 2010; Waibel et al, 2013; Zou et al, 2013). In most instances FUS 
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mutations are dominantly inherited, however it is noteworthy that a recessive inheritance pattern is 
occasionally observed in ALS patients (Bertolin et al, 2014; Kwiatkowski et al, 2009). 
FUS and TDP-43 normally shuttle between the nucleus and cytoplasm, and defective nuclear import 
may lead to both loss of their nuclear functions and dysregulation of their cytoplasmic roles. In the 
nucleus, FUS and TDP-43 are involved in regulation of pre-mRNA splicing, transcription, and 
microRNA biogenesis, all processes that may be affected by their depletion from the nucleus (Ling et al, 
2013; Morlando et al, 2012). Consistently, reductions of TDP-43 or FUS were associated with altered 
expression and splicing of several hundreds of genes (Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; 
Polymenidou et al, 2011; Rogelj et al, 2012; Tollervey et al, 2011), and both proteins are critically 
involved in the processing of long pre-mRNAs (Lagier-Tourenne et al, 2012; Ling et al, 2013; 
Polymenidou et al, 2011). Cytosolic functions of FUS and TDP-43 include transport (Alami et al, 2014) 
and/or storage (Han et al, 2012) of mRNA in the cytoplasm with a crucial role in the formation of stress 
granules (Li et al, 2013).  
Although several lines of evidence indicate that cytoplasmic mislocalization of RBPs is a key event 
in disease pathogenesis, definitive in vivo evidence is lacking and the relative contributions of loss and 
gain of function still need to be established. Indeed, it remains unknown whether loss of nuclear function 
of mutant RBPs is sufficient to trigger motor neuron disease, or whether a cytosolic gain of function is 
also involved. There have been two major hurdles in answering these questions. First, ALS-associated 
RBPs are crucial for cell physiology, and overexpression of wild type proteins causes widespread 
phenotypes (Huang et al, 2011; Mitchell et al, 2013; Sephton et al, 2014). This represents a major 
drawback when attempting to discern the pathophysiological effects of disease-causing mutations in 
overexpression models. Second, potent auto-regulatory mechanisms control cellular levels of RBPs. For 
instance, both TDP-43 (Ayala et al, 2011; D'Alton et al, 2015; Polymenidou et al, 2011) and FUS (Dini 
Modigliani et al, 2014; Lagier-Tourenne et al, 2012; Zhou et al, 2013) control their own levels by binding 
to their mRNAs. As a consequence, the levels of endogenous TDP-43 or FUS proteins are strikingly 
reduced in animal models overexpressing wild type or mutant TDP-43 and FUS (Arnold et al, 2013; 
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Huang et al, 2011; Mitchell et al, 2013; Sephton et al, 2014; Wegorzewska et al, 2009).  
Here, we use homologous recombination techniques to circumvent issues inherent to overexpression 
animal models. We systematically compare the pathological and molecular features of two novel mouse 
models either expressing a truncated FUS protein that lacks the NLS and localizes within the cytoplasm 
(knock-in mice) or harboring a genomic mutation associated with complete absence of FUS protein 
(knock-out mice). Both mice expressing mutant cytoplasmic FUS and mice completely devoid of FUS 
died at birth of respiratory insufficiency. Using genomic approaches, we determined that FUS knock-in 
mice display expression and splicing alterations consistent with loss of FUS nuclear function. However, 
mice expressing truncated cytoplasmic FUS, but not FUS knock-out mice, exhibit perinatal motor neuron 
loss, which can be rescued by motor neuron-restricted reversal of the mutant FUS gene to wild-type FUS. 
This finding demonstrates that cytoplasmic FUS leads to loss of nuclear FUS function, yet exerts a toxic 
gain of function within the cytoplasm of motor neurons necessary to trigger neuronal death.  
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Results 
 
Cytoplasmic mislocalization of mutant FUS in Fus
ΔNLS/ΔNLS 
mice  
With the aim to investigate in vivo consequences of altered FUS localization, we generated a 
mouse model with targeted deletion of the PY-NLS, encoded by the last exon of the Fus gene (exon 15). 
This mutation closely mimics ALS-causing truncating mutations of FUS (Supplementary Fig. 1). We 
opted for a strategy that would not only result in ablation of exon 15, but also allow for CRE-mediated 
reversal to the wild type locus. Due to the small size of intron 14, we engineered the Fus locus to include, 
in intron 12, a floxed cDNA encoding exons 13 and 14 of Fus, followed by 3 transcription stop cassettes 
and a poly-adenylation signal (Figure 1A). Germline transmission of the recombinant allele was obtained 
(Figure 1B) and mice heterozygous and homozygous for the targeted allele will hereafter be referred to as 
Fus
ΔNLS/+ 
and Fus
ΔNLS/ΔNLS
, respectively. Homozygous Fus
ΔNLS/ΔNLS
 mice die shortly after birth, and tissues 
dissected at birth (P0) were analyzed for expression and localization of FUS
∆NLS 
mRNA and protein. The 
ΔNLS mRNA could be detected by RT-PCR in tissues of FusΔNLS/+ and FusΔNLS/ΔNLS mice (Figure 1C and 
Supplementary Fig. 2A). FUS protein was detected by immunoblotting in Fus
ΔNLS/+ 
and Fus
ΔNLS/ΔNLS
 
brain, spinal cord and muscle protein extracts using antibodies targeting the internal or N-terminal parts 
of FUS (Figure 1D and Supplementary Fig. 2B). Contrastingly, no signal was detected in Fus
ΔNLS/ΔNLS
 
protein extracts when using two different antibodies that recognize the C-terminal NLS of FUS (Figure 
1D and Supplementary Fig. 2B), demonstrating that the engineered Fus gene leads to the generation of a 
FUS protein devoid of NLS. As expected, FUS protein localized to the nucleus in cultured mouse 
embryonic fibroblasts (MEF) of Fus
+/+
 mice. In striking contrast, FUS redistributed from the nuclear 
compartment to the cytoplasm in Fus
ΔNLS/ΔNLS
 MEFs (Supplementary Fig. 2C) and was detected in both 
the nucleus and the cytoplasm of Fus
ΔNLS/+
 MEFs (Supplementary Fig. 2C). Consistently, in Fus
ΔNLS/ΔNLS
 
newborn mice, immunostaining revealed that mutant FUS is localized to the cytoplasm of spinal motor 
neurons, contrasting with the normal nuclear localization in Fus
+/+
 motor neurons (Figure 1E). In 
Fus
ΔNLS/+
 mice, FUS is detected in both the nucleus and the cytoplasm of motor neurons (Figure 1E). 
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Thus, the Fus
ΔNLS
 allele effectively leads to the expression of a truncated FUS protein that lacks the NLS 
and localizes predominantly to the cytoplasm. 
 
Cytoplasmic mislocalization of FUS and complete loss of FUS both result in perinatal lethality  
Fus
ΔNLS/ΔNLS
 mice were born alive, but died within minutes after birth, while Fus
ΔNLS/+
 mice survived the 
perinatal period. The body length and weight of Fus
ΔNLS/ΔNLS
 pups was slightly but significantly reduced as 
compared to Fus
+/+
 and Fus
ΔNLS/+
 newborn mice (Supplementary Fig. 3A-C). The cause of death 
appeared to be respiratory insufficiency, as Fus
ΔNLS/ΔNLS
 animals showed poor respiratory movements and 
cyanosis, and H&E staining of sections through the lung revealed uninflated lungs with complete alveolar 
atelectasis (Supplementary Fig. 3D).  
Cytoplasmic FUS mislocalization could have detrimental effects either through toxicity resulting from 
increased cytoplasmic FUS levels or through loss of its normal nuclear function. To distinguish between 
these possibilities, we investigated whether complete loss of FUS recapitulates the perinatal lethality 
phenotype of Fus
ΔNLS/ΔNLS
 mice. Mice with a gene trap insertion in exons 8 or 12 of the Fus gene have 
been described previously (Hicks et al, 2000; Kuroda et al, 2000), yet both of these Fus gene trap lines 
express low amounts of truncated FUS protein, thus precluding their use to discriminate between loss 
versus gain of function mechanisms. To tackle this issue, we generated a novel Fus knock-out model 
(hereafter referred to as Fus 
-/-
) that was systematically compared to Fus
ΔNLS/ΔNLS
 mice in the same C57Bl6 
background. In this new Fus knock-out allele, a trap cassette was inserted in intron 1 to completely 
disrupt transcription of the endogenous Fus gene (Figure 2A). Southern blot and direct sequencing 
confirmed the position and orientation of the gene trap insertion, and excluded additional insertion events 
elsewhere in the genome (not shown). FUS protein was undetectable in the central nervous system of Fus
-
/-
 newborn mice by western blot using antibodies raised against the N-terminal and C-terminal parts of the 
protein (Figure 2B-C) and Fus mRNA could not be detected by quantitative real-time PCR (Figure 2D). 
Consistently, immunostaining for FUS on spinal cord sections of E18.5 Fus
-/-
 mice did not detect FUS 
protein (Figure 2E). These data confirm that Fus
-/-
 mice are FUS protein null. Depending on the genetic 
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background, previously described Fus gene trap mice were reported either to be adult viable, to die before 
the age of weaning or within 16 hours after birth (Hicks et al, 2000; Kino et al, 2015; Kuroda et al, 2000). 
In contrast, Fus
-/-
 mice died within 30 minutes after birth due to respiratory insufficiency. Similar to 
Fus
ΔNLS/ΔNLS 
pups, the body weight and body length of Fus
-/-
 newborn mice was significantly reduced as 
compared to litermate controls (Supplementary Figure 3E-F). Thus, both complete loss of FUS or its 
cytoplasmic mislocalization trigger a similar perinatal phenotype in C57Bl6 mice. 
 
Substantial overlap of RNA expression changes induced by cytoplasmic FUS mislocalization and 
complete loss of FUS  
The phenotypic similarity of Fus
ΔNLS/ΔNLS 
and Fus
-/-
 newborn mice suggests that FUS cytoplasmic 
mislocalization leads to loss of FUS nuclear function. FUS has been involved in the regulation of gene 
expression and alternative splicing of its mRNA targets (Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; 
Polymenidou et al, 2011; Rogelj et al, 2012; Tollervey et al, 2011). In addition, FUS interacts with 
several proteins, including U1-snRNP (Sun et al, 2015; Yamazaki et al, 2012), SMN (Groen et al, 2013; 
Tsuiji et al, 2013; Yamazaki et al, 2012), HDAC1 (Wang et al, 2013), Drosha (Morlando et al, 2012), 
RNA polymerase II (Schwartz et al, 2012) or PRMT1 (Tibshirani et al, 2014), known to have profound 
effects on splicing and gene expression. Hence, the expression of a truncated cytoplasmic form of FUS 
may primarily lead to loss of nuclear FUS function and defective regulation of direct FUS RNA targets. 
In addition, cytoplasmic accumulation of FUS may also alter the function and/or subcellular localization 
of FUS-interacting proteins, and result in additional gene expression and splicing alterations. To 
discriminate between gain- and loss-of-function changes, we systematically compared RNA profiles in 
brains from Fus
ΔNLS/ΔNLS
 and Fus
-/- 
mice. First, we used strand-specific, genome wide sequencing of RNAs 
(Parkhomchuk et al, 2009) (RNA-seq) to evaluate RNA expression levels in brains of Fus
ΔNLS/ΔNLS
 and 
Fus
-/- 
mice. Total RNA was extracted from E18.5 embryonic brains of Fus
ΔNLS/ΔNLS
 mice (N=5) and wild-
type littermates (N=4), as well as homozygous Fus
-/- 
(N=5) and their control Fus
+/+
 littermates (N=5). 
Expression levels for each annotated protein-coding gene were determined by the number of mapped 
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fragments per kilobase of exon, per million mapped reads (FPKM) (Mortazavi et al, 2008; Trapnell et al, 
2012). The FPKM ratio of the Fus gene confirmed that Fus was expressed in Fus
ΔNLS/ΔNLS
 mice, but not in 
Fus
-/-
 mice (Supplementary Fig. 4A). Inspection of the reads mapped on the Fus gene demonstrated the 
absence of reads throughout all exons for the Fus
-/- 
mice while only exon 15 was not integrated in Fus 
transcripts of Fus
ΔNLS/ΔNLS
 mice (Figure 3A). Unsupervised hierarchical clustering with all genes reliably 
discriminated mutant genotypes from their controls (Supplementary Fig. 4B-C), indicating that both Fus 
mutation and Fus deletion displayed RNA expression profiles divergent from wild-type. Statistical 
comparison of FPKM values identified 237 genes upregulated and 549 genes downregulated 
(Supplementary Table 1) in Fus
ΔNLS/ΔNLS 
mice (as defined by P<0.05 adjusted for multiple testing) 
(Figure 3B). Of note, only 9 genes and 56 genes were upregulated and downregulated more than 1.5 fold, 
respectively (Supplementary Table 1). Identical analysis in Fus
-/- 
mice identified 669 upregulated genes 
(29 genes more than 1.5 fold) and 889 downregulated genes (72 genes more than 1.5 fold) 
(Supplementary Table 2 and Figure 3C).  Comparison of both models identified 353 genes that were 
altered in the same direction, consistent with loss of FUS nuclear function underlying the altered levels of 
these transcripts (Figure 3D and Supplementary Table 3).  
Downregulation of selected genes in both mouse models was confirmed by qRT-PCR 
(Supplementary Fig. 5A), yielding data similar to the RNA-seq results (Figure 3E). Out of these, 
several genes have been previously involved in neurological diseases such as the Abelson helper 
integration site 1 (Ahi1) gene mutated in the neurodevelopmental Joubert syndrome (Ferland et al, 2004), 
the Dystrophia myotonica protein kinase (Dmpk) gene implicated in myotonic dystrophy type 1, the low 
and medium molecular weight neurofilament subunits (Nefl and Nefm) (Bergeron et al, 1994)and the gene 
encoding tubulin alpha 4A (Tuba4a) that was recently implicated in ALS (Smith et al, 2014). Similarly, 
selected upregulated genes were confirmed by qRT-PCR (Figure 3E and Supplementary Fig. 5A), 
including Taf15, a FUS family member also mutant in ALS (Couthouis et al, 2011). Increased levels of 
Taf15 in Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice is consistent with the presence of FUS binding sites on the Taf15 
transcript (Lagier-Tourenne et al, 2012) and may illustrate a mechanism of compensation induced by loss 
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of FUS nuclear function. Overall, a substantial overlap in RNA expression changes was found in 
Fus
ΔNLS/ΔNLS
 and Fus
-/-
 brains consistent with loss of FUS nuclear function in knock-in mice. 
 
Cytoplasmic mislocalization of FUS leads to unique RNA expression changes  
A number of the genes identified by RNA-seq as uniquely regulated in Fus
ΔNLS/ΔNLS
 mice displayed 
similar trends in both mouse models when evaluated by qRT-PCR (Supplementary Fig. 5B-C), 
suggesting that the set of genes commonly regulated by truncation and loss of FUS was underestimated. 
However, a subset of transcripts were altered uniquely in Fus
ΔNLS/ΔNLS
 animals (Figure 3F and 
Supplementary Fig. 5D),, including the Vitronectin (Vtn) gene, the small nuclear ribonucleoprotein 
polypeptides B and B1 (Snrpb) gene, the Trove2 gene encoding for the 60 kDa SS-A/Ro 
ribonucleoprotein and the U2AF homology motif kinase 1 (Uhmk1) gene encoding for the Kinase 
interacting with Stathmin (KIS) protein that was implicated in schizophrenia and the regulation of 
splicing (Manceau et al, 2008) and local translation in neuritic projections (Cambray et al, 2009; Pedraza 
et al, 2014). Interestingly, Fus
ΔNLS/ΔNLS
 animals displayed increased mRNA levels of Ephb3, a member of 
Eph/Ephrin signalling pathways crucial in synaptogenesis and previously involved in Alzheimer’s disease 
(Sheffler-Collins & Dalva, 2012), while EphA4, another member of Eph/ephrin system has been recently 
involved in ALS (Van Hoecke et al, 2012) (Figure 3F and Supplementary Fig. 5D). Thus, Fus
ΔNLS/ΔNLS
 
expression profiles largely recapitulated expression profiles of Fus
-/-
 brains, yet a subset of genes was 
found specifically associated with the expression of cytoplasmic truncated FUS in Fus
ΔNLS/ΔNLS
 brains. 
Gene ontology analysis showed that transcripts whose expression was upregulated in Fus
ΔNLS/ΔNLS
 
animals were enriched for genes involved in mRNA translation and extracellular matrix constituents 
(Supplementary Table 4). In contrast, transcripts upregulated in Fus
-/-
 brains revealed an enrichment for 
nuclear and nucleolar proteins involved in the regulation of transcription, DNA replication or regulation 
of RNA metabolic processes (Supplementary Table 5). Gene ontology analysis revealed a similar 
enrichment for synaptic activity and function among transcripts downregulated in Fus
ΔNLS/ΔNLS 
and Fus
-/-
 
animals (Supplementary Tables 4 and 5). Altogether, these data suggest that cytoplasmic 
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mislocalization of FUS alters expression of genes involved in synaptogenesis, as a direct consequence of 
FUS loss of function. Contrastingly, gain of function elicited by cytoplasmic FUS might be more related 
with alterations in genes related with mRNA translation, especially in neurites, and extracellular matrix.  
 
Widespread splicing alterations induced by cytoplasmic mislocalization and loss of FUS  
To further compare the molecular changes elicited by cytoplasmic FUS mislocalization and FUS loss 
of function, we asked whether regulation of mRNA splicing was commonly affected in E18.5 brains of 
Fus
ΔNLS/ΔNLS
 mice and Fus
-/-
 mice. To characterize mRNA splicing, we exploited the RNA-mediated 
oligonucleotide Annealing, Selection, and Ligation with Next-Generation sequencing (RASL-seq) 
method (Li et al, 2012; Zhou et al, 2012). This approach allowed us to quantitatively profile 3859 unique 
alternative splicing events that correspond to exon inclusion or skipping events conserved between mouse 
and human (Supplementary Fig. 6A). After filtering, ratios of shorter to longer isoform counts were 
calculated and used to statistically compare the splicing changes between different groups. Unsupervised 
hierarchical clustering for all splicing events showed that both mutant Fus genotypes clustered apart from 
their controls (Supplementary Fig. 6B-C). Thus, both Fus deletion and expression of truncated FUS led 
to splicing profiles distinct from controls. In Fus
ΔNLS/ΔNLS
 brains, 9.3% (173 events) of the 1852 detected 
splicing events were different from controls, with 101 increased long splicing isoforms and 72 enhanced 
short isoforms (defined by t-test with p<0.05 and average fold change >1.5) (Figure 4A and 
Supplementary Table 6). In Fus
-/-
 brains, 17.9% (252 events) of the 1406 detected splicing events were 
different from control littermates, with 118 increased long isoforms and 134 enhanced short isoforms 
(Figure 4B and Supplementary Table 7). 
Comparison of the splicing changes between Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice revealed a striking overlap 
between both models. Seventy-five splicing events were commonly regulated in Fus
ΔNLS/ΔNLS
 and Fus
-/-
 
mice, 100% of which were differentially included or excluded in the same direction (Supplementary Fig. 
6D-E and Supplementary Table 8). 
Semi-quantitative RT-PCR of selected RNAs confirmed these FUS-dependent splicing changes 
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(Figure 4C and Supplementary Fig. 6F), including transcripts previously implicated in 
neurodegenerative diseases such as the N-myc downstream-regulated gene 2 (Ndrg2) that is 
misaccumulated in Alzheimer’s disease (Mitchelmore et al, 2004), the microtubule-associated protein tau 
(Mapt) gene mutated in frontotemporal dementia (Hutton et al, 1998), the ataxin 2 (Atxn2) gene mutated 
in ALS (Elden et al, 2010) and spinocerebellar ataxia type 2 (SCA2) (Imbert et al, 1996) and the pro-
neurotrophin receptor sortilin 1 (Sort1) (Hu et al, 2010). Interestingly, inclusion of sortilin 1 exon 17b 
(also referred as exon 18 in (Polymenidou et al, 2011)) was previously associated with low levels of TDP-
43 (Polymenidou et al, 2011; Prudencio et al, 2012) and found significantly increased in cortex of FTD 
patients with TDP-43 proteinopathy (Prudencio et al, 2012). Here, we observe that Fus mutation and 
deletion have an opposite effect on sortilin 1 as compared to TDP-43 on sortilin 1 exon17b, with 
decreased inclusion of exon 17b in embryonic brains from both Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice (Figure 4C 
and Supplementary Fig. 6F).  
Despite expected developmental differences in the alternative splicing patterns of embryonic and 
adult brains, 57 splicing events found misregulated by RASL-seq in Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice were also 
identified by Affymetrix microarrays in striatum from adult wild-type mice with acute depletion of Fus 
by antisense oligonucleotide treatment (Lagier-Tourenne et al, 2012), or in embryonic brains from 
another Fus knock-out model that expresses low levels of truncated FUS protein (Hicks et al, 2000; 
Lagier-Tourenne et al, 2012). Among FUS-dependent alterations, abnormal splicing of Mapt exon 10 
(Figure 4C and Supplementary Fig. 6F) is of particular relevance for disease pathogenesis as mutations 
enhancing exon 10 inclusion are linked to frontotemporal dementia (Liu & Gong, 2008). While in 
embryonic mouse brains the predominant mRNA isoforms of Mapt do not include exon 10 and encode 
for tau protein with three microtubule binding repeats (3R-tau) (Dillman et al, 2013; McMillan et al, 
2008), we observed increased inclusion of exon 10 encoding for the 4-repeat tau isoform (4R tau) in both 
Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice. In all, splicing alterations caused by cytoplasmic FUS mislocalization are 
largely overlapping with those elicited by complete loss of FUS. Nevertheless, a subset of events were 
uniquely found in Fus
ΔNLS/ΔNLS 
(Supplementary Fig. 6D),
 
which may be the consequence of functional 
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disruption of other RNA binding proteins by abnormal accumulation of FUS in the cytoplasm. 
 
Cytoplasmic mislocalization of FUS leads to increased perinatal motor neuron apoptosis 
We next asked whether perinatal death of Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice was accompanied by loss of 
motor neurons in the lumbar spinal cord. Immunostaining for choline acetyltransferase (ChAT), which 
specifically labels large motor neurons in the spinal cord ventral horn, revealed that the number of motor 
neurons was reduced by approximately 30% in Fus
ΔNLS/ΔNLS
 mice as compared with both Fus
+/+
 and 
Fus
ΔNLS/+
 mice (Figure 5A-B). To exclude the possibility that this reduced number of ChAT-positive 
motor neurons reflects downregulation of ChAT expression rather than loss of motor neurons, we also 
performed Nissl staining, a histochemical stain independent of marker gene expression. Quantification of 
neurons with an area of ≥80μm2 revealed a 50% reduction of the number of large motor neurons in the 
ventral horn of Fus
ΔNLS/ΔNLS
 newborn mice (Figure 5C). Interestingly, Fus
ΔNLS/+
 mice displayed a smaller 
but statistically significant loss of large Nissl stained cells, suggesting that motor neurons were also 
affected in these mice despite showing normal numbers of ChAT positive cells. In striking contrast with 
the situation in Fus
ΔNLS/ΔNLS
 mice, spinal motor neuron counts were similar between Fus
-/- 
mice and their 
wild type littermates (Figure 5A, D), demonstrating that the mutant FUS protein expressed in Fus
ΔNLS/ΔNLS
 
mice is toxic to motor neurons during development. 
At birth, mouse motor neurons are still in the developmental period, and motor neurons that did 
not efficiently create synaptic contacts with muscles undergo apoptosis until P10 (Kanning et al, 2010). 
We hypothesized that the reduced number of motor neurons in the lumbar spinal cord of Fus
ΔNLS/ΔNLS
 mice 
could be due to increased perinatal motor neuron apoptosis. Consistently, the  number of apoptotic cells 
detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was significantly 
increased in lumbar spinal cord sections of Fus
ΔNLS/ΔNLS
 newborn mice (Figure 6A-B). Furthermore, 
double-immunostaining for ChAT and active caspase 3, labeling motor neurons actively undergoing 
apoptosis, revealed that motor neuron apoptosis was twice more frequent in Fus
ΔNLS/ΔNLS
 than in wild type 
littermates (Figure 6C-E). Together, these data indicate that cytoplasmic mislocalization of FUS leads to 
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reduced numbers of lower motor neurons, at least in part attributable to increased motor neuron death. 
The absence of motor neuron loss in Fus
-/- 
mice indicates that cytoplasmic FUS accumulation leads to 
motor neuron death through a toxic gain of function mechanism.  
 
Cytoplasmic mislocalization of FUS is not sufficient to induce stress granules or alterations in RBPs 
In autopsy material of ALS-FUS patients, FUS-containing cytoplasmic aggregates are found in 
neurons and glial cells. These aggregates are usually also immunopositive for p62 and for ubiquitin 
(Baumer et al, 2010; Huang et al, 2010; Kobayashi et al, 2010; Tateishi et al, 2010; Vance et al, 2009). 
Despite motor neuron loss in Fus
ΔNLS/ΔNLS
 mice, we did not observe any FUS-positive, p62-positive, 
ubiquitin-positive or neurofilament-positive aggregates in motor neurons of newborn Fus
ΔNLS/ΔNLS
 mice 
(Supplementary Fig. 7). Furthermore, as FUS is recruited to stress granules, and since neuropathology 
revealed that cytoplasmic protein aggregates in ALS-FUS patients stain positive for stress granule 
markers (Baumer et al, 2010; Dormann et al, 2010; Liu-Yesucevitz et al, 2010), we evaluated the 
distribution of stress granule markers in the spinal cord ventral horn in Fus
ΔNLS/ΔNLS
 mice. This analysis 
revealed that markers for stress granules such as phosphorylated eIF2α or TIAR1 displayed a similar 
pattern in Fus
ΔNLS/ΔNLS
 and control mice (Supplementary Fig. 8). Finally, we asked whether cytoplasmic 
mislocalization of FUS in Fus
ΔNLS/ΔNLS
 mice would affect the subcellular localization of other RBPs. In the 
ventral horn of the spinal cord, nuclear immunoreactivities of other RBPs, such as TDP43 and TAF15 
were unaltered in Fus
ΔNLS/ΔNLS
 mice (Supplementary Fig. 9). Taken together, newborn Fus
ΔNLS/ΔNLS
 mice 
displayed cytoplasmic mislocalization of FUS that was accompanied by motor neuron death without 
detectable protein aggregation, stress granule formation or altered subcellular localization of other RBPs. 
 
Cytoplasmic FUS mislocalization is intrinsically toxic to motor neurons 
We subsequently asked whether FUS mislocalization within motor neurons is necessary to induce 
motor neuron loss in Fus
ΔNLS/ΔNLS
 mice or whether restricted expression of wild type FUS in motor 
neurons could rescue their survival despite accumulation of the mutant protein in neighboring cells. We 
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therefore exploited the presence of loxP sites flanking the STOP cassette (Figure 1A) to selectively revert 
the ∆NLS allele to wild type in motor neurons. For this purpose, FusΔNLS/+ mice were crossed to mice 
expressing the CRE recombinase from the ChAT locus, which leads to CRE recombinase activity in 
virtually all cholinergic neurons (Rossi et al, 2011; Saxena et al, 2013). We expected that 
Fus
ΔNLS/ΔNLS
/ChAT-CRE mice would express truncated FUS protein ubiquitously, except for cholinergic 
neurons. Double-immunostaining for FUS and ChAT on spinal cord sections of Fus
ΔNLS/ΔNLS
/ChAT-CRE 
newborn mice revealed that FUS nuclear localization was indeed restored in cholinergic neurons in the 
ventral spinal cord, but not in other neighboring cells, consistent with motor neuron selective CRE 
expression (Figure 7A). FUS nuclear localization was either completely restored or partially corrected 
with a mixed cytoplasmic/nuclear FUS localization (Figure 7A), consistent with CRE having 
successfully at least one of Fus
ΔNLS
 allele to wild type. Neonatal lethality of Fus
ΔNLS/ΔNLS
 mice was not 
rescued by the ChAT-CRE allele, indicating that expression of mutant FUS in motor neurons is not the 
main contributor of neonatal lethality in homozygous mice. Last, we evaluated whether restoration of 
FUS nuclear localization in motor neurons would prevent motor neuron loss in Fus
ΔNLS/ΔNLS
 mice. This 
approach revealed that the presence of a ChAT-CRE allele was indeed sufficient to fully rescue motor 
neuron loss (Figure 7B-D), as well as restore a normal number of caspase 3-positive motor neurons 
(Figure 7E). These findings establish that cytoplasmic FUS mislocalization within motor neurons is 
required to induce their loss in Fus
ΔNLS/ΔNLS
 mice.  
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Discussion 
FUS and other related RBPs form cytoplasmic inclusions associated with nuclear clearance in 
affected cells from ALS and FTD patients. An outstanding question is whether disease is caused by gain 
of cytoplasmic toxicity or by loss of the nuclear function of the respective RBP. To gain insight into this 
conundrum, we targeted the FUS locus to generate two novel mouse models. In the first model, the last 
exon of Fus is no longer transcribed, resulting in the production of a truncated FUS protein that lacks the 
NLS and localizes almost exclusively to the cytoplasm (Figure 1). The second model results in complete 
loss of FUS expression (Figure 2). A thorough comparison of these two models allowed us to distinguish 
phenotypes induced by loss of FUS function from phenotypes contributed by gain of a toxic cytoplasmic 
function. 
Interestingly, this approach revealed that Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice share several features: both 
mouse models die shortly after birth due to respiratory insufficiency and exhibit reduced body weight and 
size. Transcriptomic analysis also revealed overlapping alterations in RNA levels and splicing. However, 
a reduced number of spinal motor neurons associated with increased perinatal motor neuron apoptosis and 
a subset of expression and splicing changes were uniquely found in Fus
ΔNLS/ΔNLS
 mice (Figures 3, 4, 5 and 
6). Thus, FUS mislocalization to the cytoplasm with reduced levels of nuclear FUS is associated with 
phenotypes linked to loss of FUS function, but also with motor neuron death induced by a gain of toxicity 
mechanism that is not recapitulated in the knock-out mouse model (Figure 5). The notion that loss of 
FUS function may not be sufficient to induce motor neuron degeneration is also supported by two recent 
reports. First, in an outbred genetic background, homozygous Fus gene trap mice reached 2 years of age 
without manifesting ALS-like phenotypes or motor neuron loss (Kino et al, 2015). Second, selective 
inactivation of the FUS homolog cabeza in neurons of adult Drosophila did not affect motor performance 
or life span, indicating that cabeza is not required for maintenance of neuronal function in adults 
(Frickenhaus et al, 2015). Here, we demonstrate that loss of FUS function is not sufficient and that gain of 
function by cytoplasmic redistribution of FUS is necessary to elicit motor neuron apoptosis. Notably, 
RNA-seq and RASL-seq experiments showed that the ∆NLS mutation triggered a partial loss of FUS 
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function in splicing and gene expression regulation. Loss of function, although not sufficient, may be 
necessary in Fus
ΔNLS/ΔNLS
 mice to induce motor neuron death. Indeed, a number of genes involved in 
synaptogenesis and/or in neurodegenerative diseases show altered expression (Ahi1, Dmpk, Nefl, Nefm, 
Tuba4a, Taf15) or splicing (Ndrg2, Mapt, Atxn2, Sort1) in Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice (Figure 3 and 
Figure 4), and these alterations linked to loss of FUS nuclear function may weaken the motor neuron and 
sensitize it to the toxic effects of cytoplasmic FUS accumulation. 
Importantly, we showed that motor neuron death in Fus
ΔNLS/ΔNLS
 mice could be prevented by 
selectively restoring FUS nuclear import in motor neurons (Figure 7), demonstrating that FUS 
cytoplasmic mislocalization within motor neurons is required to induce motor neuron loss. The 
observation that cytoplasmic mislocalization of FUS is intrinsically toxic to motor neurons contrasts with 
the non-cell-autonomous contribution to motor neuron degeneration demonstrated for SOD1 mutations 
(Boillee et al, 2006). Indeed, abrogation of mutant SOD1 expression in motor neurons delayed, but did 
not prevent, motor neuron degeneration, and a contribution of neighboring cells to SOD1 mediated 
toxicity is well established (Ilieva et al, 2009). Moreover, our data support a degenerative rather than 
developmental origin of motor neuron loss in newborn Fus
ΔNLS/ΔNLS
 mice. Indeed, the reduced number of 
motor neurons could have a developmental origin, either by impaired proliferation of motor neuron 
progenitors or secondary to defects in acquisition of motor neuron fate. However, this scenario is unlikely 
since motor neuron loss in Fus
ΔNLS/ΔNLS
 mice can be prevented by ChAT-CRE induced reversal of the 
Fus
ΔNLS
 locus to wild type (Figure 7). Indeed, expression of the ChAT gene, which encodes choline acetyl 
transferase, an enzyme essential for the biosynthesis of acetylcholine, is detectable only in postmitotic 
motor neurons, thus after exit from the cell cycle and acquisition of motor neuron fate (Alaynick et al, 
2011; Cho et al, 2014). Therefore, the pathogenic events driving motor neuron loss in Fus
ΔNLS/ΔNLS
 mice 
occur after motor neuron specification. An attractive hypothesis is that excessive motor neuron apoptosis 
in Fus
ΔNLS/ΔNLS
 mice happens during the so-called ‘natural cell death period’. During development, motor 
neurons are generated in excess and approximately 40% of the initially generated motor neurons are 
progressively removed. This process ensures the generation of the appropriate number of motor neurons 
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and guarantees the elimination of aberrant cells. According to the ‘neurotrophin hypothesis’, developing 
motor neurons compete for limited amounts of neurotrophic factors produced by the muscle targets. Only 
motor axons that establish stable and functional neuromuscular junctions receive sufficient survival 
signals and are maintained (Kanning et al, 2010; Oppenheim, 1991). Importantly, we found that motor 
neuron loss elicited by cytoplasmic FUS mislocalization is associated with increased apoptosis of spinal 
motor neurons (Figure 6). Several motor neuron intrinsic mechanisms may underlie increased motor 
neuron apoptosis in Fus
ΔNLS/ΔNLS
 mice and future studies are needed to investigate these possible 
mechanisms. For instance, expression of axon guidance receptors may be dysregulated in Fus
ΔNLS/ΔNLS
 
mice, leading to defects in motor axon targeting and failure to receive neurotrophic support. Alternatively, 
Fus
ΔNLS/ΔNLS
 motor axons may reach their targets, but reduced expression of receptors for muscle-derived 
neurotrophic factors may render a fraction of motor neurons insensitive to survival signals.  
Previous work suggested various potential toxic mechanisms for cytoplasmic FUS, and our study 
sheds light on several of these candidate pathways. First, cytoplasmic FUS could generate toxic FUS 
aggregates in the cytosol, as shown in yeast models of FUSopathies (Ju et al, 2011; Sun et al, 2011). 
Here, we detected neither FUS-positive nor ubiquitin- or p62-positive aggregates expected to occur in 
case of strong ubiquitin proteasome system (UPS) or autophagy impairment. Thus, at least in this model 
and at this perinatal age, FUS aggregation or robust FUS-mediated impairment of protein clearance 
pathways are dispensable for toxicity towards motor neurons. Cytoplasmic FUS could also alter stress 
granule (SGs) dynamics through its localization to SGs upon stress and its regulatory properties towards 
SGs assembly (Li et al, 2013). However, in Fus
∆NLS/∆NLS
 mice, we observed neither altered eIF2α 
phosphorylation, nor formation of SGs in spinal cord motor neurons, suggesting that major impairment of 
SGs biology is not required for FUS toxicity in vivo in this model. Further studies will be necessary to re-
evaluate the presence of FUS-containing cytoplasmic aggregates, stress granule alterations or pathology 
involving other RBPs in aged heterozygous Fus
ΔNLS/+
 mice and Fus
+/-
 mice. Finally, impaired FUS 
nuclear import could affect nuclear function in a manner distinct from pure loss of function. Indeed, FUS 
is a binding partner of multiple proteins, including SMN (Tsuiji et al, 2013; Yamazaki et al, 2012), 
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HDAC1 (Wang et al, 2013), Drosha (Morlando et al, 2012), RNA polymerase II (Schwartz et al, 2012), 
and PRMT1 (Tibshirani et al, 2014), known to have profound effects on splicing and gene expression. 
The cytoplasmic retention of one, or several, of these proteins by cytoplasmic FUS could lead to 
differences in splicing or gene expression. Genomewide RNA analysis showed that splicing and gene 
expression in Fus
∆NLS/∆NLS
 mice resembled that of Fus
-/-
 mice, consistent with loss of nuclear FUS 
function, yet this similarity was only partial. Gene ontology analysis pointed to alterations in mRNA 
translation and extracellular matrix as potential functions uniquely altered in Fus
∆NLS/∆NLS
 mice, an 
interesting example being upregulation of KIS, a kinase involved in dendritic mRNA translation. 
Importantly, FUS has been involved in local mRNA translation at cell protrusions (de Hoog et al, 2004; 
Yasuda et al, 2013) and SMN, a major FUS interacting partner, is also important in mRNA transport and 
translation (Jablonka et al, 2007; Rathod et al, 2012; Rossoll et al, 2003; Sanchez et al, 2013; Zhang et al, 
2006). Our work provides additional support to the hypothesis that impairment of local mRNA translation 
may contribute to neuronal death in FUS-associated diseases.  
An interesting observation is that both Fus
ΔNLS/ΔNLS
 and Fus
-/-
 mice die shortly after birth of 
respiratory insufficiency, presumably caused by loss of FUS function. A concerted action of several 
physiological systems is required for newborn mice to breathe normally, and defects in any of these 
systems can lead to neonatal lethality (Turgeon & Meloche, 2009). Firstly, the respiratory rhythm is 
generated in the respiratory center in the brainstem and transmitted through the spinal motor neurons to 
the respiratory muscles (diaphragm and intercostal muscles). Therefore, structural or functional defects of 
neurons in the respiratory center, motor neurons, neuromuscular junctions and/or respiratory muscles can 
lead to respiratory distress. Our observation that neonatal lethality of Fus
ΔNLS/ΔNLS
 mice is not rescued by 
restoration of FUS nuclear import in motor neurons indicates that loss of FUS function in cell types other 
than motor neurons is sufficient to trigger neonatal lethality. Alternatively, we cannot exclude that the 
rescued motor neurons, despite being histologically normal, remain functionally abnormal, in a manner 
analogous to Nova double knock-out animals rescued with neuronal agrin (Ruggiu et al, 2009). 
Electrophysiological characterization of neuromuscular transmission could help discriminate between 
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these two possibilities. Apart from neuromuscular alterations, defects in lung morphogenesis or 
maturation, cardiovascular defects, hematological defects or skeletal defects can all result in poor blood 
oxygenation and the characteristic cyanosis observed in Fus
ΔNLS/ΔNLS
 and Fus
-/-
 neonates. It will be 
interesting to investigate these possible causes of neonatal lethality due to loss of FUS function in future 
studies. In particular, generation of conditional Fus knock-out mice would provide a valuable tool to 
evaluate whether selective FUS inactivation in all neurons, muscle, lung epithelium or the vasculature 
would result in respiratory insufficiency and neonatal death. Possibly, loss of FUS function in a 
combination of these tissues is necessary to induce this phenotype. 
The recessive pattern of inheritance of FUS mutations in a few families (Bertolin et al, 2014; 
Kwiatkowski et al, 2009) render our studies of Fus
ΔNLS/ΔNLS
 mice clinically relevant. However, the vast 
majority of FUS mutations are characterized by a dominant inheritance pattern. In this respect, it will be 
highly interesting to age heterozygous Fus
ΔNLS/+
 mice and Fus
+/-
 mice and characterize their phenotype. 
Indeed, some mechanisms apparently not at play in homozygous Fus
ΔNLS/ΔNLS
 mice, such as FUS-
containing cytoplasmic aggregates, stress granule alterations or pathology involving other RBPs, will 
have to be re-evaluated in these mice. The very severe phenotype of Fus
∆NLS/∆NLS 
mice resembles spinal 
muscular atrophy, which is caused by mutations in the SMN1 gene, whose product SMN interacts directly 
with FUS and is an integral component of the spliceosome (Gerbino et al, 2013; Groen et al, 2013; Sun et 
al, 2015; Tsuiji et al, 2013; Yamazaki et al, 2012; Yu et al, 2015). This is further reinforced by the strong 
splicing defects observed in Fus
∆NLS/∆NLS 
mice and is consistent with juvenile onset in many FUS-ALS 
patients with C-terminal truncation mutations. These similarities strengthen the links between ALS and 
SMA, and suggest that SMA, ALS and FTD could constitute extremes of the same disease continuum.  
 In conclusion, this study provides in vivo genetic evidence that cytoplasmic mislocalization of 
FUS triggers apoptotic motor neuron degeneration and demonstrates a crucial role for a gain of toxic 
function in this process. Motor neuron loss occurs at least partially through a cell autonomous gain of 
function mechanism, since complete loss of FUS is not associated with motor neuron death, and rescue of 
nuclear FUS within motor neurons prevents neuronal death. 
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Materials and Methods: 
 
Generation of conditional knock-in Fus
 ΔNLS/ΔNLS
 and Fus
-/-
 mice 
Knock-in Fus mice with the conditional ablation of exon 15 were generated in the Institut Clinique de la 
Souris (ICS, Illkirch, Strasbourg) using standard procedures. The Fus locus was engineered to include, in 
between the exons 12 and 13 of the gene, an inserted floxed cDNA encoding exons 13 and 14 of FUS, 
followed by 3 STOP cassettes. We obtained germline transmission of the recombinant allele. 
Homozygous Fus
 ΔNLS/ΔNLS
 mice were generated by intercrossing Fus
 ΔNLS/+
 animals.  
For generation of Fus
-/-
 mice, the mouse ES cell clone EUCE0131_G08 was obtained from the European 
Conditional Mouse Mutagenesis Consortium (EUCOMM)(Friedel et al, 2007). Southern blotting and 
sequencing of PCR-amplified genomic sequences confirmed a single gene trap insertion event in the first 
intron of Fus. Blastocyst injection of ES cells resulted in chimeric mice, which allowed for germline 
transmission of the mutant Fus allele. As the ES cells were generated in a 129P2 background, the 
resulting offspring was backcrossed at least five times to C57Bl6 mice. The genetic background of all 
mice used in this study is C57Bl6. 
 
Animal breeding and genotyping  
Fus
 ΔNLS
 and ChAT-CRE mice were housed in the animal facility of the Faculty of medicine from 
Strasbourg University, with 12/12 hours of light/dark cycle. The animals had unrestricted access to 
standard diet and water. Fus
+/+
, Fus
 ΔNLS/+ 
and Fus
 ΔNLS/ ΔNLS
 mice were produced by interbreeding Fus
 ΔNLS/+ 
mice, and littermates were systematically used as controls. Fus
 ΔNLS/ΔNLS
/ChAT-CRE mice were generated 
by a two-step breeding strategy. First, heterozygous Fus
 ΔNLS/+ 
mice were crossed with ChAT-CRE mice. 
Fus
 ΔNLS/ΔNLS
/ChAT-CRE were then crossed with heterozygous Fus
 ΔNLS/+ 
mice and these F2 litters were 
used in experiments. Fus
 ΔNLS
 mice were genotyped by PCR on tail DNA using following primers: GAT 
TTG AAG TGG GTA GAT AGA TAG TGC AGG and CCT TTC CAC ACT TTA GGT TAG TCA 
CAG. ChAT-CRE mice were genotyped by PCR on tail DNA using following primers: CCA TCT GCC 
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ACC AGC CAG and TCG CCA TCT TCC AGC AGG.  
Fus
-/-
, Fus
+/-
 and Fus
+/+
 mice were generated by crossing Fus
+/-
 mice and PCR genotyped using a 
combination of three primers: (i) a common forward primer (CTC TCC TGG CCC GGT CAC) which 
anneals upstream of the gene trap insertion, (ii) a reverse primer (GCC AGA GGA GCG CGT GC) which 
anneals downstream of the gene trap insertion and gives rise to a 150 bp band for wild type Fus, but no 
band for the gene trap allele under the cycling conditions used, and (iii) a reverse primer (CTG GAC TAC 
TGC GCC CTA C) which anneals in the gene trap and gives rise to a 715 bp band when the gene trap 
allele is present. 
All experiments were approved by the local ethical committees of Strasbourg and Muenster universities. 
 
Western blot 
For western blotting, tissue powder (brain, spinal cord and gastrocnemius muscle) was homogenized in 
lysis buffer (250 mM Sucrose solution, 1 mM EDTA, 2% SDT, 1 mM DTT, 10 mM Tris HCl pH 7.4) 
containing protease inhibitor (Sigma P8340) and phosphatase inhibitor cocktail (Sigma 8345) and 
centrifuged at 12000 x rpm for 15 minutes at room temperature. Protein concentration was measured 
using BCA Protein Assay. Equal amounts of protein (20µg) were separated by SDS-PAGE 10% and 
blotted onto a nitrocellulose membrane. Membranes were saturated with 10% non-fat milk and then 
incubated with the primary antibodies against the N-terminal part of FUS (Proteintech
TM
, 18592-1-AP; 
1:1000 and Bethyl A303-839A; 1:1000) diluted in 3% non-fat milk , and antibodies against the C-
terminal part of FUS   (Bethyl A300-294A;  1:10000 and Bethyl A300-302A; 1:10000), followed by anti-
rabbit (P.A.R.I.S.; BI2413) or anti-goat (Sigma A5420) secondary antibody diluted 1:5000. Of note, the 
Bethyl antibody A300-302A is reported by the company as raised against the N-terminal part of the 
protein, but evidence supports that this antibody recognizes the C-terminal NLS of FUS.. Antibodies 
against Histone 3 (Cell signaling, #9715; 1:1000) was used as loading control. All blots were analyzed 
with chemiluminescence (ECL; Luminata Forte Kit, Millipore WBLUF0500) using the Molecular Imager 
Chemidoc XRS (Biorad) as detection system. 
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Immunodetection of FUS in mouse embryonic fibroblasts and motor neurons 
Localization of FUS protein was analyzed in spinal cord motor neurons on cryosections prepared as 
described below and double stained for FUS (Proteintech
TM
; 11570-1-AP; 1:100), and ChAT (Millipore, 
AB144-P; 1:50)  or  for FUS (Proteintech
TM
; 11570-1-AP; 1:100 and NeuN (Millipore, ABN78; 1:100). 
Fus immunoreactivity was visualized with a confocal microscope (LSM 510; Carl Zeiss, Thornwood, 
NY), within mouse embryonic fibroblasts (MEF) double stained with antibodies against the internal or N-
terminal part of FUS (Proteintech
TM
, 11570-1-AP; 1:100 and Bethyl A303-839A; 1:100) and Draq5 (Cell 
Signaling, 4084; 1:1000) followed by fluorescent secondary antibodies donkey anti-rabbit Alexa 488 
(Jackson, A21206) and donkey anti-goat Alexa 594 (Molecular Probes, A11058) diluted 1:500. This 
experiment was repeated three times; data shown are from one representative experiment. 
 
Quantification of spinal cord motor neurons 
Spinal cords were removed and immersed in fixative for 2 h at 4°C. Samples were transferred overnight 
into 30% sucrose in 0.1 M phosphate buffer (PB) at 4°C for cryoprotection, embedded in medium 
(Tissue-Tek® O.C.T.Compound, SAKURA#4583) and cut with a cryostat (Leica CM 3050S). P0 spinal 
cords were cut in serial 25 μm-thick sections and mounted onto 2% gelatin-coated slides to be processed 
for immunostaining.  
For Nissl staining slides were air-dried overnight. Sections were then hydrated through 100% and 95% 
alcohol to distilled water, immersed in 0.1% Cresyl violet acetate Certistain®, MERCK#5235) and cover-
slipped with Roti-histokitt (Roth, 6638.1). 
For immunohistochemistry (IHC), unspecific binding sites were blocked with 5% horse serum (HS), 
0.5% Triton X-100 for 30 minutes at room temperature (RT), immersed in 3% hydrogen peroxide (H2O2) 
to remove the endogenous peroxidase activity, rinsed in phosphate buffered saline (PBS) and incubated 
with goat polyclonal anti-Choline Acetyl Transferase (ChAT) antibody (Millipore, AB144-P; diluted 
1:50) overnight at RT in a humidified chamber. After rinsing in PBS, sections were incubated with 
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biotinylated donkey anti-goat IgG (Jackson, 705-066-147; 1:250) for 1.5 h, rinsed in PBS and then 
incubated with ABC kit (Vektor, PK7200; 1:4000) for 1 h. All antibodies were diluted in 0.01M PBS, 
0.1% Triton X-100. Peroxidase staining was obtained by incubating the sections in 0.075% 3,3’-
diaminobenzidine tetrahydrochloride (DAB; Sigma Aldrich) and 0.002% H2O2 in 50 mM Tris-HCl pH 
7.5. Sections were dehydrated, air dried and coverslipped with Roti-histokitt (Roth, 6638.1).  
Motor neurons were counted at L1–L5 on both cresyl violet and ChAT stained sections at 20X 
magnification (for each genotype: exact numbers of animals per group are provided in figure legends). 
The counting was performed per ventral horn in every tenth section for ten sections in total per animal. In 
Nissl-stained sections, only neurons with an area ≥ 80 μm2 and located in a position congruent with that 
of motor neuron groups were counted(d'Errico et al, 2013). All ChAT
+
 profiles located in the ventral 
horns of immunostained sections clearly displayed on the plane of the section were counted. Total 
estimated motor neuron numbers were obtained using a computer-assisted microscope (Nicon Eclipse 
E800) and the software (Nis Elements version 4.0). Cells were counted on the computer screen using a 
digital camera (Nicon Digital Sight DS-U3) mounted on a microscope. The soma size of Nissl+ motor 
neurons was also analyzed by measuring cross-sectional areas at 20X magnification using ImageJ 
software(Schneider et al, 2012). 
This experiment was repeated two times for both groups of animals Fus
 ΔNLS
 and ChAT-CRE; images 
shown are from one representative experiment. 
 
In situ detection of apoptosis in spinal cord cells by TUNEL assay 
For TUNEL staining, the spinal cord cryosections prepared as described above were treated with TUNEL 
reagent (Trevigen, 4812-30-K) according to the kit instructions. The tissue sections were permeabilized 
with Cytonnin
TM
. All TUNEL-positive cells were counted and examined for the typical pathological 
feature of apoptosis under a fluorescent microscope (Nikon Eclipse E800) at a 20x magnification. The 
numbers in each set of sections were summed up and divided by number of the sections in a set. The 
mean number of TUNEL-positive cells for each genotype group was calculated. 
Scekic-Zahirovic et al.          98 
 
Caspase 3 immunostaining and apoptotic events 
Apoptotic bodies across the lumbar spinal cord cross-sectional area were determined by fluorescence 
microscopy. For detection of caspase-positive motor neurons sections were double-stained with goat-anti-
ChAT (Millipore, AB144-P; diluted 1:50) and rabbit-anti-cleaved caspase-3 (R&D Systems, AF835; 
1:100) and combination of secondary antibodies Alexa 594 anti-goat (Molecular Probes, A11058; 1:500) 
and Alexa 488 anti-rabbit (Jacson, A21206; 1:500)  plus Draq5 (both 1:1000). Total number of apoptotic 
bodies were counted all over the cross sectional area for every tenth section for 10 sections in total per 
animal. Apoptotic motoneurons were counted as cells triple positive for ChAT, caspase and condensed 
chromatin by Draq5. Information on the total numbers of apoptotic counts and further details are 
presented along with the description of the results. This experiment was repeated two times for both 
groups of animals Fus
 ΔNLS
 and ChAT-CRE  mice; images shown are from one representative experiment. 
 
Lungs histology 
Lungs were harvested and fixed with  4% formaldehyde solution (Sigma 47608) for 24 h and embedded 
in paraffin; Sections of 6 µm were stained with hematoxylin (Vector H-3401) and eosin (Eosin Y-solution 
0.5%; Roth X883.1) for light microscope observation (Nikon Eclipse E800) at a 40x magnification. 
 
Other immunostainings  
For detection of protein aggregation spinal cord sections were double immunostained with N-terminal 
part of FUS (Bethyl A303-839A; 1:100) and either  anti-Sqstm1 (p62, Abcam 56416; 1:100) or anti-
Neurofilament (Abcam 24574, clone SMI-312; 1:100) or anti-Ubiquitin (Millipore,  MAB1510; 1:100) 
and Draq5 (Cell Signaling, 4084; 1:1000) followed by fluorescent secondary antibodies donkey anti-
mouseAlexa 488 (Jackson, 715-545-150) and donkey anti-goat Alexa 594 (Molecular Probes, A11058) 
diluted 1:500. Peroxidase staining was performed on the spinal cord for analyzing the localization of 
TARDBP (Proteintech 10782-2-AP; 1:100) and TAF15 (Abcam 134916; 1:100) followed by biotinylated 
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donkey anti-rabbit IgG (Jackson, 711-165-152; 1:250). For stress granule markers we used following 
antibodies eIF2a phosphorylated at Ser51 (rabbit monoclonal, Abcam 32157 ; 1 :500 ), and TIAR (mouse 
monoclonal, BD Biosciences ; 1 :500) with DAPI (Molecular Probes D1306 ; 1 ug/ml). 
 
Imaging 
Single-layer images (except for mouse embryonic fibroblasts (MEF) were acquired using a laser-scanning 
microscope (confocal Leica SP5 Leica Microsystems CMS GmbH) equipped with 63×oil objective 
(NA1.4). Excitation rays are sequential argon laser 488nm, diode 561nm, Helium Neon laser 633nm. 
Emission bandwidths are 500-550nm for Alexa488, 570-620nm for Alexa594, and 650-750nm for Draq5. 
 
Analysis of expression changes by RNA-seq 
Total RNA from brains of Fus
ΔNLS/ΔNLS
, Fus
-/- 
and their control littermates were extracted with 
TRIzol (Invitrogen). RNA quality was measured using the Agilent Bioanalyzer system or RNA screen 
Tape (Agilent technologies) according to the manufacturer’s recommendations, and processed using the 
Illumina TruSeq Stranded mRNA Sample Preparation Kit according to manufacturer’s protocol. 
Generated cDNA libraries were sequenced using an Illumina HiSeq 2000 sequencer with 4-5 biological 
replicates sequenced per condition using single read, 50 cycle runs. Quality of sequencing reads was 
assessed using FastQC (Babraham Bioinformatics) and then aligned to a mouse reference genome (mm9, 
UCSC Genome Browser) using TopHat (version v2.0.10). Sequencing yielded, on average, 15 million 
non-redundant reads per sample with a 48.4 - 58.7% mapping rate. Cufflinks (version v2.1.1) was used to 
generate transcript abundance for each annotated protein-coding gene as Fragments Per Kilobase of 
transcript per Million mapped reads (FPKM), and statistical analysis and comparison of FPKM values 
was calculated using Cuffdiff (version v2.1.1). Genome-wide unsupervised clustering analysis and heat 
maps with significant changes between different groups were generated using R (Bioconductor). 
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Confirmation of expression changes by quantitative RT-PCR  
RNA samples from brains of Fus
ΔNLS/ΔNLS
, Fus
-/- 
and their control littermates were treated with 
DnaseI (Invitrogen) and converted to cDNA using SuperScript III kit (Invitrogen) with random hexamers 
or the Iscript Reverse Transcriptase (Bio-Rad). qRT-PCR reactions were performed with 3-5 mice for 
each group and two technical replicates using the iQ SYBR green Supermix (Bio-Rad) on either the IQ5, 
the CFX96 Touch or the CFX384 Touch Real-Time PCR detection system (Bio-Rad). Analysis was 
performed using the iQ5 optical system software (Bio-Rad; version 2.1) or the CFX manager system 
software (Bio-Rad; version 3.1). Expression values were normalized to the control gene Rsp9, and were 
expressed as a percentage of the average expression of the control samples. Primer sequences were 
designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) and are available in Supplementary 
Table 9. 
 
Analysis of splicing alterations by RASL-seq 
RNA-mediated oligonucleotide Annealing, Selection, and Ligation with Next-Generation 
sequencing (RASL-seq) analysis of alternative splicing changes was carried out as already described 
elsewhere(Li et al, 2012; Zhou et al, 2012). In brief, a pool of oligonucleotides was designed to detect 
3859 alternative splicing events in mice. One hundred fmol of RASL-seq oligos were annealed to 1 μg of 
total RNA isolated from brains of Fus
ΔNLS/ΔNLS
, Fus
-/- 
and their control littermates. After ligation, 5 μl 
eluted ligated oligos was used for 16 ~ 18 cycles of PCR amplification, and the bar-coded PCR products 
were sequenced using an Illumina HiSeq 2000 sequencer with 24-30 samples per lanes. Sequencing data 
was decoded allowing no mismatch with each barcode, and target sequences were mapped with RASL-
seq oligo pool sequences using the short read alignment software bowtie allowing for 1 mismatch at both 
the left and right side of the ligated oligos. An average of ~5 million reads from each sample was mapped, 
with events with less than 4 counts in one of the isoforms removed. Ratios of the counts of shorter to 
longer isoforms were calculated. The significantly changed events were identified by t-test and average 
fold change. Unsupervised clustering analysis and heat maps with significant changes between different 
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groups were generated using R (Bioconductor). 
 
Confirmation of splicing changes by semi-quantitative RT-PCR  
Semi-quantitative RT-PCR (25-30 cycles) was used to validate alternative splicing changes. 
Isoform products were separated on 10% polyacrylamide gels and stained with SYBR gold (Invitrogen) 
and quantified with ImageJ software to record the intensity of the bands corresponding to different 
splicing isoforms. Intensity ratios of long and short isoforms were averaged from three biological 
replicates per group. Primer sequences were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/) in exons flanking the alternatively spliced exon. PCR primer sequences 
are shown in Supplementary Table 9.  
 
Statistics 
For the animal experiments, the values from each animal were averaged for each genotype group and 
analyzed by unpaired Student’s t-test, two tailed. Comparison of three or four groups was performed 
using One-way ANOVA and Tukey post-hoc test. Data were analyzed by using the Graphics Prism 
Program (Graph Pad Software, San Diego, CA) and expressed as mean ± SEM (standard error of the 
mean) and differences were considered significant when p ≤ 0.05. 
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Figure Legends: 
 
Figure 1: FUS mislocalization in Fus
ΔNLS/ΔNLS 
 mice. 
(A) Schematic representation of the Fus gene locus (upper panel). Lower panels depict exons 11-15 in the 
wild type allele (left) and ∆NLS allele (right) with localization of PCR primers used for genotyping 
(gDNA, used in B) and for RT-PCR (Total and ∆NLS, used in C). Arrow: translational start site. STOP 
cassettes are indicated in red; loxP sites as black triangles; coding regions are in dark blue and UTRs in 
light blue. Location of the region encoding the nuclear localization signal (NLS) is indicated in exon 15. 
(B) Representative PCR genotyping results from 2 Fus
+/+
, 2 Fus
ΔNLS/+
 and 2 Fus
ΔNLS/ΔNLS
 knock-in mice 
using primers designed around the distal loxP site of the Fus
ΔNLS 
allele and shown as gDNA in panel A. 
The expected size of the PCR product of the ∆NLS allele is 240 bp; the size of wild type allele is 160 bp. 
(C) RT-PCR analysis of brain from 2 Fus
+/+
, 2 Fus
ΔNLS/+
 and 2 Fus
ΔNLS/ΔNLS
 knock-in P0 mice using 
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primers located in the STOP cassette, and thus specific to the ∆NLS mRNA (∆NLS, upper panel), or 
primers located in exon 11, i.e. upstream of the floxed cDNA insertion, and thus amplifying total Fus-
derived mRNA (Total, middle panel). PCR amplification of 18S rRNA is shown as standard gene (lower 
panel). Presence of the ∆NLS mRNA is detected in both FusΔNLS/+ and FusΔNLS/ΔNLS while absent in Fus+/+ 
tissues.  
(D) Immunoblot analysis of FUS protein in cerebral cortex of 2 Fus
+/+
, 2 Fus
ΔNLS/+
 and 2 Fus
ΔNLS/ΔNLS 
knock-in mice using a combination of two different antibodies targeting either the C-terminal (C-ter. 1 
and C-ter. 2) NLS, the N-terminal part (N-ter. 1) or an internal part (N-ter. 2) of FUS. Note that 
immunoblots with C-terminal antibodies show a complete disappearance of immunoreactive bands in 
Fus
ΔNLS/ΔNLS
 knock-in tissues confirming that FUS protein derived from the ∆NLS allele lacks NLS. 
Histone 3 (HIST3) was used as a loading control. Molecular weight markers are shown on the left, and 
apparent MW is indicated. 
(E) Double immunostaining for the motor neuronal marker ChAT and the Fus N-terminal part on the 
ventral horn of spinal cord.  
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Figure 2: Generation of a complete Fus
-/-
 loss of function mouse model. 
(A) Schematic representation of the Fus gene locus (upper panel). Lower panels depict exons 1-3 in the 
wild type allele (left) and loss of function allele (right). Arrow: translational start site; SA: splice 
acceptor; βgeo: β-galactosidase/neomycin phosphotransferase fusion gene; pA: polyA.  
(B) Representative immunoblot for FUS on protein extracts of E18.5 brain. Histone 3 is used as loading 
control.  
(C) Quantification of FUS protein levels from immunoblots (c) revealed that Fus
-/- 
mice do not express 
FUS protein. (**) p<0.01. 
(D) Quantitative real-time PCR showing absence of Fus transcript in Fus
-/- 
mice. (**) p<0.01. 
(E) Immunostaining for the neuronal marker NeuN and FUS on the spinal cord ventral horn of E18.5 
Fus
+/+ 
and
 
Fus
-/- 
mice.  
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Figure 3: FUS-dependent expression changes in mouse brain 
(A) RNA-seq reads from brain of homozygous knock-in (Fus
ΔNLS/ΔNLS
, upper panel), homozygous knock-
out (Fus
-/-
, middle panel) and control (Fus
+/+
, lower panel) mice showing the absence of exon 15 (red 
arrow) in Fus mRNA in Fus
ΔNLS/ΔNLS
 mice while the entire Fus transcript is absent in Fus
-/-
mice (green 
arrows).  
(B) Heatmap with hierarchical clustering of RNA-seq data from biological replicates of Fus
ΔNLS/ΔNLS
 
(N=5) and control littermates (N=4), showing genes differentially regulated between both genotypes 
among which 237 are upregulated and 549 are downregulated in Fus
ΔNLS/ΔNLS 
animals.  
(C) Heatmap with hierarchical clustering of RNA-seq data from biological replicates of Fus
-/- 
(N=5)
 
and 
control littermates (N=5), showing genes differentially regulated between both genotypes among which 
669 are upregulated and 889 are downregulated in Fus
-/- 
animals.  
(D) Venn diagram showing the number of overlapping genes misregulated in Fus
ΔNLS/ΔNLS
 (blue circle) and 
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Fus
-/- 
(red circle) brains with 353 genes similarly downregulated or upregulated upon cytoplasmic 
mislocalization or complete loss of FUS.  
(E) Normalized expression (based on FPKM from RNA-seq) of genes identified by RNA-seq to be 
significantly downregulated (Ahi1, Kcnip1, Nefm, Nefl, Tuba4a, Dmpk, Rad9b, Stac3, Hist1h2bc, 
Hist1h1c) or upregulated (Fam193b, Pmm2, Bphl, Taf15) in both Fus
ΔNLS/ΔNLS
 and Fus
-/- 
compared to their 
control. RNA-seq results are consistent with expression levels measured by qRT-PCR for these genes 
(Supplementary Fig. 5A). Error bars represent SEM in 4-5 biological replicates. 
(F) Normalized expression (based on FPKM from RNA-seq) of genes identified by RNA-seq to be 
uniquely changed in Fus
ΔNLS/ΔNLS
 mice (Trove2, Uhmk1, Ssh3, Vtn, Snrpb, Ephb3). RNA-seq results are 
consistent with expression levels measured by qRT-PCR for these genes (Supplementary Fig. 5D). Error 
bars represent SEM in 4-5 biological replicates.  
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Figure 4: FUS-dependent alternative splicing alterations in mouse brain 
(A) Heatmap with hierarchical clustering of RASL-seq data from biological replicates of Fus
ΔNLS/ΔNLS
 
(N=4) and control littermates (N=4), showing 173 alternative splicing alterations associated with 
expression of cytoplasmic FUS in knock-in animals. (B) Heatmap with hierarchical clustering of RASL-
seq data from biological replicates of Fus
-/- 
(N=5)
 
and control littermates (N=5), showing 252 alternative 
splicing alterations associated with loss of FUS in knock-out animals. (C) Semi-quantitative RT-PCR 
analyses of selected targets confirmed alternative splicing changes in Fus
ΔNLS/ΔNLS
 and Fus
-/- 
compared to 
their respective littermate controls. Left panels show representative acrylamide gel pictures of RT-PCR 
products. Quantification of splicing changes from at least three biological replicates of Fus
ΔNLS/ΔNLS
 (blue 
bars) and Fus
-/- 
(red bars) compared to their control littermates (Fus
+/+
, black bars) by semi-quantitative 
RT-PCR (middle panel) and RASL-seq (right panel) are shown. Error bars represent SEM.  
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Figure 5: Motor neuron loss in Fus
ΔNLS/ΔNLS 
mice 
(A) Representative light microscopy images of spinal cord sections of Fus
+/+
, Fus
ΔNLS/+
, Fus
ΔNLS/ΔNLS 
and 
Fus
-/- 
 mice at birth stained with cresyl violet (Nissl, A
1
, A
3
 A
5
, A
7
), or anti-choline acetyl transferase 
(ChAT, A
2
, A
4
 A
6
, A
8
). Note the significantly decreased number of motor neurons in Fus
ΔNLS/ΔNLS
 mice.  
(B-C) Quantification of motor neurons per spinal cord ventral horn in Fus
ΔNLS/ΔNLS 
mice .  The number of 
ChAT+ motor neurons (B) and Nissl+ motor neurons (defined as Nissl positive cells with a soma area 
>80µm
2
) (C) is significantly lower in Fus
ΔNLS/ΔNLS
 mice. For Nissl+ N=8-5; and for ChAT+  N=7 per 
genotype, (**) p<0.01 vs Fus
+/+
, (##) p<0.01 vs Fus
∆NLS/+
 ; One way ANOVA followed by Tukey post 
hoc test. 
(D-E) Quantification of motor neurons per spinal cord ventral horn in Fus
-/- 
 mice. Number of ChAT+ (D) 
and Nissl+ (E) motor neurons is not altered in Fus
-/- 
mice. N=6 per genotype, (ns) non significant, by 
Student’s unpaired t-test. 
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Figure 6: Motor neuron apoptosis in Fus
ΔNLS/ΔNLS 
mice 
(A) In situ detection of apoptotic cells in the spinal cord by TUNEL assay. Representative images 
showing increased DNA fragmentation (TUNEL+ cells in green), a characteristic hallmark of apoptosis, 
in spinal cord of Fus
ΔNLS/ΔNLS
 mice (panels A
4
-A
6
).  
(B) Quantification of the total number of TUNEL and DRAQ5 (blue) double-positive cells in Fus
ΔNLS/ΔNLS 
and Fus
+/+
 per spinal cord section. N=3 per genotype, (*) p<0.05, by Student’s unpaired t-test. 
(C-D) Immunofluorescence microscopy of spinal cord of Fus
+/+
 (C) and Fus
ΔNLS/ΔNLS 
(D) mice showing 
active-caspase 3 (green), ChAT (red) and DNA (cyan, DRAQ5). Note increased co-localization of 
apoptotic bodies, Cas3-positive with fragmented nuclei, and ChAT-positive motor neurons.  
(E) Quantification of caspase3 (CAS3)/ChAT/DRAQ5 triple positive cells shows significant increase of 
apoptotic motor neurons in Fus
ΔNLS/ΔNLS
 mice. N=7 per genotype, (**) p<0.01, by Student’s unpaired t-
test. 
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Figure 7: Selective restoration of FUS nuclear import in motor neurons rescues motor neuron loss 
(A) Double-immunolabeling of spinal cord neurons with ChAT (red) and N-terminal FUS antibody 
(green). Nuclei were visualized with DRAQ5 (blue). Cellular localization of FUS was analyzed in the 
ventral spinal cord of Fus
+/+
/ChAT-CRE (A
1
-A
4
), Fus
ΔNLS/ΔNLS
/- (A
5
-A
8
), and Fus
ΔNLS/ΔNLS
/ChAT-CRE (A
9
-
A
12
). 
FUS was completely nuclear in ChAT+ neurons of Fus
+/+
/ChAT-CRE, while cytoplasmic in Fus
ΔNLS/ΔNLS
/-, 
In the ventral horn of Fus
ΔNLS/ΔNLS
/ChAT-CRE mice, ChAT+ neurons (motor neurons, e.g. within the 
dashed square) displayed nuclear FUS immunoreactivity, while ChAT negative cells (arrows) retained 
cytoplasmic FUS immunoreactivity (A
9
-A
12
). Thus, the ChAT-CRE allele induced successful 
recombination and restoration of FUS nuclear import in motor neurons. (B) Representative light 
microscopy images of spinal cord sections of Fus
+/+
/ChAT-CRE (B
1
, B
4
), Fus
ΔNLS/ΔNLS
/- (B
2
, B
5
) and 
Fus
ΔNLS/ΔNLS
/ChAT-CRE (B
3
, B
6
) mice at birth stained with cresyl violet (Nissl, B
1
-B
3
) or anti-choline 
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acetyl transferase (ChAT, B
4
-B
6
). Note the fully restored number of motor neurons in Fus
ΔNLS/ΔNLS
/ChAT-
CRE mice.  
(C-D) Quantification of motor neurons per spinal cord ventral horn. The number of Nissl+ (C) and 
ChAT+ (D) motoneurons is restored in Fus
ΔNLS/ΔNLS
/ChAT-CRE mice while significantly lower in 
Fus
ΔNLS/ΔNLS
 mice. N=11 Fus
+/+
/ChAT-CRE, N=7 Fus
ΔNLS/ΔNLS
/- and N=8 Fus
ΔNLS/ΔNLS
/ChAT-CRE; (**) 
p<0.01 vs Fus
+/+
, (##) p<0.01 vs Fus
∆NLS/+
 ; One way ANOVA followed by Tukey post hoc test. 
(E) Total numbers of caspase3 (Cas3)/ChAT/DAPI triple positive cells show a similar number of 
apoptotic motor neurons in Fus
ΔNLS/ΔNLS
/ChAT-CRE and Fus
+/+
/ChAT-CRE, but significantly lower 
numbers than in  Fus
ΔNLS/ΔNLS
/- mice. N=9 Fus
+/+
/ChAT-CRE, N=7 Fus
ΔNLS/ΔNLS
/- and N=8 
Fus
ΔNLS/ΔNLS
/ChAT-CRE;, (**) p<0.01 vs Fus
+/+
, (#) p<0.05 vs Fus
∆NLS/+
 ; (ns) non-significant; One way 
ANOVA followed by Tukey post hoc test. 
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Supplementary Figure 1: Relevance of Fus
∆NLS 
 mice to human ALS 
Upper panel: scheme of the wild type FUS protein. The NLS, encoded by exon 15, includes the C-terminal amino-acids 
(from 507-526, boundaries shown as the two dashed lines). 
Middle panels: 11 frameshift mutations (upper middle panel) and 2 truncating mutations (lower middle panel) in the FUS 
gene have been identified in ALS families. The corresponding mutant FUS proteins are shown. Insertions of abnormal 
polypeptide sequences induced by frameshift mutations are shown as red boxes. 
Lower panel: structure of FUS
∆NLS
 protein in Fus
∆NLS
 mice. 
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Supplementary Figure 2: Expression of the Fus gene in various tissues of Fus
∆NLS 
mice 
(A) RT-PCR analysis of spinal cord and gastrocnemius muscle from 2 Fus
+/+
, 2 Fus
ΔNLS/+
 and 2 Fus
ΔNLS/ΔNLS
 P0 mice using 
primers located in the STOP cassette, and thus specific to the Fus ∆NLS mRNA  (∆NLS, upper panel), or primers located 
in exon 11, i.e. upstream the floxed cDNA insertion, and thus amplifying total Fus mRNA (Total, lower panel). Presence of 
the Fus ∆NLS mRNA is observed in both FusΔNLS/+ and FusΔNLS/ΔNLS while absent in Fus+/+ tissues.  
(B) Immunoblot analysis of FUS protein in spinal cord and gastrocnemius of 2 Fus
+/+
, 2 Fus
ΔNLS/+
 and 2 Fus
ΔNLS/ΔNLS
 mice 
using two different antibodies targeting the C-terminal (C-ter. 1 and C-ter. 2) nuclear localization signal (NLS), or 
antibodies targeting the N-terminal (N-ter. 1) and internal parts (N-ter. 2) of FUS. Note the complete absence of 
immunoreactive bands when using C-terminal antibodies in Fus
ΔNLS/ΔNLS
 tissues, confirming that the FUS protein derived 
from the ∆NLS allele lacks NLS.  
(C) Representative confocal images for fluorescent immunocytochemical localization of FUS protein in mouse embryonic 
fibroblasts (MEF). A complete loss of FUS staining from the nucleus (marked in blue, DRAQ5) in Fus
ΔNLS/ΔNLS 
was 
demonstrated using the two N-terminal FUS antibodies used in B (red and green). A combination of cytoplasmic and 
nuclear localization is seen in Fus
ΔNLS/+
 MEFs. 
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Supplementary Figure 3: Perinatal letality in Fus
∆NLS/∆NLS 
 and Fus
-/- 
mice 
(A) Photographs of Fus
+/+
 and Fus
ΔNLS/ΔNLS 
pups immediately after birth (P0 animals). Note the difference in skin color with 
cyanotic appearance indicating insufficient blood oxygenation in Fus
ΔNLS/ΔNLS
 mice.  
(B-C) Fus
ΔNLS/ΔNLS 
mice showed significantly reduced body weight (C) and length (D). Weight and length values normalized 
to wild type (Fus
+/+
) are presented. N=11 Fus
+/+
, N=26 Fus
ΔNLS/+
 and N=14 Fus
ΔNLS/ΔNLS
; (*) p<0.05 (**) p<0.01 vs Fus
+/+
, 
(#) p<0.05 (##) p<0.01 vs Fus
∆NLS/+
; One way ANOVA followed by Tukey post hoc test. 
(D) Representative hematoxylin and eosin stainings of lungs of Fus
+/+
 and Fus
ΔNLS/ΔNLS 
at birth.   
(E, F) Body weight (E) and length (F) of Fus
+/+
, Fus
+/- 
and Fus
-/- 
pups at birth; N=14 Fus
+/+
, N=36 Fus
+/-
 and N=13 Fus
-/-
 for 
body weight; N=6 per genotype for body length; (**) p<0.01 vs Fus
+/+
, (##) p<0.01 vs Fus
+/-
 ; One way ANOVA followed 
by Tukey post hoc test. 
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Supplementary Figure 4: Genome-wide expression changes identified by RNA-seq in Fus
∆NLS/∆NLS
 and Fus
-/-
 brains 
(A) Quantification of Fus RNA levels by strand-specific RNA sequencing in brains from Fus
ΔNLS/ΔNLS 
(blue bars), Fus
-/- 
(red 
bars) and control littermates (Fus
+/+
, black bars). RNA levels were determined by Fragments Per Kilobase of transcript per 
Million mapped reads (FPKM) values.  
(B) Unsupervised hierarchical cluster analysis using all RNAs expressed in brains of Fus
ΔNLS/ΔNLS 
mice (KI-1 to KI-5) and 
their control littermates (Ctrl-1 to Ctrl-4) showing that mice expressing truncated FUS have an expression profile distinct 
from control mice.  
(C) Unsupervised hierarchical cluster analysis using all RNAs expressed in brains of Fus
-/- 
mice (KO-1 to KO-5) and their 
control littermates (Ctrl-1 to Ctrl-5) showing that mice with complete loss of FUS have an expression profile distinct from 
control mice. 
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Supplementary Figure 5: Validation of expression changes identified by RNA-seq in Fus
∆NLS/∆NLS
 and Fus
-/-
 mouse 
brain 
Expression levels of selected genes in Fus
ΔNLS/ΔNLS
 (blue bars) and Fus
-/- 
(red bars) compared to their control littermates 
(Fus
+/+
, black bars).  
(A) Quantitative RT-PCR (qRT-PCR) for genes identified by RNA-seq to be significantly downregulated (Ahi1, Kcnip1, 
Nefm, Nefl, Tuba4a, Dmpk, Rad9b, Stac3, Hist1h2bc, Hist1h1c) or upregulated (Fam193b, Pmm2, Bphl, Taf15) in both 
Fus
ΔNLS/ΔNLS
 (blue bars) and Fus
-/- 
(red bars) compared to their control littermates (Fus
+/+
, black bars). Error bars represent 
SEM in 3-5 biological replicates.  
(B) Normalized expression (based on FPKM from RNA-seq) of genes identified by RNA-seq to be significantly 
downregulated only in Fus
ΔNLS/ΔNLS
 mice (Slc39a2, Dok3, Slc2a4rg-ps, Dnase1l2, Ccdc24, Mmp9, Ipw). Error bars represent 
SEM in 4-5 biological replicates.  
(C) qRT-PCR analysis of the genes shown in (b) found that this set of genes was consistently downregulated in Fus
ΔNLS/ΔNLS
 
brains but also presented a similar trend in Fus
-/- 
animals despite not being significantly changed by RNA-seq. Error bars 
represent SEM in 3-5 biological replicates.  
127 
 
(D) qRT-PCR for Trove2, Uhmk1, Ssh3, Vtn, Snrpb and Ephb3 in brains from Fus
ΔNLS/ΔNLS 
(blue bars), Fus
-/- 
(red bars) and 
control littermates (Fus
+/+
, black bars), showing genes identified by RNA-seq to be associated with the presence of 
truncated FUS in Fus
ΔNLS/ΔNLS
 animals and not modified by loss of FUS in Fus
-/- 
mice. Error bars represent SEM in 3-5 
biological replicates. 
 
 
Supplementary figure 6: FUS-dependent splicing alterations identified by RASL-seq 
 
(A) Schematic representation of the RASL-seq strategy to measure ratios of alternative splicing isoforms from thousands of 
selected splicing events by high-throughput sequencing.  
(B) Unsupervised hierarchical cluster analysis using all splicing events sequenced in brains of Fus
ΔNLS/ΔNLS 
mice (KI-1 to KI-
4) and their control littermates (Ctrl-1 to Ctrl-4) showing that mice expressing truncated FUS have an RNA splicing profile 
distinct from control mice.  
(C) Unsupervised hierarchical cluster analysis using all splicing events in brains of Fus
-/- 
mice (KO-1 to KO-5) and their 
control littermates (Ctrl-1 to Ctrl-5) showing that mice with complete loss of FUS have an RNA splicing profile distinct 
from control mice.  
(D) Venn diagram showing the number of overlapping splicing events that are misregulated in Fus
ΔNLS/ΔNLS
 (blue circle) and 
Fus
-/- 
(red circle) brains with 75 exons similarly altered upon cytoplasmic mislocalization or complete loss of FUS.  
(E) Heatmap using the fold changes of the 75 splicing events commonly regulated in Fus
ΔNLS/ΔNLS 
and Fus
-/- 
mice showing 
that 100% of the events were differentially included or excluded in the same direction. 
(F) Semi-quantitative RT-PCR analyses of selected targets shown in Fig. 4C with alternatively spliced exons depicted in 
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orange boxes with their flanking constitutive exons in blue boxes.  
 
 
Supplementary Figure 7: Absence of protein aggregates in Fus
ΔNLS/ΔNLS
 mice 
(A-C) Representative images of double immunostaining of spinal cord neurons with N-terminal FUS antibody (red) and 
p62 (A), ubiquitin (B), or neurofilament (C) (green). DRAQ5 (blue) was used to mark nuclei. Upper panels: Fus
+/+
; lower 
panels: Fus
ΔNLS/ΔNLS 
. 
We did not observe FUS-, ubiquitin-, p62- or neurofilament-positive aggregates in Fus
ΔNLS/ΔNLS 
animals.  
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Supplementary Figure 8: Stress granules in Fus
ΔNLS/ΔNLS
 mice 
(A, B) Representative images of immunofluorescent staining of spinal cord neurons with antibodies against phosphorylated 
eIF2α (A, green), a general stress response marker, or TIAR (B, green), a stress granule marker. DNA is labeled in blue 
with DAPI. Upper panels: Fus
+/+
; lower panels: Fus
ΔNLS/ΔNLS
. 
No difference between Fus
+/+
 and Fus
ΔNLS/ΔNLS 
animals was detected.  
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Supplementary Figure 9: Subcellular distribution of TDP-43 and TAF15 proteins in Fus
ΔNLS/ΔNLS
 mice 
(A, B) TDP-43 (A) and TAF-15 (B) immunoreactivities in spinal cord sections of Fus
+/+ 
(upper panels) and Fus
ΔNLS/ΔNLS 
(lower panels) mice. Both proteins were mostly nuclear in spinal cord neurons of both genotypes. 
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II. PUBLICATION N⁰2 
(Manuscript in preparation) 
 
 
 
Partial cytoplasmic mislocalization of FUS leads to motor 
neuron disease and behavioural symptoms relevant to FTLD 
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A. Summary – publication n⁰2 
We next sought to investigate if the partial suppression (Figure 26) of FUS nuclear 
import, through heterozygous ∆NLS mutation, with aging could precipitate ALS and/or FTLD 
phenotype. To test our assumption we followed up two large cohorts of wild type Fus+/+and 
heterozygous FusΔNLS/+mice. At different age time points we looked for motor behavioural 
changes characteristic for ALS, accompanied with pathohistological analysis. 
Figure 26. Comparative analysis and follow up of mice during aging 
 
Schematically represented (by yellow color) FUS subcellular localization in Fus
+/+
 with nuclear enrichment 
Fus
+/+
, and partialy mislocalized to cytoplasm in Fus
ΔNLS/+
mice 
 
Since FUS pathology is also observed in a subset of FTLD patients, we performed 
behavioural tests that are relevant for frontal lobe function and for presence of FTLD like 
symptoms. Although, finding the right test corresponding to human FLTD symptoms is quite 
challenging and frontal cortex in mice is much less developed, tests are crucial for model 
validation and therapeutic approaches. We focused on several commonly used in existing FTLD 
models to evaluate disinibition, anxiety, apathy or social disinterest and memory. 
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Results 
Partial cytoplasmic mislocalization of FUS in FusΔNLS/+mice  
We recently generated a conditional knock-in mouse model (FusΔNLS mice) allowing 
the deletion of the last 19 amino acids of the FUS protein, constituting the atypical nuclear 
localization signal (PY-NLS) (Figure 1A). This part of FUS protein is responsible for 
importing FUS protein from cytoplasm to nucleus and the complete deletion of the PY-NLS 
leads to complete mislocalization of FUS (Scekic-Zahirovic et al, 2015). Here, we examine 
the phenotype of FusΔNLS/+ mice. FusΔNLS/+ mice  are fertile and able to transmit the ∆NLS 
allele to their progreny (Figure 1B). While absent in wild type Fus+/+ mice, the ΔNLS mRNA 
could be detected by RT-PCR in multiple tissues of FusΔNLS/+ mice (Figure 1C). Endogenous 
Fus expression was modestly increased in FusΔNLS/+ mice at the mRNA level in spinal cord 
and frontal cortex (Figure 1D), yet not at the protein level (Figure 1E). Importantly, the 
expression of Taf15 and Ewsr1, the two other FET family members, was unchanged in 
FusΔNLS/+ mice (Figure1D, 1E). 
To determine whether bearing one ∆NLS allele of the Fus gene leads to partial 
mislocalization of FUS, we first performed subcellular fractionation followed by western 
blotting. Interestingly, we were able to detect a robust FUS signal from cytoplasmic fractions 
of FusΔNLS/+ spinal cord, but not from cytoplasmic fractions of wild type littermates spinal cord 
(Figure 2A). Consistently, we observed generally increased cytoplasmic FUS staining in 
FusΔNLS/+ motor neurons using immunohistochemistry (Figure 2B). It should be noted 
however that cytoplasmic redistribution of FUS protein was heterogeneous, at least in spinal 
cord neurons with large nucleus (Figure 2B). Thus, FusΔNLS/+ mice express a truncated FUS 
protein that partially localizes to the cytoplasm. 
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Figure 1: Genetic strategy for Fus
ΔNLS/+
  mice. 
(A) Schematic representation of the truncated FUS protein  completely devoid of NLS in Fus
ΔNLS/+
 knock-in mice (right panel).  
(B) Representative PCR genotyping results from Fus
+/+
and Fus
ΔNLS/+
 knock-in mice using primers designed around the distal 
loxP site of the Fus
ΔNLS 
allele and shown as gDNA. The expected size of the PCR product of the ∆NLS allele is 240 bp; the size 
of wild type allele is 160 bp. 
(C) RT-PCR analysis of spinal cord and frontal cortex from 2 Fus
+/+
and 2 Fus
ΔNLS/+
 knock-in 22 months mice using primers 
located in the STOP cassette, and thus specific to the ∆NLS mRNA  (∆NLS, upper panel), or primers located in exon 11, i.e. 
upstream of the floxed cDNA insertion, and thus amplifying total Fus-derived  mRNA (Total, middle panel). PCR amplification of 
18S rRNA is shown as standard gene (lower panel). Presence of the ∆NLS mRNA is detected in Fus
ΔNLS/+
 while absent in the 
Fus
+/+
 tissues.  
(D, E) Expression levels of total Fus, Taf-15, Ewsr1 and Tardbp mRNA in spinal cord and frontal cortex.Total Fus were slightly 
increased in both tissues of Fus
ΔNLS/+
 knock-in mice as revealed by quantitative real-time PCR analysis. N=7 Fus
+/+
, N=8 
Fus
ΔNLS/+
. (*) p<0.05, (***) p<0.01; One way ANOVA followed by Tukey post hoc test. 
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Figure 2: Partial cytoplasmic mislocalization of FUS in Fus
ΔNLS/+
mice 
(A) Immunoblot analysis of FUS protein in total (TF), cytoplasmic (CF) and nuclear (NF) fractions from spinal cord of Fus
+/+
 and 
Fus
ΔNLS/+
 knock-in mice using an antibody targeting the N-terminal part of FUS. Note that immunoblots show immunoreactive 
band in cytoplasm of Fus
ΔNLS/+
knock-in tissues confirming the redistribution of FUS truncated protein. Histone 3 (HIST3) was 
used as a loading control for nuclear fractions and GAPDH for cytoplasmic fractions. Molecular weight markers are shown on 
the left. 
(B) Illustrative light microscopy images of peroxidase immunostaining of spinal cord ventral horn using an antibody against the 
N-terminal part of FUS. FUS redistributes to the cytoplasm in Fus
ΔNLS/+
. Scale bars: 70 μm. 
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Partial cytoplasmic mislocalization of FUS leads to mild, late onset motor deficit 
We next intended to investigate whether FusΔNLS/+ mice develop ALS like motor 
symptoms during their lifespan. To this aim, we performed a large breeding effort and 
obtained 14 Fus+/+ male mice, and 14 male FusΔNLS/+mice. Animals were weekly followed up 
for general health, neurological symptoms, body weight, grip test and accelerating rotarod 
performance. Until 22 months of age when mice were sacrificed, we did not observe onset of 
massive paralysis, nor important weight loss related to genotype (Figure 3A-C). The 
absence of robust motor phenotype was further confirmed by similar distance and velocity of 
Fus+/+ mice and FusΔNLS/+ mice  during open field test(Figure 5E, 5F). 
Although, grip test and rotarod are among the most commonly used tests to assess motor 
function in mice (1), they often lack the sensitivity needed to detect subtle alterations in the 
motor system. For example, parkin deficient mice with subtle alterations in dopamine function 
do not display impairments on the rotarod but do display motor impairments on adhesive 
removal test (2). In addition, mice treated with moderate doses of the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) do not show impairments on the rotarod but do 
have significant alterations in gait and impairments on an inverted grid test (3). Therefore, we 
turned to additional tests to evaluate motor function in FusΔNLS/+mice. 
In an adhesive removal test we did not observe changes in initiation and completion of 
movement in FusΔNLS/+mice compared to Fus+/+ for both examined ages 10 and 22 months old 
mice, indicating preserved basal ganglia function (2). (Figure 4A-B). However, FusΔNLS/+mice 
displayed a significantly shorter hanging time in an inverted grid test (Figure 4C) for both 
ages as well as shorter holding impulse (Figure 4D). This result was the first indication of a 
motor defect in FusΔNLS/+mice. To further confirm this motor defect, we performed Catwalk 
analysis to study in detail gait of the mice. We observed a decrease in the stride length in 22 
months old, but not in 10 months old (Figure 4E-H) FusΔNLS/+ mice, along with an increase in 
body speed variation for both ages compared to the control mice (Figure 4F). Thus, our 
results indicate that partial cytoplasmic mislocalization of FUS leads to a mild, late onset 
progressive motor deficit in mice. 
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Figure 3: Motor behavioral performances in Fus
ΔNLS/+
 mice. 
(A) Grip strength, (B)  accelerating rotarod performance, (C) monthly weight follow up for 14 Fus
+/+
and 14 Fus
ΔNLS/+
male mice. 
(*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; One way ANOVA followed by Tukeypost hoc tes. 
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Figure 4: Mild, late motor deficit in Fus
ΔNLS/+
 mice. 
(A, B) The graphs represent adhesive removal performance - time to contact (A) or to remove (B) the adhesive tape. N=3 for 10 
months; N=6 for 22 months. 
(C, D) Age-dependent changes in the mean hanging time (C) and  holding impulse (D) of the four limb wire inverted grid test in 
Fus
+/+ 
and Fus
ΔNLS/+
mice. N=7 for 10 months; N=5 for 22 months. 
(E, F)Gait changes and variability in Fus
ΔNLS/+
mice. (E) Stride length: distance between successive placements of the same 
paw.(F) Bodyspeed variation: regularity of body speed. N=3 for 10 months; N=5 for 22 months. 
(G, H) Representative illuminations of footprints. 
All graphs show the meansand standard errors at various ages (10 months; 22 months) for Fus
+/+ 
(blue histobars) and Fus
ΔNLS/+
 
(red histobars) mice. (*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; One way ANOVA followed by Tukey post hoc test. 
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Partial cytoplasmic mislocalization of FUS induces morphological defects at the 
neuromuscular junction  
To determine whether this mild motor behavioral phenotype could be due to an 
underlying motor neuron disease, we performed electromyographical analysis (EMG) on 
Fus+/+and FusΔNLS/+ mice at 10 and 22 months of age. We did not observe stereotypical 
denervation-related electrical activities in gastrocnemius (GA) or tibialis anterior (TA) muscle 
of 10 month old Fus+/+and FusΔNLS/+ mice (Figure 5A). However, 22 month old FusΔNLS/+ mice 
analyzed in parallel showed typical fibrillations and fasciculation in both muscles (Figure 5A). 
Consistent with qualitative observations, a quantitative analysis of pathological EMG 
demonstrated significantly increased frequency of abnormal EMG in 22 month old FusΔNLS/+ 
mice, but not at 10 months of age (Figure 5B). To determine whether alteration of EMG 
patter reflect morphological changes of the individual neuromuscular junctions (NMJ) we 
analyzed TA of 10 months and of 22 months mice for both genotypes (Figure 6A). We 
performed morphometric analysis of the post-synaptic apparatus in these mice and found 
that the area of the NMJ was smaller in FusΔNLS/+ at both ages (Figure 6B). However, there 
was no obvious effect of Fus genotype on either NMJs fragmentation or complexity (Figure 
6C-D). 
Thus, partial cytoplasmic mislocalization of FUS triggers electrophysiological defects 
in muscle, associated with morphological defects of the post-synaptic end plates of NMJs. 
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Figure 5: Electromyographical analysis (EMG) on Fus
+/+
and Fus
ΔNLS/+
 mice at 10 and 22 months of age 
(A) Representative electromyograms of Fus
+/+
 and Fus
ΔNLS/+
mice in two gastrocnemius (GA) and one tibialis anterior (TA) 
muscles in 10 months (left panels) and 22 months (right panels). Note the presence of typical spontaneous denervation 
activities in Fus
ΔNLS/+ 
mice muscles. Scale bars= 50ms and 50µV per division 
(B) Graph showing valuse of EMG recording score for Fus
+/+ 
(blue histobars) and Fus
ΔNLS/+
 (red histobars) mice. Note significant 
diffrence detected only for 22 months old animals.  (*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; N=7 for 10 months; N=9 for 22 
months; One way ANOVA followed by Tukey post hoc test 
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Figure 6: NMJsmorphology in Fus
ΔNLS/+
 mice. 
(A) Representative epifluorescent microphotographs of NMJ post-synaptic apparatus in tibialis anterior (TA) muscles from Fus
+/+
 
and Fus
ΔNLS/+ 
mice at 10 months of age (left panels) and 22 months of age (right panels). Note the smaller but normally pretzel-
shaped morphology of NMJs. Scale bar: 20 µm.  
(B, C, D) Quantitative morphometry of NMJs in tibialis anterior (TA) from Fus
+/+
 and Fus
ΔNLS/+ 
mice at 10 and 22 months showed 
decreased area (B) but preserved complexity of post-synaptic apparatus (C, D). (*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; 
N=3 for 10 months; N=3 for 22 months; Oneway ANOVA followed by Tukey post hoc test. 
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Partial cytoplasmic mislocalization of FUS drives age-dependent, progressive motor 
neuron degeneration  
We next asked whether the mild motor deficit in FusΔNLS/+ mice was accompanied by 
degeneration of motor neurons in the lumbar spinal cord. We observed loss of lumbar spinal 
cord motor neurons in 22 months old FusΔNLS/+ mice, using either Nissl Staining (Figure 7A-
C) or immunostaining for choline acetyltransferase (ChAT) (Figure 7 D-F). Quantitative 
analysis using either Nissl or ChaT staining demonstrated that the number of motor neurons 
was reduced by ≈30% in older FusΔNLS/+ mice as compared with Fus+/+ mice (Figure 7C- 7F). 
Importantly, the number of lumbar spinal cord motor neurons was preserved at earlier age, 
for 10 months old animals indicating that the pathological process is progressive.  In addition, 
some of the remaining neurons appear shrunken and/or chromatolytic (indicated with arrows 
Figure 7B), and we noted a decresement of synaptic buttons (indicated with arrows Figure 
7E). Thus, partial cytoplasmic mislocalization of FUS triggers to a late onset progressive 
motor neuron degeneration consistent with the mild motor deficit observed. 
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Figure 7: Degeneration and loss of spinal motorneurons in Fus
ΔNLS/+
 mice. 
(A-E) Representative images of cresyl violet (A-B) and ChAT (D-E) stained sections through ventral spinal cord horn of 10 
months old (A-D) and 22 months old (B-E) Fus
+/+
 and Fus
ΔNLS/+ 
animals. Left panels present lower and two panels on the right 
side higher magnification images. In the lowest panels (B-E) arrows show degenerative changes (shrinking, chromatolysis) and 
loss of synaptic buttons in surviving motor neurons of 22 months old Fus
ΔNLS/+ 
animals. 
(C, F) Bar charts showing means and standard errors for Nissl+ (C) and ChAT+(F) motor neuron number in the ventral horn of 
the spinal cord at various ages (10 months; 22 months) for Fus
+/+
(blue histobars) and Fus
ΔNLS/+
 (red histobars) mice. (*) p<0.05, 
(***) p<0.01 with respect to Fus
+/+
; N=3 for 10 months; N=6 for 22 months; Oneway ANOVA followed by Tukeypost hoc test. 
Scale bars: lower magnification : 70μm; higher magnification : 70μm and 35μm. 
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Partial cytoplasmic mislocalization of FUS leads to hyperactivity, in the absence of 
anxiety like behaviours 
Since FUS mislocalization and aggregation is also observed in a subset of FTLD 
patients, we then asked whether FusΔNLS/+ mice might develop FTLD-like symptoms. A 
number of FTLD patients display behavioural disinhibitions, in particular impulsivity and 
unawareness of consequences of their actions. This type of behavior is measured in mice 
with anxiety tests. A reduced anxiety in mice is often interpreted as disinhibition. We used an 
open field and the dark/ light box test to assess the state of disinhibition of FusΔNLS/+ mice. In 
an open field, mice tend to show preference for peripheral quadrants over central quadrants, 
considered as more anxiogenic. FusΔNLS/+ mice showed identical preference as wild type 
littermates for the peripheral quadrants, either at 10 months or at 22 months of age (Figure 
8A-F). To further confirm this initial test, we used the dark/light box, a test more sensitive 
than open field for evaluating anxiety levels. This test is based on the preference of mice for 
dark compartments over illuminated places. In this test, FusΔNLS/+ mice showed a trend 
towards shorter latency to enter illuminated compartment (Figure 9A), as well as tended to 
explore more the illuminated compartment (Figure 9B-C) as well as transitioning more 
frequently from light to dark compartments (Figure 9D). None of these parameters however 
reached significance, suggesting that the decrease in anxiety of FusΔNLS/+ mice, if any, is very 
low. We then recorded spontaneous activity in the homecage during three consecutive days. 
Interestingly, FusΔNLS/+ mice displayed significant hyperactivity during early morning, just 
before the light was turned on, from 5 am to 7 am (Figure 9E). In all, partial cytoplasmic FUS 
mislocalization leads to barely normal anxiety levels, along with increased spontaneous 
activity. 
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Figure 8: Lack of anxiety in Fus
ΔNLS/+
 mice. 
(A-B) Representative images of heat maps (A) and trajectory trackings (B) in the open field of 10 month sold (upper pannels) 
and 22 monthsold (lower pannels) Fus
+/+
 and Fus
ΔNLS/+ 
animals.  
(C-E) Bar chart showing mean sand standard errors of time spent in peripheral quadrants (C) and central quadrants (D) of the 
open field at various ages (10 months; 22 months) for Fus
+/+
(blue histobars) and Fus
ΔNLS/+
 (red histobars) mice. Total distance 
traveled is shown (E) and avarage speed velocity (F). (*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; N=3 for 10 months; N=6 for 
22 months; Oneway ANOVA followed by Tukey post hoc test. 
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Figure 9: Lack of anxiety in Fus
ΔNLS/+
 mice. 
(A, B) Bar chart showing means and standard errors of latency time to enter the illuminated compartment (A), absolut time 
spent in the illuminated compartment (B), percentage of total exploration time spent in the illuminated compartment (C) and 
number of transitions between dark and the illuminated compartments (D) in the dark-light box at 10 monthsfor Fus
+/+
(blue 
histobars) and Fus
ΔNLS/+
 (red histobars) mice. (*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; N=14-15 for 10 months; Student t-
test. 
(E) Graph represents mice activity during three consecutive days at 10 months old Fus
+/+ 
(blue lines) and Fus
ΔNLS/+
 (red lines) 
mice. (*) p<0.05, (***) p<0.01 with respect to Fus
+/+
; N=14-15 for 10 months.  Oneway ANOVA followed by Tukey post hoc test. 
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Partial cytoplasmic mislocalization of FUS leads to impairment of social behaviour 
Marked changes in social behaviour such as either social withdrawal or social 
disinhibition, obsessive-compulsive behaviours, euphoria or apathy are common in subjects 
with bvFTD (4,5). Social deficits were also reported in progranulin haploinsufficient mice, an 
independent mouse model of FTLD (6). To determine whether our mice have disease-
relevant social behavioral deficits we performed tests specific for evaluating sociability in 
mice. In order to exclude possible olfactory dysfunction that can affect social behavior we 
first performed olfactory preference test. Results showed no differences between genotypes 
at 22 months of age in the time spent sniffing filter paper covered with either attractive scent 
(vanilla) or an aversive scent (2-methyl butyrate) (Figure 10) suggesting that the olfactory 
function of FusΔNLS/+ mice was preserved. 
To evaluate social behaviour of FusΔNLS/+ mice, we first used the resident-intruder test 
(Figure 11A). Interestingly, two distinct cohorts of 10 months old FusΔNLS/+ mice displayed 
higher interaction times with the intruder as compared with Fus+/+ mice (Figure 11B). Such a 
social disinhibition was no longer observed in 22 months old mice (Figure 11C). To further 
characterize the social behavioral impairement, we used a modified version of the three-
chamber social paradigm (Figure 12A). In this test, the test mouse is introduced in the 
middle compartment of a set up composed of 3 communicating chambers. After a first trial of 
habituation using an empty set up, a stranger mouse is introduced in a second compartment. 
The interactions initiated by the test mouse with either the stranger mouse or the empty cage 
are quantified. In Trial 2, both Fus+/+ and FusΔNLS/+ mice interacted three to four times more 
with the stranger mouse than with the empty cage (Figure 12 B-C). Across the different 
trials, we observed that 10 months FusΔNLS/+ mice consistently interacted more with the 
stranger mouse than Fus+/+ mice (Figure 12 D-E). This was not observed at 22 months of 
age. Thus, both resident intruder test and 3 chamber test indicate that FusΔNLS/+ mice display 
social disinhibition that disappears with older mice. 
The 3 chamber test was also used to evaluate social memory. In a fifth trial, both a familiar 
mouse (Stranger 1) and an unknown mouse (Stranger 2) were introduced in the two empty 
compartments (Figure 13A). The time spent interacting with either mice is then measured. If 
the interaction time is higher with the Stranger 2 than with Stranger 1, this suggests that the 
tested mouse was able to recognize Stranger 1 as familiar. In this test, FusΔNLS/+ mice and 
Fus+/+ mice displayed similarly increased interaction with the novel mouse, suggesting 
preserved social memory at both ages, independent of the genotype (Figure 13B-C). In all, 
these results indicate that partial cytoplasmic mislocalization of FUS leads to a selective 
transient impairment in sociability that could recapitulate some of the clinical symptoms of 
bvFTD, like social disinhibition that already have been reported in patients (5). 
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Figure 10: Olfactory preference test in Fus
ΔNLS/+
 mice. 
(A) Analysis of olfactory preference in Fus
+/+
 and Fus
ΔNLS/+
mice at 22 months.  All values are means and standard errors. 
(*) p<0.05, (***) p<0.01 with respect to corresponding Fus
+/+
; N=6 for 22 months; Student t-test. 
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Figure 11: Fus
ΔNLS/+
 mice showed age-dependent impairment of social behaviour – resident intruder test. 
(A) Schematic representation of resident intruder test  
(B-C) Interaction in home cage task in 10 (B) and 22 (C) months old Fus
+/+ 
(blue lines) and Fus
ΔNLS/+
 (red lines) mice. The 
difference in interaction time (defined as the time the test mouse explores the intruder mouse in 1-min intervals) is significant at 
the first and two last points of the task (1, 4 and 5 min time points in 10 months old animals (B). (*) p<0.05, (***) p<0.01 with 
respect to Fus
+/+
; N=15 for 10 months; N=10 for 22 months; Student t-test.and Twoway ANOVA. 
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Figure 12: Fus
ΔNLS/+
 mice showed age-dependent impairment of social behavior – three chamber task. 
(A) Schematic representation of three chamber task across the trials 
(B-C) Social recognition, namely time spent interacting with Stranger 1 and time exploring empty wired cage (object) in Trial 2 , 
10 months (B) and 22 months (C) for Fus
+/+
(blue histobars) and Fus
ΔNLS/+
 (red histobars) mice. (*) p<0.05, (***) p<0.01 with 
respect to Stranger 1; N=15 for 10 months; N=10 for 22 months; Oneway ANOVA followed by Tukeypost hoc test 
(D-E) Sociability of Fus
+/+ 
(blue lines) and Fus
ΔNLS/+
 (red lines) mice, 10 months (D)  and 22 months (E)  are measured based on 
interaction time with Stranger 1 across trials. N=15 for 10 months; N=10 for 22 months; Twoway ANOVA 
(F-G)Time exploring empty wired cage (object) across trials of Fus
+/+ 
(blue lines) and Fus
ΔNLS/+
 (red lines) mice 10 months(G) 
and 22 months(H). N=15 for 10 months; N=10 for 22 months; Twoway ANOVA. 
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Figure 13: Fus
ΔNLS/+
 mice showed age-dependent impairment of social behavior – three chamber task. 
(A) Schematic representation of three chamber task in the Trial 5 
(B-C) Graphs showing interaction time spent with Stranger 2 in Trial 5 that was measured as an indicator for social memory and 
novelty in Fus
+/+ 
(blue histobars) and Fus
ΔNLS/+
 (red histobars) for 10 months (B) and 22 months (C) mice. N=15 for 10 months; 
N=10 for 22 months; All values are mean and standard errors. Twoway ANOVA. 
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Partial cytoplasmic mislocalization of FUS leads to cognitive defect and altered 
memory consolidation. 
To further explore the possibility that a subset of phenotypes of FusΔNLS/+ mice is related 
with frontal lobe dysfunction, we tested spatial reference memory in the Morris water maze. 
This task requires the hippocampal function, at least during acquisition and to form a recent 
memory, but relies on a proper (fronto)cortico-hippocampal dialog for longer retention times 
or remote memory (7). As shown in Figure 14A-C, FusΔNLS/+ mice displayed a significant 
acquisition regarding distance travel and latency to find hidden platform over training days 
similar to their Fus+/+ littermates. We then performed a probe trial 18 days after the last 
training followed by two extinction tests and observed that FusΔNLS/+ mice displayed a 
significantly decreased performance at this retention time point (Figure 14D). Furthermore, 
FusΔNLS/+ mice extinguished their previous memory much faster than wild type mice as an 
extinction test performed 2 hours after the probe trial showed a weaker memory trace in wild 
type mice, while FusΔNLS/+ mice did not show a performance superior to chance (Figure 14E), 
and this was maintained in a second extinction test (Figure 14F).  All together, these data 
show that FusΔNLS/+ mice are able to learn, but display alterations in the persistence of 
memory consolidation in agreement with a dysfunction in the fronto-cortical regions. 
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Figure 14: Cognitive defect, altered memory consolidation in Fus
ΔNLS/+
mice. 
(A) Distance swimed (in meters) (B)latency (in seconds) and (C) speed velocity (in meters per secons) to find the platform of 10 
Fus
+/+ 
and 11 Fus
ΔNLS/+
male mice tested for spatial reference memory in the Morris water maze. Both genotypes improved 
similarly their performance between day 1 and 5. Fus
+/+
(blue lines) and Fus
ΔNLS/+
 (red lines) mice 10 months. N=10 ; Twoway 
ANOVA (A )« days»: F(4,76)=24,35; p=0,00000 « genotype »: F(1,19)=1,10; p=0,64 (B)« days »: F(4,76)=35,62; p=0,00000 
« genotype »: F(1,19)=0,21; p=0,64(C) « days »: F(4,76)=16,41; p=0,00000 « genotype »: F(1,19)=1,13; p=0,29 
(D) Mice were tested for retention in a probe trial (60sec) performed 18 days after the last training session as indicated. The 
time spent in the target quadrant (target) is represented and compared with the average of the time spent in the three other 
quadrants (others). Chance is shown as a dashed line (15s per quadrant; i.e.25%). Fus
ΔNLS/+
mice performed significantly worse 
than +/+ littermates. Fus
+/+ 
(blue histobars) and Fus
ΔNLS/+
 (red histobars) for 10 months  N=10. (***) Oneway ANOVA genotype 
effect F(1,19)=6,33, p=0,02 ; Student t test comparaison to chance level (#) Target quadrant: Fus
+/+
=0,0008 Mean 3 others: 
Fus
+/+
=0,0008 Target quadrant: Fus
ΔNLS/+
=0,006 Mean 3 others: Fus
ΔNLS/+
=0,005 
(E-F) Two extinction test: the first 2 hours after completing probe trial and the second 2 hours after the first. 
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Partial cytoplasmic mislocalization of FUS triggers fronto-temporal atrophy 
Since our results suggested that the partial mislocalization of FUS to the cytoplasm 
leads to a neurological deficit that could be reminiscent of FTD, we began to study fronto-
temporal lobe morphology. Interestingly, we observed significant frontotemporal lobes 
atrophy in FusΔNLS/+ mice at both 10 and 22 months of age (Figure 15A-C). Interestingly, 
younger mice showed asymmetrical pattern of atrophy (Figure 15B), while in older animals it 
was presented along whole length of frontal and temporal lobes bilaterally (Figure 15C). This 
shows that FusΔNLS/+ mice develop progressive fronto-temporal atrophy, and histopathological 
analysis of these brains is currently ongoing to characterize the neuroanatomical substrate of 
this atrophy. 
 
In all our current results demonstrate that the partial cytoplasmic mislocalization of 
FUS is sufficient to trigger a mild and progressive motor deficit associated with motor neuron 
degeneration, reminiscent of FUS-ALS. Intriguingly, partial cytoplasmic mislocalization of 
FUS also triggers behavioural and anatomical impairments suggestive of FTLD. 
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Figure 15: Asymmetrical frontotemporal brain atrophy in Fus
ΔNLS/+
 mice. 
(A) Representative images of whole brain for Fus
+/+
 and Fus
ΔNLS/+
mice in 10 month (upper panels) and 22 months (lower 
panels). 
(B-C) Graphs showing level of atrophy in Fus
+/+
(blue lines) and Fus
ΔNLS/+
 (red lines) for 10 months (B)  and 22 months(C) mice. 
N=3 for 10 months; N=6 for 22 months; All values are mean and standard errors. (*) p<0.05, (***) p<0.01 with respect 
toFus
+/+
Oneway ANOVA followed by Tukeypost hoc test. 
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Material and methods 
Animal housing and genotyping  
Wild type and heterozygous Fus∆NLS/+mice, generated as described previously (Scekic-
Zahirovic et al., 2015), were bred and housed in the central animal facility of the faculty of 
medecine of Strasbourg, with a regular 12-h light and dark cycle (light on at 7:00 am) under 
constant conditions (21 ± 1 °C; 60% humidity). Standard laboratory rodent food and water 
were available ad libitum throughout all experiments. These protocols were approved by the 
local ethical committee (Cremeas), under reference number AL/27/34/02/13. 
Mice were genotyped by PCR of genomic DNA from tail biopsies as described previously 
(Scekic-Zahirovic et al., 2015). 
Ten- to twenty two-months-old male littermates of each genotype (Fus+/+and FusΔNLS/+) on a 
pure genetic background (C57/Bl6) were subjected to behavioral tests and molecular 
analyses. Behavioral test were done during the light phase of their light/dark cycle except for 
indicated experiments, in collaboration with JC Cassel and AL Boutillier (Laboratoire de 
Neurosciences Cognitives et Adaptatives, UMR7364, CNRS, Université de Strasbourg). 
 
RT-PCR analysis  
RT-PCR analysis  was done in microdissected frontal cortex and spinal cord tissue from 
Fus+/+ and  2 FusΔNLS/+ and FusΔNLS/ΔNLS using primers located in the STOP cassette, and thus 
specific to the ∆NLS mRNA  (∆NLS), or primers located in exon 11, i.e. upstream of the 
floxed cDNA insertion, and thus amplifying total Fus-derived mRNA (Total Fus) and PCR 
amplification of 18S rRNA as standard gene. The correspondent primer list was published 
previously (Scekic-Zahirovic et al., 2015).  
Frontal cortex and spinal cord were harvested, rapidly frozen in liquid nitrogen and stored at -
80°C until the time of analysis. For RT-qPCR, frozen tissues were placed into tubes 
containing a 5 mm stainless steel bead (Qiagen, Courtaboeuf, France) and 1 ml of Trizol 
reagent (Invitrogen, Paisley, UK) and homogenized using a TissueLyser (Qiagen). RNA was 
prepared on tissue homogenates following Trizol manufacturer’s instructions. RNA reverse 
transcription and SYBR Green real-time PCR assays were performed using the Bio-Rad 
(Biorad, Marnes la Coquette, France) iCycler kits and protocols. PCR conditions were 3 min 
at 94°C, followed by 40 cycles of 45 s at 94°C and 10 s at 60°C. Three standard genes: 18S 
(18S Ribosomal RNA), Pol2 (Polr2 polymerase RNA 2 DNA directed polypeptide A) and Tbp 
(TATA-box binding protein) were used to compute a normalization factor using Genorm 
software v3.5. Primers sequences are provided in (Scekic-Zahirovic etal., 2015). 
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Western blot- nuclear-cytosolic fractionation 
Fresh spinal cord were homogenized by using a pre-chilled 1 ml Dounce homogenizer in a 
detergent-free lysis buffer A containing 10 mM Hepes-KOH pH 7.4, 10 mM KCl, 1.5 mM 
MgCl, 0.5 mM EDTA, 0.5 mM EGTA, 1X protease inhibitors (Roche, Berlin, Germany). A part 
of lysate was saved as total fraction. The homogenates were centrifuged at 1000G for 5 min 
at 4 °C. The supernatant was spin down at 1000G for 5 min at 4°C and then saved as the 
cytosol fraction. The pellet was resuspended in five pellet volumes of buffer B (10 mM 
Hepes-KOH, pH 7.4, 0.42 M NaCl, 2.5% v/v glycerol, 1.5 mM MgCl, 0.5 mM EDTA, 0.5 mM 
EGTA, 1 mM dithiothreitol, 1× protease inhibitors) and incubated for 60 min at 4°C while 
rotating at 60 rpm. The sample was centrifuged at 14,000 rpm for 10 min at 4°C, and the 
supernatant was saved as the nuclear fraction(8). 
Equal amounts of protein (10µg) were separated by electrophoresis on SDS-PAGE 10% and 
blotted onto a nitrocellulose membrane. Membranes were saturated with 10% non-fat milk 
and then incubated with the primary antibodies against the N-terminal part of FUS (Bethyl 
A303-839A; 1:1000) diluted in 3% non-fat milk followed by anti-goat (Sigma A5420) 
secondary antibody diluted 1:5000. Antibodies against Histone 3 (Cell signaling, #9715; 
1:1000) was used as loading control for nuclear fraction and GAPDH (Invitrogen, #398600; 
1:1000) was used as loading control for cytoplasmic fraction. All blots were analyzed with 
chemiluminescence (ECL; Luminata Forte Kit, Millipore WBLUF0500) using the Molecular 
Imager Chemidoc XRS (Biorad) as detection system. 
 
Motor coordination and muscle strength analysis 
Mice were followed weekly for general health, neurological symptoms, body weight, grip test 
and accelerating rotarod performance starting from weaning (4 weeks of age) until 22 
months of age as described previously (9,10). Briefly, mouse motor performance was 
assessed using rotarod (Ugobasile model 7650). Each session consisted of three tests of 
300 s with an acceleration period (4 to 20 rpm during 150 s) followed by 150 s at constant 
speed. To evaluate muscle strength, we used a gripmeter test (Bioseb, ALG01; France). The 
muscle force (in Newton) was measured three times per mouse. Results are presented as 
one measurement point per month. 
 
Adhesive removal test 
Adhesive removal test was performed for two different ages 10 and 22 months old mice as 
described (Bouet V et al., 2009; Fleming SM et al., 2013). Mouse was placed alone in a 
clean cage with ~3/4 of the bedding.  The test mouse was scruffed in order to restrain it 
and using a pair of small forceps one adhesive label was placed and gently pressed onto 
the snout of the mouse. After mouse was released in the cage. Time was recorded twice : 
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when the mouse made an attempt to remove the label with its forepaws as contact time 
(or initial time) and when mouse succeded to remove the label as removal (or total time). If 
the mouse did not contact or remove the sticker within 60 sec the trial was ended and the 
sticker was removed manually by the experimenter (2,11). 
 
Inverted grid test 
The four limb hang test uses a wire grid system to non-invasively measure the ability of mice 
to exhibit sustained limb tension to oppose to their gravitational force. The procedure 
measures the 4 limb hang time in seconds as well as the minimal holding impulse.  Each 
mouse was placed at the simple cage grid and was allowed to accommodate to this 
environment for 3–5 s before the grid was inverted and held approximately 35 cm over a 
mouse cage containing 5–6 cm of bedding (wood chips). Each of these holding periods 
began with all four paws of the mouse grasping the grid. Typically, the mice lose their grasp 
of the mesh one or two paws at a time. Shortly before the fall, most mice usually have only 
one or two paws grasping the screen. The wire grid hanging time (or “hang time”) was 
defined as the amount of time that it takes the mouse to fall from the inverted grid and was 
measured visually with a stop watch. In each session, the procedure was repeated three 
times with approximately 10 min between each assessment of holding time. The mouse body 
weight was obtained shortly before or after the test. The physical impulse (minimal holding 
impulse) is the hanging time multiplied by the gravitational force of the mouse (body mass (g) 
×0.00980665N/g×hanging time (s)) and represents the minimal total sustained force that was 
exerted to oppose the gravitational force (12,13). 
 
Gait analysis  
Gait parameters of freely moving mice were measured using the Catwalk gait analysis 
system (Noldus Information Technology, The Netherlands) (14–16). CatWalk instrument 
consists of a hardware system of a long, enclosed glass walkway plate, illuminated with 
green light, a high-speed video camera, and a software package for quantitative 
assessment of animal footprints. A green light emitted by a fluorescent lamp positioned 
underneath the glass plate is reflected within the glass plate except at points being 
touched where the mouse paws made contact with the glass plate. It scatters and 
illuminates the contact area. The intensity of the area of illumination, which is proportional 
to the exerted pressure, is digitally captured by the video camera connected to a computer 
that runs the CatWalk software 7.1. 
The recordings were carried out when the room was completely dark, except for the light 
from the computer screen. Each mouse was placed individually in the CatWalk walkway 
and allowed to walk freely, in an unforced manner and traverse from one side to the other 
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of the walkway glass plate. Mouse tracks that were straight without any interruption or 
hesitation were treated as successful runs. Runs with any wall climbing, grooming, and 
staying on the walkway were not analyzed. An average number of 3 replicate crossings 
made by each mouse was recorded. The CatWalk software was used to analyze 
crossings that had at least five cycles of complete steps. The software automatically 
labelled all the areas containing pixels above the set threshold. These areas were 
identified and assigned to the respective paws. Analysis of the recording generated a wide 
range of parameters of which only the following gait and co-ordination parameters were 
analysed: 
Stride length: distance between successive placements of the same paw 
Body speed variation: regularity of body speed 
 
Spinal cord histology and motor neurons quantifications 
Spinal cord were dissected and fixed by immersion in 4% paraformaldehyde in 0.1 M 
phosphate buffer pH 7.4 overnight. Spinal cords lumbar part (L1-L5) were cryoprotected in 
30% sucrose and snap frozen in melting isopropanoland embbeded in TissueTek 
(O.C.T.Compound, SAKURA#4583). Cryosections (Leica CM 3050S) of 16µm were obtained 
for histological analysis (10 sections per animal). 
To identify localization of FUS protein spinal cord neurons were stained using antibody 
against FUS N-terminal part (Bethyl A303-839A; 1:100) followed by biotinylated secondary 
antibody donkey anti-goat IgG (Jackson, 705-066-147; 1:250). To quantify motor neurons 
spinal cord section were stained with 0.1% Cresyl violet acetate (Certistain®, MERK#5235) 
and anti-ChaT (Millipore, AB144-P; diluted 1:50) followed by biotinylated secondary antibody 
donkey anti-goat IgG (Jackson, 705-066-147; 1:250). The staining was revealed using the 
ABC kit (Vektor, PK7200; 1:4000), by the avidin-botin complex immunoperoxidase technique. 
Motor neurons counting was performed in L1-L3 ventral horn in every tenth section for ten 
sections in total per animal. Total number of motor neurons were obtained using ImageJ 
freeware (http://rsbweb.nih.gov/ij/) after images acquisition at 20X under the same exposition 
parameters with a digital camera (Nikon Digital Sight DS-U3). The observer was blinded to 
the genotype of studied mice. 
 
Electromyography 
Electromyography was performed as previously described (9,10,17). Mice at 10 and 22 
month of age were anaesthetized with a solution of ketamine/xylasine (100 mg/kg; 5 mg/kg) 
and electrical activity was recorded using a monopolar needle electrode (diameter 0.3 mm; 
9013R0312; Medtronic, Minneapolis, MN) inserted into the tail of the mouse. Recordings 
were made with a concentric needle electrode (diameter 0.3 mm; 9013S0011; Medtronic). 
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Electrical activity was monitored in both m.gastrocnemius (GA) and m.tibialis (TA) on both 
legs for at least 2 min. Spontaneous activity was differentiated from voluntary activity by 
visual and auditory inspection. Results were scored as described previously (9,10,17). 
 
NMJ histology 
Muscle tissues were dissected and fixed by immersion in 4% paraformaldehyde in 0.1 M 
phosphate buffer pH 7.4 overnight. The whole muscles were dissected into fibers muscle 
bundles, stained using Alexa Fluor 594-conjugated α-Bungarotoxin (Sigma, T195; 1µg/µl) for  
post-synaptic apparatus. Images  were acquired using a under a fluorescent microscope 
(Nikon Eclipse E800) at 40x magnification and analyzed post hoc. 
 
Behavioral tests 
All experiments we conducted between 9 am and 5 pm. We conducted all behavioral studies 
using male mice and analyzed data blind to genotypes. For all tasks, we tested two cohorts 
of mice at 10 and 22 months of age. A large cohort of 15 Fus+/+ and 15 FusΔNLS/+mice was 
followed for motor behaviour until the end of 22 months of age. When mice were 10 months 
old they underwent a battery of behavioural tests: water maze, light-dark box test and beam 
walking tests. When mice were 22 months old as well as two independent group of 10 month 
old mice one of 7 and other of 8 mice per genotype were used for testing in open field, for 
resident-intruder and three chamber task. 
 
Open field  test 
We tested general exploratory locomotion and anxiety in a novel open-field environment in 
15 min sessions in a 72 × 72 × 36 cm the open field arena constructed of white plywood. The 
lines divided the floor into sixteen 18 x 18 cm squares. A central square (18 cm x 18 cm) was 
drawn in the middle of the open field. The maze was located in a test room and lit by a 600 
lux for background lighting. The open field maze was cleaned between each mouse using 70 
% ethyl alcohol. The mouse was placed in the center of the arena and allowed to freely move 
while being recorded by an overhead camera. We analyzed behaviour with an automated 
tracking system (Ethovision software, Noldus). The time spent in the center (four central 
quadrants) vs the perimeter (12 peripheral quadrants) were automatically calculated and 
were used to measure exploration and anxiety.The total distance traversed and velocity were 
used to evaluate locomotor activity. For each mouse independently a heat map and tracking 
trajectory map presenting corresponding locomotion activity were made (18). 
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The light/dark box test 
The first cohort of 10 months-old males littermates (n=6–9 per group) was tested in the 
light/dark box test to assess for anxiety level and exploratory behaviour of the mouse. Test 
was conducted during the morning. The apparatus consists of two PVC compartments of 
equal size (18.5 x 18.5 x 15cm) one opaque and the other transparent, connected with an 
opaque PVC tunnel (5 x 5.5 x 5cm). The illumination of the transparent compartment was set 
at 400 lux. The mice were placed in the dark compartment. A video camcorder located 
approximately 150 cm above the center of the box recorded the mouse’s behaviour. After 5 
minutes, mice were removed from the box by the base of their tails and returned to their 
home cage. The box was then cleaned with a solution of 70% ethyl alcohol and permitted to 
dry between tests. The latency before the first transition to the light compartment, the number 
of transitions between the two compartments and the time spent in each compartment were 
measured (19). 
 
The beam walking test - actimetry 
One session lasting for 3 days was performed in order to determine the activity of the 
subjects. The mice were placed individually in large transparent Makrolon cages (42x26x15 
cm) adapted to the shelves of the testing device (eight cages/shelve). Two infrared light 
beams, passing trough each cage, were targeted on two photocells, 2.5 cm above the cage 
floor level and 28 cm apart. The number of cage crossing was recorded by a computer. The 
experiment began at 17.00 pm and after 2 hours of habituation continued for 3 day for a 
complete 24 h nyctemeral cycle (12h dark and 12h light) (20). 
 
Olfactory preference testing 
This test is designed to identify specific detection deficiencies, namely the ability to sense 
attractive or aversive scents. After habituation to empty cages with no bedding, we tested 
mice for odor preference. In the task, mice are challenged with a filter paper embedded with 
two strong scents (vanilla and 2-methyl butyrate) or a neutral scent (water). The total 
exploratory timeis recorded (upon video viewing) for various scents during a 3 min. The time 
mouse spent sniffing the filter paperis calculated post hocwith one researcher blind to subject 
genotypes and/or condition. Those scents with total exploratory times greater than water are 
designated as “attractive” while those with times less than water are termed “aversive”. The 
researcher then considers whether the same scents are “attractive” or “aversive” for different 
test subjects (21,22). 
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Social interaction in home cage (resident-intruder test) 
We assessed social interaction in the home cage by a standard protocol. Briefly, we housed 
individual test mouse for 1 week before the task. Then, they were habituated for 30 min to 
the test room. In this task, a mouse in his home cage is allowed to freely roam in the 
absence of the cage top for 1 min. A novel male intruder mouse (non-littermate of same 
background, approximately same age, and similar weight) is then placed in the opposite 
corner as the resident subject and allowed to roam freely for 5 min. The task is video-
recorded, and total physical interaction between the two mice is quantified visually by an 
examiner blind for genotype. Social interaction is scored separately for each minute during 
test, as the time during which the resident mouse actively explores the intruder (time spent 
investigating, grooming, following or sniffing the intruder). We did not observe fighting, biting, 
or attacking in this task (23). 
Three-chamber social task 
The task consists of three consecutive parts: habituation, social recognition and sociability, 
and preference for social novelty (social discrimination or social recognition memory). 
The apparatus is made of transparent plexiglass walls (Figure16, Noldus Information and 
Technology BV, Wageningen, The Netherlands). The box measures 59 × 39.5 × 21.5 cm and 
is divided into three chambers of equal size (18.5 × 39.5 cm) by walls with a 7 × 7 cm square 
opening that could be closed by a slide door. Each of the two side chambers contains a 
cylinder. These cylinders (20 × 10 cm diameter) are made out of 18 transparent plexiglass 
bars placed 6 mm apart; the upper end of the cylinder is closed with a black lid. At the end of 
the task for each mouse the apparatus is cleaned with tap water and 70% ethyl alcohol and 
dried. 
15 Fus+/+ and 15 FusΔNLS/+ that underwent experimental procedure will be referred to as “test” 
mice and adult male mice of same background, age and weight used as the social stimulus 
are called “stranger mouse”. Test mice were housed individually for 1 week before the test. 
We habituated the mice in the testing room for at least 1 min before the start of behavioural 
tasks. One day before the start of testing, the strangers are placed into the cylinders in the 
social test apparatus for 5 min. Keeping the stranger mouse in a cylinder prevents 
aggressive and sexual interactions, also ensuring that all social approach is initiated by the 
test mouse. Sessions are video-taped and analyzed post hoc visually by an examiner blind 
for genotype. The following parameters were considered: time spent (in seconds and 
percentage) in middle and side chambers; time spent intereacting with a stranger mouse or 
an empty cylinder. 
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The experimental procedure is adapted from (24–27), and was carried out in five trials of 5 
min each (after each trial, we returned the mouse to his home cage for 15 min), separated in 
three consecutive parts. 
Trial 1 (habituation): the test mouse is placed to the middle chamber and left to explore the 
arena containing the empty wire cages (cylinders) for 5 min  
Trials 2–4 (sociability, social learning acquisition): the mouse is placed in the middle 
chamber, but an unfamiliar mouse (Stranger 1) is placed into a wire cage in one of the side-
chambers (the wire cage in the other side-chamber remains empty). The test mouse has 
access to all three chambers. Trials 2 (social recognition) defined as the ability to identify a 
conspecific (Stranger 1 versus the empty cage). Increased time spent in the chamber and in 
the perimeter around the cylinder with the stranger indicates preference for the social 
stimulus compared to the empty cage. 
Trial 5 (social novelty,social discrimination,social recognition memory and sociability): a novel 
stranger mouse (Stranger 2) is placed in the previously empty wire cage, the “old” stranger 
(Stranger 1) remains in position in its cylinder and chamber, and again the test mouse is left 
to explore for 5 min. Social novelty, defined as the ability to discriminate between a novel 
mouse (Stranger 2) and a familiar mouse (Stranger 1) It is expected that the test mouse will 
spent more time with the new stranger than the old stranger. Increased time spent with the 
new stranger is a measure for the discriminative ability of the test mouse, also indicative for 
intact working memory. 
Sociability reflects the motivation of the test mouse to spontaneously interact with target mice 
in Trials 2-5. 
 
Figure 16. Social apparatus three chamber test. (A) A picture of the apparatus containing 
the two cylinders; (B) Close-up of an interaction between the stranger mouse in the cylinder 
and the test mouse. 
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Water maze task 
The water maze consisted of a circular pool (diameter 160 cm; height 60 cm) filled with water 
(21 ± 1°C) made opaque by addition of powdered milk (about 1.5 g/L). The first day 
consisted in one 4-trial session using a visible platform (diameter 11 cm, painted black, 
protruding 1 cm above the water surface and located in the South-East quadrant of the pool), 
starting randomly from each of the four cardinal points at the edge of the pool. During this 
pre-training day, a blue curtain surrounded the pool to prevent the use of distal cues and thus 
incidental encoding of spatial information. For the following days, the curtain was removed. 
Mice were given a 5-day training period (4 consecutive trials/day, maximum duration of a trial 
= 60 s, inter-trial interval = 10–15 s) with a hidden platform located at a fixed position in the 
North-West quadrant. Animals were starting randomly from each of the four cardinal points at 
the edge of the pool and the sequence of the start points was randomized over days. Mice 
were tested for retention in a 18-days delay probe trial and two extintion tests : first 2 h after 
probe trial and secon 2 hour after the first. For the probe trial, the platform was removed; the 
mice were introduced in the pool from the North-East (a start point never used during 
acquisition) and allowed a 60-s swimming time to explore the pool. Data analyses used 
(computed by a video-tracking system (SMART; PanLab)) for the visible platform and training 
trials were : the distance traveled as well as the latency before reaching the platform and 
avarage speed. For the probe trial and extinction tests the time (in %) spent in the target 
quadrant (i.e., where the platform was located during acquisition) was analyzed (28). 
 
Statistical analysis 
Unless otherwise indicated, the values from each animal were averaged for each genotype 
group and analyzed by unpaired Student’s t-test, two tailed or comparison between groups 
was performed by Oneway ANOVA followed by Tukey's post-hoc test using the Graphics 
Prism Program (Graph Pad Software, San Diego, CA). The null hypothesis was rejected at 
the level of 0.05. 
Twoway ANOVA with repeated measure factors was used for resident intruder test and three 
chamber task using genotype and trial as interaction factors. 
Water maze data were analyzed by analysis of variance using a twoway- ANOVA with 
repeated measure factors to study interactions between genotype and trial, day, quadrant 
(Statistica 8.0; Statsoft, Inc., Tulsa, OK). The time spent in the target quadrant of the water 
maze was compared to the 15 s chance value by one-sample Student’s t test. The 15 s 
chance value corresponds to the time spent for random search in four quadrants during the 
60 s probe test.  
All data are expressed as mean ± standard error of the mean (SEM). 
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DISCUSSION 
This section will be mostly dedicated to the discussion of the current results obtained in 
adult heterozygous FusΔNLS/+ mice. I will first discuss the points that are currently missing in this 
study and that will need to be completed before submission.      I will then compare our FusΔNLS/+ 
mice with the currently existing FUS-based mouse models, discuss the relevance of our model 
for ALS and FTLD, and draw mechanistic and clinical perspectives. 
I. A STUDY TO BE COMPLETED 
We observe a number of behavioural phenotypes in our FusΔNLS/+ mice, and began to 
characterize the anatomical substrate of these behavioural deficits in the spinal cord. We also 
obtained preliminary evidence of fronto-temporal atrophy. A number of key anatomical 
pathology studies are however missing. First, we did not directly show motor neuron 
degeneration, and markers of apoptosis, necroptosis or dysfunctional autophagy should be 
studied. It would be particularly interesting to determine whether FusΔNLS/+ motor neurons 
develop ubiquitin positive and/or p62 positive aggregates. In the same line, it would be of 
importance to reevaluate the appearance of stress granules in our old FusΔNLS/+ mice. In the 
frontal cortex, we currently have no evidence of actual neurodegeneration, and neuronal counts, 
as well as microgliosis and astrocytosis should be evaluated as a function of age and correlated 
with behavioural deficit. 
A second important series of studies that need to be completed is to determine the exact 
fate of the FUS protein in FusΔNLS/+ mice with age. First, a quantitative analysis of nuclear vs 
cytoplasmic FUS remains to be done. This is critical to determine whether FusΔNLS/+ mice are 
indeed haplo-insufficient mice, or whether the phenotypes observed could be entirely ascribed 
to gain of function. Indeed, nuclear clearing of FUS is not as evident as observed for TDP-43 
(83), suggesting that loss of function might not be key to the pathogenesis of FUSopathies. 
Consistently, complete FUS knock out mice outbred to favour survival show several traits also 
observed in our FusΔNLS/+ mice, in particular hyperactivity (221), yet these mice do not develop 
motor neuron degeneration as our FusΔNLS/+ mice. Second, we did not observe large, FUS 
positive inclusions in FusΔNLS/+ mice, yet smaller punctate inclusions could be occasionnally 
observed, and it is currently unknown whether this truncated FUS protein becomes hyper-
methylated, or not. This would be of importance to understand the relevance of our findings to 
ALS and FTLD since methylation of FUS appears differentially involved in FUS-ALS and FUS-
FTLD (151,262). Third, it is critical to determine whether FUS itself becomes ubiquitinated in 
FusΔNLS/+ mice. Indeed, ubiquitinated cytoplasmic inclusions of brains and spinal cords from 
TDP-43 negative ALS and FTLD patients identified FUS as the major ubiquitinated protein 
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component (128,256). However some studies demonstrated that mutant FUS protein itself is not 
ubiquitinated, hyperphosphorylated or cleaved, yet insoluble (29). Our FusΔNLS/+ mice could help 
to shed light on the biochemical modifications of mutant FUS when expressed from the 
endogenous locus, and whether this could be relevant for disease pathogenesis. Last, it will be 
critical to determine whether the truncated FUS modifies the nuclear localization and/or 
aggregation of other FET proteins or related proteins. Indeed, ALS-FUS is characterized by the 
selective deposition of FUS, while FTLD-FUS shows co-accumulation together with TAF15 and 
EWSR1 and their nuclear import receptor Transportin (149). In contrast, in cases of ALS-FUS, 
TAF15 and EWSR1 remained localized to the nucleus and did not label FUS-positive inclusions 
(149). It is of utmost importance to determine which of these proteins display alterations in 
localization and/or levels in our FusΔNLS/+ mice. 
 
II. FUSΔNLS/+ MICE AS A GENETICALLY RELEVANT MODEL OF FUS-ALS 
Our study  in homozygous FusΔNLS/∆NLS mice provided in vivo genetic evidence that 
cytoplasmic mislocalization of FUS triggers apoptotic motor neuron degeneration and 
demonstrated a crucial role for a gain of toxic function in this process. Motor neuron loss 
occured at least partially through a cell autonomous gain of function mechanism, since complete 
loss of FUS was not associated with motor neuron death, and rescue of nuclear FUS within 
motor neurons prevented neuronal death (Scekic-Zahirovic et al., 2015). However, we did not 
detect the presence of FUS-containing cytoplasmic aggregates, ubiquitin or p62 positive, stress 
granule alterations or pathology involving other proteins. This could be due to early perinatal 
lethality of both FusΔNLS/ΔNLS and  Fus-/- mice, which prevented us to examine in detail potential 
toxic mechanisms for cytoplasmic  FUS, and our study only shed light on several posible 
candidate pathways. Interstingly, a number of genes involved in synaptogenesis and/or in 
neurodegenerative diseases show altered expression (Ahi1, Dmpk, Nefl, Nefm, Tuba4a, Taf15) 
or splicing (Ndrg2, Mapt, Atxn2, Sort1) in FusΔNLS/ΔNLS mice. The most important an upregulation 
of KIS, a kinase involved in dendritic mRNA translation supporting finding (286) that impairment 
of local mRNA translation may contribute to neuronal death in FUS-mediated diseases. Despite 
the potential interest of homozygous FusΔNLS/ΔNLS mice, only two families have been shown to 
display homozygous mutations in the FUS gene, suggesting a recessive pattern of inheritance 
(50,251). The vast majority of FUS mutations are dominantly inherited, suggesting that FusΔNLS/+ 
mice are a much better model of FUS-ALS from a genetic point of view. 
How do FusΔNLS/+ mice compare with other FUS-based mouse models ? Previous in vivo 
studies using transgenic FUS rodent models (194–197,283) have established that elevated 
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levels of both wild-type and mutant FUS, can be inherently toxic to neurons. This suggests that 
transgenic based overexpression will be limited in the possibility to differentiate between 
neurotoxicity due to overexpression from disease relevant toxicity due to mutation. A major 
advantage of our model is that it is a knock-in, and, as such that FusΔNLS/+ mice bear one copy of 
ALS-linked truncated mutation of FUS expressed from the endogenous promoter. A minor 
drawback is that this exact truncating mutation (leading to a R506X truncation) has not been 
observed in human patients. However R495X, G497AFs, R502EFs G504WFs and K510Wfs 
(249,257) and rewieved in (230) mutations have been linked to ALS, and truncation mutations 
spanning the exact amino acid mutant in our mice thus exist in ALS families. The heterozygous 
∆NLS mutation leads to a moderate overexpression of FUS at the mRNA level (1–1.3x). This 
increased expression is expected since two mechanisms of autoregulation of FUS have been 
documented, exon 7 exclusion (238) and microRNA autoregulatory loop (287). Both of these 
mechanisms could in principle account for the observed overexpression. However, this mild 
overexpression is unlikely to be the cause of the observed phenotypes. First, it is not observed 
at the protein level, suggesting either decreased translation of FUS mRNA or decreased stability 
of FUS protein. Second, the overexpression is mostly observed in peripheral tissues 
(muscle>liver>>brain and spinal cord), suggesting it has little relevance to the CNS phenotype. 
In all, our FusΔNLS/+ mice display a quasi-identical genetic situation as many FUS-ALS patients, 
suggesting that they represent a good model of FUS-ALS, likely more relevant than classical 
transgenic overexpressors. A comparative summary of pros and cons of existing FUS models 
with our FusΔNLS/+ mice is provided in Annex (Table 4-5). 
 
III. ARE FUSΔNLS/+ MICE A MODEL OF ALS USEFUL FOR PRECLINICAL STUDIES? 
Analysis of FusΔNLS/+ mice revealed that truncated FUS, partially mislocalized to 
cytoplasm and led to late, mild, adult-onset, lower motor neuron deficits in a mutant-dependent, 
age-dependent manner. FusΔNLS/+ mice developed subtle motor deficits by the age of 10 
months, characterized by subtle reduction of muscle strength, whereas Fus+/+ mice remained 
phenotypically normal (Figure 3, 4). Importantly, this motor phenotype was progressing with 
age, since 22 months old animals showed further deterioration in muscle strength, developped 
more severe motor deficits leading to gait abnormalities. Indeed, the 22 months old animals 
fulfilled two major criteria of ALS, with abnormal EMGs, defective neuromuscular junctions and 
motor neuron loss. Motor phenotype was histologically caracterized by defective NMJ and loss 
of spinal cord motor neurons up to ∼30%. These defects are thus adult onset, and progressive, 
and this is analogous to ALS in humans that appears with a median age 65 years. It is intriguing 
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that truncation of FUS, that leads to very severe disease, with sometimes juvenile onset in 
humans, does lead to a mild and late onset disease in mice. This could be due to a species 
difference, and can be influenced by the genetic background of the mice. Indeed, the C57Bl6 
background of FusΔNLS/+ mice is known to be resistant to ALS induced by SOD1 mutations (288). 
Backcrossing in a more sensitive genetic background might unveil a more pronounced 
phenotype. 
Importantly, ALS-like defects observed in FusΔNLS/+ mice are similar, yet milder, to those 
observed in other commonly used ALS models, in particular those based on SOD1 mutations 
(64,289,290) or TDP-43 (82,83). However, these defects are not sufficient to trigger paralysis of 
the mice and shortened survival, and this would be a major drawback for the use of FusΔNLS/+ 
mice for preclinical studies. In all, FusΔNLS/+ mice constitute a relevant model of FUS-ALS, but 
will be difficult to use, at least in their current C57Bl6 background, for preclinical studies. 
 
IV. ARE FUSΔNLS/+ MICE A MODEL OF FTLD? 
Analysis of FusΔNLS/+ mice revealed that these mice developed behavioural deficits that could be 
similar to those observed in FTLD patients, as well as prominent fronto-temporal atrophy. 
Bearing in mind that we currently lack anatomical pathology of these mice, thus precluding us to 
definitely conclude on a potential FTLD phenotype in these mice, it would be tempting to 
speculate that FusΔNLS/+ mice could constitute a mouse model of  FTLD-FUS.  
Several notes of caution should however be raised. First, we surprisingly observed hyperactivity 
and increased social behaviour in FusΔNLS/+ mice, while most studies to date in FTLD mouse 
models rather described apathetic behaviours and decresed social interests (190–193,291–298) 
as well in a model recently characterized in our laboratory bearing CHMP2Bintron5 (A. Verney 
& F. Rene, in preparation). Our findings could be relevant for FTLD since a number of FTLD 
patients initially develop social disinhibitions, that could be translated in our experiments as 
increased social interest. It is thus possible that the lifespan of a mouse is not long enough so 
that FusΔNLS/+ mice then develop a secondary apathy and decreased social behaviour. Here 
again, backcrossing in another genetic background might accelerate these age-dependent 
processes. Second, it is important to consider that FUS mutations, in particular truncating 
mutations, are very rare in FTLD patients, and that FUS-ALS patients develop in general pure 
ALS, in the absence of FTLD. The difference between clinical observations and our mouse 
models could be due to either a lack of sensitivity in the neuropsychological tests in clinical 
settings, or to an intrinsic difference of sensitivity between mice and humans. It is critical to 
characterize the biochemical alterations of FUS in our FusΔNLS/+ mice to determine whether 
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FusΔNLS/+ mice develop FTLD-like alterations (hypomethylation) rather than ALS-like 
(hypermethylation) of FUS protein. This might provide a mechanistic explanation to our results. 
 
V. GAIN VS. LOSS OF FUNCTION 
It is interesting to observe that FusΔNLS/+ mice develop motor neuron disease  without 
massive loss of endogenous nuclear FUS, with modest redistribution, partial mislocalization of 
truncated FUS to cytoplasm and without massive aggregation of truncated FUS within the 
nucleus or cytoplasm, contrary to what has been reported in human ALS (50,51,143,256,299) or 
FTLD (29,106,128,145,147) patients. In this respect, findings in FusΔNLS/+ mice are consistent 
with our prior study, wherein motor neuron degeneration occured only with cytoplasmic 
accumulation of truncated FUS and not in case of complete absnce of FUS (Scekic-Zahirovic et 
al., 2015). Despite there is no complete nuclear clearance of FUS in FusΔNLS/+ mice, there could 
nevertheless be haploinsufficiency. To answer this question, we are currently performing 
parallel transcriptomic analysis of spinal cord and frontal cortex of 10 and 22 months old 
FusΔNLS/+ mice and compare to Fus+/+ mice. The contribution of loss of function will also be 
investigated by crossing our FusΔNLS/+ mice with BAC transgenic mice expressing either wild 
type or mutant FUS protein. If loss of function is required for the development of perinatal death 
and motor neuron degeneration, it would be expected that the BAC transgenic expressing wild 
type FUS protein would rescue at least partially the FusΔNLS/ΔNLS and FusΔNLS/+ mice phenotypes. 
 
VI. WHY IS FUSΔNLS/+ MICE PHENOTYPE SO MILD? THE SECOND HIT THEORY 
Despite the genetic situation in FusΔNLS/+ mice is identical to human FUS-ALS patients, these 
mice develop only mild motor neuron disease while FUS-ALS in humans is extremely severe. A 
potential explantation to this dyscrepancy is that a second hit is necessary to trigger the full 
blown phenotype. In this last paragraph, I would like to speculate on several potential second 
hits. 
First, the second hit could be a genetic modifier. Indeed, ALS is now considered as an 
oligogenic disease (3,87), and multiple examples arose in the litterature of ALS and FTLD 
patients with more than one disease-linked mutation. For example, the C9orf72 expansion has 
been described in association with TARDBP, FUS, and SOD1 mutations in patients with ALS, 
with PGRN, MAPT, PSEN-2, and SQSTM1 mutations in FTD patients. Patients harboring 
mutations in TARDBP and FUS have been found to carry variants in angiogenin (ANG), a gene 
associated with ALS but considered as low-risk as well as with SETX mutations (rewieved in 
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(3)). In this respect, the backcrossing in a more sensitive genetic background could be 
considered as a second genetic hit. 
Second, the second hit could be environmental. Brain trauma (300), electric shocks, increased 
physical activity and dietary alterations (301) are all considered to be potential modifiers of ALS 
pathogenesis. In this respect, the involvement of FUS in stress granules could be key in the 
understanding of its pathogenic function. It is possible that the full blown toxicity of ∆NLS FUS 
will only uncover in situations of stress, either traumatic or energetic. A tempting speculation 
would be that mutant FUS aggregates in response to stress, in a discrete number of neurones, 
and that this initial nucleus of aggregation then spreads through pathological seeding of 
aggregated FUS. Such a scenario would be entirely consistent with the general spreading 
pattern of proteinopathy in ALS (302) as well as with the global spreading of symptoms from 
one region to another. This hypothesis should be further tested using our FusΔNLS/+ mice, 
subjected to either stress situations or seeding of pathological proteins. 
 
VII. GENERAL CONCLUSION 
The work presented in this thesis shows that the cytoplasmic mislocalization of FUS triggers a 
gain of toxic function, leading to a dose-dependent death of motor neurons. Complete 
cytoplasmic mislocalization leads to global loss of FUS function but also to important motor 
neuron apoptosis not observed in full knock-out animals. Partial FUS cytoplasmic 
mislocalization leads to a milder, adult onset, progressive motor neuron disease phenotype, 
associated with a number of behavioural abnormalities relevant to frontal lobe dysfunction. 
Importantly, the toxicity of FUS mislocalization appears, at least in homozygous mice, to be cell 
autonomous, and the rescue of mislocalization in motor neurons is sufficient to counteract motor 
neuron apoptosis. 
These novel animal models of FUS-ALS will allow to gain deeper understanding of the 
pathogenic mechanisms and hopefully help in the design of therapeutic strategies. 
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Abstract
Mutations in VAPB/ALS8 are associated with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), two
motor neuron diseases that often include alterations in energy metabolism. We have shown that C. elegans and Drosophila
neurons secrete a cleavage product of VAPB, the N-terminal major sperm protein domain (vMSP). Secreted vMSPs signal
through Roundabout and Lar-like receptors expressed on striated muscle. The muscle signaling pathway localizes
mitochondria to myofilaments, alters their fission/fusion balance, and promotes energy production. Here, we show that
neuronal loss of the C. elegans VAPB homolog triggers metabolic alterations that appear to compensate for muscle
mitochondrial dysfunction. When vMSP levels drop, cytoskeletal or mitochondrial abnormalities in muscle induce elevated
DAF-16, the Forkhead Box O (FoxO) homolog, transcription factor activity. DAF-16 promotes muscle triacylglycerol
accumulation, increases ATP levels in adults, and extends lifespan, despite reduced muscle mitochondria electron transport
chain activity. Finally, Vapb knock-out mice exhibit abnormal muscular triacylglycerol levels and FoxO target gene
transcriptional responses to fasting and refeeding. Our data indicate that impaired vMSP signaling to striated muscle alters
FoxO activity, which affects energy metabolism. Abnormalities in energy metabolism of ALS patients may thus constitute a
compensatory mechanism counterbalancing skeletal muscle mitochondrial dysfunction.
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Introduction
ALS is a lethal neurodegenerative disease characterized by
the combined degeneration of lower and upper motor neurons
[1]. Most ALS cases occur sporadically, but about 10% are
familial. These genetic cases are caused by mutations in multiple
genes, including in the Vapb (VAMP/synaptobrevin-associated
protein B) gene. Mutations in Vapb lead to ALS8 that manifests
as ALS or late-onset SMA, a motor neuron disease restricted to
lower motor neurons [2–4]. While Vapb mutations are rare,
reduced VAPB mRNA or protein levels have been reported in
sporadic ALS patients, a mSOD1 ALS mouse model, and ALS8
patient motor neurons derived from induced pluripotent stem
cells [5–7]. Hence, a loss of VAPB might be relevant in non-
ALS8 patients.
VAPB, and its paralog VAPA, are broadly expressed type II
membrane proteins that are evolutionarily conserved. These VAPs
have been implicated in regulating lipid transport and homeostasis
at intracellular organelle contact sites, endoplasmic reticulum (ER)
dynamics, and membrane trafficking [8–12]. In addition to these
cell autonomous functions, the VAP vMSP is cleaved from the
transmembrane domain in the cytoplasm and secreted in a cell-
type specific fashion [13–15]. Secreted vMSPs antagonize Eph
receptor signaling through a direct interaction with the extracel-
lular domain [13]. More recently, we have shown in C. elegans and
Drosophila that neurons secrete vMSPs to regulate mitochondrial
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localization and function in striated muscle [15]. vMSPs interact
with muscle SAX-3 Roundabout and CLR-1 Lar-like protein-
tyrosine phosphatase receptors to down-regulate CLR-1 signaling.
VAP loss causes uncontrolled CLR-1 Lar-like receptor activation
in body wall muscle. CLR-1 stimulates actin filament assembly in
the muscle belly that requires the actin-related protein 2/3 (Arp2/
3) complex. These ectopic actin filaments displace mitochondria
from I-bands, cause aberrant fission and fusion balance, and
impair respiratory chain activity. Hence, vMSPs secreted by
neurons promote muscle mitochondrial localization and function,
perhaps in an effort to modulate energy homeostasis.
vMSP signaling to muscle mitochondria might be relevant for
the energy balance in ALS8 disease. Out of five ALS8 patients
studied, five had increased cholesterol levels, four had reduced
HDL, three had elevated triacylglycerol levels, and one was
diabetic [16]. More generally, ALS is associated with a spectrum
of abnormalities in energy metabolism, including mitochondrial
defects in neurons and skeletal muscle, insulin resistance,
dyslipidemia, and hypermetabolism [17]. These metabolic abnor-
malities are positively correlated with survival. For instance,
increased prediagnostic body fat is associated with decreased risk
of ALS mortality [18] and in some patient populations, higher
LDL/HDL ratios correlate with increased survival time [19,20].
However, the cause(s) of the metabolic defects and their
relationship to each other are not well understood.
Here we show in C. elegans that loss of the VAP homolog VPR-1
causes triacylglycerol (TAG) accumulation in striated body wall
muscle. Mosaic analysis and tissue-specific expression studies
provide compelling evidence that VPR-1 acts in neurons, not
muscles to regulate fat levels. Multiple lines of evidence support
the model that impaired vMSP signaling from neurons to muscle
increases TAG levels in muscle. We propose that this fat
metabolism alteration is part of a compensatory response mediated
by the DAF-16/FoxO transcription factor. FoxO promotes muscle
fat accumulation, maintains ATP levels during aging, and extends
lifespan without influencing muscle mitochondrial morphology,
localization, or function. Finally, we provide evidence that skeletal
muscle metabolism is abnormal in Vapb mutant mice. Our results
support the model that disrupting vMSP signaling to muscle triggers
a compensatory response involving FoxO transcription factors.
Results
vpr-1/vap loss increases fat levels in adult body wall
muscle
In our studies of vpr-1(tm1411) null mutant hermaphrodites, we
noticed that body wall muscles often contain large lipid-like
droplets not observed in wild-type controls. These apparent lipid-
like droplets were visible in young adults (1–3 days post L4 stage) by
differential interference contrast (DIC) microscopy (Figure 1A). In
transgenic vpr-1 mutants expressing mitochondrial matrix-targeted
GFP (mitoGFP) in muscle, droplets are observed in the muscle belly
surrounded by mitochondria (Figure S1). The vast majority of
visible droplets in peripheral tissues are found in muscle.
Transmission electron microscopy (TEM) of vpr-1(tm1411) mutant
muscle shows an expanded muscle belly filled with mitochondria, as
previously reported [15], and large droplets (Figures 1B and S2).
The droplets are often found in close proximity to mitochondria and
ER. Large muscle droplets were not observed in young adult wild-
type muscle (Figures 1B and S2). However, muscle lipid droplets
and abnormal mitochondria are observed in very old (18 day) wild-
type adults [21,22]. In these old worms, large lipid droplets
accumulate in the muscle, intestine, and epidermis. We did not
detect abnormally large droplets in young vpr-1 mutant intestinal
and epidermal tissues by TEM. Instead, intestinal and epidermal
tissues looked similar to wild-type controls, although it is difficult to
assess minor differences (Figure S2). Hence, muscle droplets
accumulate in aging vpr-1 mutant worms.
To directly test whether these droplets contain lipid, we fed vpr-1
mutant worms E. coli incubated with Bodipy-conjugated fatty acids
(Bodipy-FAs). These fluorescent compounds can be used to
directly visualize fat stores in live tissue [23,24]. In wild-type
hermaphrodite controls, dietary Bodipy-FAs were observed
primarily in the intestine with a few small droplets present in
muscle. In contrast, muscles of vpr-1(tm1411) null mutants
contained numerous large Bodipy-FA-stained droplets
(Figure 1C). The fluorescent droplets fully overlapped with those
observed in muscle by DIC microscopy (Figure 1D). Similar results
are observed with Sudan Black B, which darkly stains neutral
TAGs in fixed opaque worms (Figure S3). Bodipy-FAs are
continuously transported from the diet, to the worm’s intestinal
cells, and then to the muscle, where they are tightly packed in
membrane-bound vesicles. Bodipy-FAs are also incorporated into
yolk lipoprotein complexes [23], which are specifically endocy-
tosed by oocytes [25]. Although yolk accumulates in the
pseudocoelom of vpr-1 mutants (due to defective oogenesis), it is
not up-taken by muscle (Figure S4). Both Bodipy-FA and Sudan
Black staining show a mild increase in intestinal fat content in vpr-1
mutants. Whether this apparent increase is due to fat accumula-
tion or increased fat synthesis is not clear.
We also performed mass spectrometry of lipid extracts to
determine the lipid composition of wild-type and vpr-1 mutant
adult hermaphrodites. Lipids were analyzed by electrospray
ionization tandem mass spectrometry (ESI-MS/MS). ESI-MS/
MS analysis of the extracts detected a robust increase in TAGs in
vpr-1 mutant extracts, but not in the membrane phospholipids
phosphatidylethanolamine and phosphatidylcholine (Figure 1E
and data not shown). These data indicate that loss of vpr-1 causes
TAG accumulation in muscle of adult hermaphrodite worms.
Author Summary
ALS patients often present with systemic alterations in
energy metabolism, such as dyslipidemia and hyperme-
tabolism of unknown origin. Reduction of Vapb function is
thought to cause motor neuron disease in ALS8 patients
and may predispose individuals to ALS, in general. We
have shown that neurons secrete the N-terminal VAPB
vMSP into the extracellular environment. The secreted
vMSPs signal through Roundabout and Lar-like receptors
on striated muscles. This neuron to muscle signaling
pathway localizes mitochondria to myofilament I-bands
and promotes mitochondrial function. Here we show that
loss of VAPB in C. elegans neurons causes metabolic
changes in muscles, including altered fat metabolism and
elevated DAF-16 FoxO transcription factor activity. DAF-16
promotes muscle triacylglycerol accumulation, increases
ATP levels, and prolongs survival in Vapb mutants.
However, it does not influence muscle mitochondrial
localization nor does it affect oxygen consumption. We
also show that Vapb knockout mice exhibit disrupted
muscular triacylglycerol and FoxO target gene transcrip-
tional responses to fasting and refeeding. These data
indicate that impaired vMSP signaling to muscle triggers
an energy deficiency, which induces a protective meta-
bolic response involving FoxO. Hence, some energy
metabolism alterations observed in ALS patients might
be a consequence of striated muscle mitochondrial
dysfunction.
VAPB/ALS8 in Muscle Energy Metabolism
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Increased ER stress does not cause muscle TAG
accumulation in vpr-1/vap mutants
VAP homologs have been implicated in ER stress pathways
[13,26,27], which can modulate lipid metabolism and homeostasis
[28]. Furthermore, mitochondrial dysfunction is sometimes
associated with ER stress. We considered the possibility that
increased ER stress might cause the high muscle fat levels in vpr-1
mutants. Three lines of evidence argue against this possibility.
First, an integrated hsp-4/BiPp::gfp ER stress reporter [29] did not
show elevated stress levels in vpr-1 mutants (Figure S5A). Second,
vpr-1 mutants are not more sensitive than wild type to tunicamycin
treatment, which induces ER stress (Figure S5B). Third, RNA-
mediated interference (RNAi) of xbp-1, an ER stress-responsive
transcription factor, in vpr-1 mutants had no effect on muscle fat
levels in 3-day old adults (18.063.6 droplets/mm2 for vpr-
1(tm1411) [n = 12] versus 17.363.6 droplets/mm2 for vpr-
1(tm1411) xbp-1 RNAi [n = 10]; P=0.28). These data indicate that
increased ER stress does not cause the muscle TAG defect in vpr-1
mutants.
vpr-1/vap acts cell nonautonomously to regulate fat
accumulation
vpr-1 is ubiquitously expressed and its homologs have been
implicated in regulating lipid dynamics via a cell autonomous
mechanism [10,30–32]. To determine in which cell type(s) VPR-1
functions to regulate muscle fat, we first used genetic mosaic
analysis. Transgenic vpr-1(tm1411) mutant hermaphrodites were
generated containing the vpr-1 genomic locus and the lineage
marker sur-5::GFP expressed from an extrachromosomal array
[33]. In C. elegans, extrachromosomal arrays are spontaneously lost
at low frequency during cell division, thereby generating mosaic
worms. When these events occur early in development, mosaic
worms can be generated with losses in neurons, body wall muscles,
intestinal cells, and the germ line.
Expressing the vpr-1 genomic locus in vpr-1(tm1411) null worms
rescued the fat metabolism defect in muscle (Figure 2), as well as
the muscle mitochondrial defects, sterility, slow growth, and other
phenotypes. Body wall muscles are generated from multiple cell
lineages, including the EMS lineage. Transgene array loss in the
EMS lineage generates mosaic worms that have a subset of
muscles lacking vpr-1 expression. These muscle cells exhibited low
fat levels, identical to muscle cells that express vpr-1 (Figure 2).
Therefore, VPR-1 is not required in body wall muscle for fat
accumulation. Mosaic worms lacking vpr-1 in the E lineage, which
generates the intestine, also did not exhibit elevated muscle fat
droplets, indicating that vpr-1 is not required in the intestine. In
contrast to muscle and intestine loss, vpr-1 loss in the AB lineage,
which generates the neurons, did cause increased fat droplets in
muscles (Figure 2). Unexpectedly, we also found that vpr-1 loss in
the germ cell lineage causes muscle fat accumulation (Figure 2).
These results indicate that VPR-1 acts cell nonautonomously in
Figure 1. Fat levels in body wall muscle of wild-type and vpr-1 mutant worms. (A) DIC images of muscle in live adult hermaphrodites.
Arrowheads indicate lipid-like droplets. Bar, 5 mm. (B) Transmission electron micrographs of body wall muscle cytoplasm in wild-type and vpr-
1(tm1411) mutant hermaphrodites. Light blue color demarcates muscle boundary. L, Lipid-like droplet. Bar, 0.5 mm. (C) Fluorescent images of muscle
in live adult hermaphrodites fed Bodipy-FAs. Close-up images of boxed areas are shown below. Arrowheads indicate examples of Bodipy-FA-stained
droplets. Anterior is to the left in all panels. Bars, 50 mm. (D) High magnification images of muscle showing Bodipy-FA-stained fluorescent droplets
and droplets observed by DIC microscopy. Bar, 5 mm. (E) Comparison of total ion chromatograms of wild-type and vpr-1(tm1411) mutant adults
extracts for 18:0 TAG (Neutral Loss 284) and phosphatidylethanolamine (Neutral Loss 141).
doi:10.1371/journal.pgen.1003738.g001
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neurons and germ cells (or their differentiation products) to
modulate fat levels in muscle.
vpr-1 null mutants are sterile, due to a failure of germ cells to
differentiate into sperm and oocytes. Sperm secrete signaling
molecules, such as MSPs that may influence fat metabolism [14].
To test whether sperm affect fat levels, we mated sterile 1-day-old
adult vpr-1(tm1411) hermaphrodites to wild-type males. Supplying
sperm to the reproductive tract reduces muscle fat levels in vpr-
1(tm1411) mutants, as visualized with Bodipy-FAs (Figure S6A).
Sperm did not rescue the sterility or muscle mitochondrial defects
of vpr-1 mutants (data not shown). However, preventing sper-
matogenesis in wild-type hermaphrodites using the fog-3(q443) null
mutation causes mild muscle fat accumulation, as well as mild
mitochondrial morphology defects (Figure S6B), without affecting
oxygen consumption [34]. These data indicate that the spermato-
genesis defects in vpr-1 mutants contribute to muscle fat levels and
perhaps mitochondrial defects. Two mechanisms appear to affect
muscle fat levels, one mechanism involving neuronal vpr-1 and a
second mechanism involving sperm, which can modify specific vpr-
1-dependent pathways. Here, we focus on the neuronal mecha-
nism.
Genetic mosaics assess the effect of vpr-1 loss from cells within
an otherwise vpr-1(+) background. To test whether VPR-1
expression is sufficient in neurons, we expressed VPR-1 under
the control of tissue-specific promoters in vpr-1 null mutants.
Consistent with genetic mosaic analysis, VPR-1 expression using
the myo-3 muscle-specific promoter or the ges-1 intestine-specific
promoter did not influence muscle fat levels. In contrast, over-
expressing the vpr-1 cDNA with the unc-119 pan-neuronal
promoter completely rescued the muscle fat levels in approxi-
mately 30–40% of transgenic mutant worms (Figures 3A and 3B).
These rescued transgenic mutants were still sterile. The incomplete
rescue appears to be due to the germ line defects (i.e. lack of
sperm) and missing vpr-1 introns or 39UTR in the transgene (P.
Cottee and M. Miller, unpublished). Consistent with these
observations, driving neuronal expression of the vpr-1 genomic
locus instead of the cDNA rescued several vpr-1 mutant
phenotypes with increased efficiency. These results indicate that
VPR-1 acts cell nonautonomously in neurons to regulate muscle
fat levels.
vMSP signaling to muscle regulates muscle fat levels
The VAPB P56S mutation acts as a dominant negative by
inhibiting secretion of the wild-type and mutant vMSPs [13,15].
To test whether neuronal vMSP secretion affects muscle fat levels,
we generated transgenic worms expressing P56S VPR-1 under the
unc-119 neuronal promoter. P56S VPR-1 overexpression in wild-
type worms causes increased muscle lipid droplets in most worms
(Figure 3A), suggesting that vMSP secretion from neurons
influences muscle fat accumulation.
Figure 2. vpr-1 mosaic analysis. (A) Analysis of vpr-1 genetic mosaics showing the lineages of major tissues. Each circle indicates one genetic
mosaic worm. Points at which the genomic copy of vpr-1(+) was lost and the resulting phenotype are shown. (B) Representative DIC images of muscle
in vpr-1(tm1411) mutant mosaic worms. Ex vpr-1(+) indicates expression of the vpr-1 genomic locus via an extrachromosomal array. Arrowheads
indicate fat droplets. Bar, 5 mm.
doi:10.1371/journal.pgen.1003738.g002
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vMSP signaling to muscle is transduced via muscle SAX-3
Robo and CLR-1 Lar-like receptors [15]. sax-3 mutations cause
incompletely penetrant and variably expressed defects in muscle
mitochondrial morphology [15]. Similarly, we observed incom-
pletely penetrant defects in muscle fat accumulation by TEM
and DIC microscopy (Figure S2; 11.1613.2 fat droplets/mm2
for sax-3(ky123) [n = 13] versus 0.961.8 droplets/mm2 for wild
type [n = 8]). Impaired vMSP signaling causes uncontrolled
CLR-1 Lar receptor activity and ectopic Arp2/3-dependent
actin filaments in muscle. A reduction of clr-1 or arx-2, which
encodes Arp2, rescues the muscle mitochondrial defects, but not
the sterility in vpr-1 mutants [15]. To test whether excess CLR-1
Lar and Arp2/3 activities cause muscle lipid accumulation, we
used RNAi to down-regulate their functions in vpr-1 mutants.
clr-1 or arx-2 RNAi restored mitochondria to I-bands, as
previously reported [15], and reduced muscle fat droplets in
vpr-1(tm1411) mutants when compared to the mutant control
(Figure 4; 18.063.6 droplets/mm2 for vpr-1(tm1411) [n = 12]
versus 0.661.3 droplets/mm2 for vpr-1(tm1411) clr-1 RNAi
[n = 9, P,0.001] and 3.162.0 droplets/mm2 for vpr-1(tm1411)
arx-2 RNAi [n = 6, P,0.001]). Similar results were observed
using TEM [15]. We also found that overexpressing arx-2/arp2
specifically in wild-type muscle causes mild mitochondrial
morphology and fat accumulation defects (Figure S7). Taken
together, the data strongly support the hypothesis that impaired
vMSP signaling from neurons to muscle causes elevated fat
levels in muscle.
DAF-16/FoxO is required for fat accumulation in vpr-1/
vap mutants
The elevated TAGs in vpr-1 mutants and continuous accumu-
lation of dietary Bodipy-FAs in muscle suggested that fat
metabolism and transport pathways are altered. Reduced energy
production triggers enhanced activity of the DAF-16/FoxO
transcription factor, which controls expression of genes involved
in fat synthesis, fat transport, b-oxidation, and stress resistance
[35–39]. We hypothesized that the muscle cytoskeletal or
mitochondrial defects trigger elevated FoxO activity. To investi-
Figure 3. Effect of tissue-specific vpr-1 expression on fat levels. (A) DIC images of muscle in live wild-type and vpr-1(tm1411) mutant
hermaphrodites expressing wild-type VPR-1 or VPR-1(P56S) under indicated tissue-specific promoters. Arrowheads indicate lipid-like droplets. Bar,
5 mm. (B) Sudan Black B staining images of vpr-1 mutants expressing vpr-1 under the unc-119 pan-neuronal promoter. Arrows indicate muscle fat
droplets. Anterior is to the left in all panels. Wild-type controls (Figure S3) are similar to transgenic vpr-1(tm1411) mutants expressing unc119p::vpr-1.
Low magnification bars, 50 mm; high magnification bars, 25 mm.
doi:10.1371/journal.pgen.1003738.g003
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gate if DAF-16 affects fat metabolism in vpr-1 mutants, we
generated vpr-1(tm1411) daf-16(mu86) double mutants. Muscles of
daf-16(mu86) null mutants contain few Bodipy-FA-stained droplets,
similar to muscles of wild-type controls. However, muscle fat levels
in the double mutants are also low, and strongly reduced when
compared to those in vpr-1(tm1411) mutants alone (Figure 5A). daf-
16 loss did not affect food intake, assessed by measuring
pharyngeal pumping rates (Figure 5B; P.0.05), muscle mitochon-
dria (see below), or sterility of vpr-1(tm1411) mutants. We conclude
that the elevated fat levels in vpr-1 null mutants require DAF-16/
FoxO activity.
We next examined DAF-16/FoxO transcriptional activity using
an integrated transgenic line that expresses GFP under the sod-3
promoter (sod-3p::GFP), a direct DAF-16 target [35,40]. When
worms were cultured under normal growth conditions, about 40–
50% of 1-day-old adult vpr-1(tm1411) transgenic worms showed
increased GFP expression relative to control transgenic animals
(Figure 5C). By day three of adulthood, most vpr-1(tm1411)
mutants show broad GFP expression throughout the body,
including the intestine, neurons, vulva muscles, and body wall
muscles. The elevated GFP expression is due to DAF-16 because
GFP expression is suppressed in transgenic vpr-1(tm1411) daf-
16(mu86) double mutants (Figure 5C). These data indicate that vpr-
1 loss causes elevated DAF-16 activity in muscles and other cell
types.
To investigate the mechanism(s) by which VPR-1 controls
DAF-16/FoxO, we analyzed DAF-16 subcellular localization in
vpr-1(tm1411) mutants. An integrated and rescuing transgenic
line was used to express DAF-16::GFP under its endogenous
promoter. DAF-16::GFP translocates from cytoplasm to nucleus
upon loss of insulin signaling, although other mechanisms exist
that regulate nuclear DAF-16 activity independent of translo-
cation [41,42]. Under normal growth conditions at 20uC, DAF-
16::GFP in vpr-1 mutant and control transgenic strains was
distributed throughout the cytoplasm and nucleus with no
significant difference between the two strains (Figures 6A and
6B). However, vpr-1 mutants appear more sensitive to higher
temperatures that require increased metabolic activity
(Figures 6A and 6B). We conclude that VPR-1 does not have
a strong effect on DAF-16 nuclear translocation under standard
conditions.
DAF-16/FoxO likely acts downstream of the Arp2/3
complex
The results thus far strongly support the model that impaired
vMSP signaling to muscle triggers DAF-16-dependent muscle
fat accumulation. We hypothesized that cytoskeletal or mito-
chondrial abnormalities in vpr-1 mutant muscles induce elevated
DAF-16 transcriptional activity. If this idea is correct, then
inactivating the Arp2/3 complex in vpr-1 mutants should
attenuate DAF-16 activity. To assess DAF-16 transcriptional
activity, we used the integrated sod-3p::GFP transgenic reporter.
arx-2/arp2 RNAi in vpr-1(tm1411) mutants causes a strong
reduction in sod-3p::GFP expression in body wall muscle, the
intestine, and other cells (Figure 6C). arx-2 RNAi in wild-type
worms has little effect on GFP expression. Therefore, the
elevated DAF-16 activity in vpr-1 mutants is at least partially
dependent on the Arp2/3 complex.
One possibility is that DAF-16 causes the mitochondrial
abnormalities in vpr-1 mutants. To test this model, we first
evaluated mitochondria using the mitoGFP transgene expressed
in body wall muscle. As previously documented [15], wild-type
muscles contain linear mitochondrial tubules positioned along I-
bands. In contrast, vpr-1(tm1411) mutants contain disorganized
and interconnected mitochondrial networks in the muscle belly
(Figure 7A). Loss of daf-16 in vpr-1(tm1411) mutants did not
affect muscle mitochondrial morphology or localization
(Figure 7A). Next, we examined mitochondrial functional status
using MitoTracker CMXRos, which accumulates in the
mitochondrial matrix depending on membrane potential, and
oxygen consumption of whole worms. DAF-16 loss did not affect
the reduced MitoTracker CMXRos accumulation (Figure 7B) or
the low oxygen consumption rates of vpr-1 mutants (Figures 7C
and 7D). We conclude that DAF-16 does not affect the muscle
mitochondrial defects in vpr-1 mutants and likely acts down-
stream of Arp2/3.
Figure 4. Effect of Arp2/3 inactivation on muscle fat levels. DIC and fluorescent images of muscle in live 3-day-old hermaphrodite worms fed
Bodipy-FAs. arx-2 encodes the Arp2 component of the Arp2/3 complex. Arrowheads indicate Bodipy-FA-stained fat droplets. Bar, 5 mm.
doi:10.1371/journal.pgen.1003738.g004
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DAF-16/FoxO increases ATP levels and extends lifespan
of vpr-1/vap mutants
As the intestine and epidermis are fat storage sites in C. elegans,
we hypothesized that the increase in muscle fat is an attempt to
provide fuel for energy production. Our previous studies showed
that 1-day-old adult vpr-1(tm1411) mutants have reduced ATP
levels when compared to controls [15]. However, the ATP levels in
vpr-1 mutants did not decrease over the next two days, as observed
in the wild type (Figure 8A). 3-day-old adult vpr-1(tm1411) mutants
had higher ATP levels than wild-type controls at the same age
(Figure 8A). Similar ATP dynamics have been observed in aging
worms with mutations in the daf-2 insulin receptor or clk-1, a
mitochondrial protein involved in ubiquinone biosynthesis
[43,44]. Hence, DAF-16 may help maintain ATP levels in these
aging worms. To test whether DAF-16 affects the energy balance
of vpr-1 mutants, we measured ATP levels in single and double
mutant extracts. daf-16 loss did not influence ATP levels in 1-day-
old adult vpr-1(tm1411) mutants (Figure 8A). However, daf-16 is
required for the high ATP concentration in 3-day old mutant
adults (Figure 8A; P,0.001). ATP levels in daf-16 mutants are
similar to wild-type controls (data not shown), as previously shown
[43,44]. These data indicate that DAF-16/FoxO helps vpr-1
mutants maintain ATP levels during aging.
Based on the abnormalities in energy metabolism, we tested
whether DAF-16 influences lifespan in vpr-1 mutants. Similar to
other worm mutants with mild or tissue-specific reduction in
mitochondrial function, vpr-1(tm1411) mutants have slightly
extended adult lifespan compared to wild-type worms (Figure 8B;
mean adult lifespan 6 SD of 12.964.4 days [n = 154] for vpr-
1(tm1411) versus 10.562.1 days [n= 159] for wild type, P,0.001).
daf-16 loss in vpr-1(tm1411) mutants causes a strong reduction in
lifespan relative to vpr-1 mutants and wild-type controls (Figure 8B;
6.962.5 days for vpr-1(tm1411) daf-16(mu86) [n = 250]; P,0.001).
The lifespan of daf-16 single mutants was similar to wild type (data
not shown), as previously shown [38,45]. These data indicate that
DAF-16/FoxO activity extends survival of vpr-1 mutants.
Vapb knockout mice exhibit signs of abnormal skeletal
muscle energy metabolism
The data thus far indicate that VPR-1 loss causes profound
defects in muscle energy metabolism. We hypothesized that the
regulatory function of vMSPs on energy metabolism was
conserved in mammals, and studied energy metabolism of Vapb
2/2 mice [4]. In basal conditions, Vapb 2/2 mice do not exhibit
overt defects in energy metabolism. In particular, body weight and
glycemia appear normal with age (L. Dupuis, unpublished results).
However, an energy metabolism defect of Vapb deficient mice
might be unmasked by modifying insulin supply through feeding
and fasting paradigms. In worms and mice, fasting reduces insulin
signaling and increases FoxO activity, resulting in altered
metabolic gene expression. We used Vapb 2/2 mice of 2–6
months of age to avoid any confounding effect of the motor
dysfunction observed at 18 months [4]. Mice were either fasted for
24 hours (fasted group) or fasted for 16 hours and refed for
8 hours to synchronize meals (fed group). In +/+ mice, fasting
decreased the TAG levels in the gastrocnemius (GA) muscle
(Figure 9A; P,0.05). In contrast, TAG levels remained unchanged
upon fasting in Vapb 2/2 GA and tibialis anterior (TA) muscles
(Figure 9A and data not shown). In liver, TAG levels were
unchanged upon fasting and feeding in either +/+ or 2/2 mice
(Figure 9A). Thus, Vapb ablation increases the resistance of muscle
lipid stores to fasting induced mobilization.
We next looked at mRNA levels of metabolic genes by
quantitative RT-PCR. In liver, Vapb ablation potentiated induc-
tion of the direct FoxO1 target gene phosphoenolpyruvate
carboxykinase (PEPCK) in response to fasting, but had no effect
on fasting induction of other FoxO1 targets such as glucose 6-
phosphatase (G6Pase) and pyruvate dehydrogenase kinase (PDK4)
(Figure 9B). FoxO1 and FoxO3 mRNA and proteins were similar
Figure 5. DAF-16 activity in vpr-1mutants. (A) DIC and fluorescent
images of muscle in live 3-day-old hermaphrodite worms fed Bodipy-
FAs. Arrowheads indicate Bodipy-FA-stained droplets. Wild-type con-
trols (not shown) are similar to daf-16(mu86) mutants (See figures 1C
and 4). Bar, 5 mm. (B) Pharyngeal pumping rates of 1-day-old adult
hermaphrodites. Wild type (236.7621.1 [n = 11]) and vpr-1(tm1411)
mutants (220.169.6 [n = 11]) have similar pharyngeal pumping rate.
Error bars represent SD. *P.0.05 compared to wild type. **P.0.05
compared to vpr-1(tm1411) mutant. (C) Transgenic worms expressing
GFP under control of the sod-3 promoter, a direct DAF-16/FoxO target.
Anterior is to the left in all panels. Bar, 50 mm.
doi:10.1371/journal.pgen.1003738.g005
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in +/+ and 2/2 livers, and FoxO1 up-regulation by fasting
appeared normal in 2/2 liver (Figure 9B).
We also examined putative FoxO1 and FoxO3 target genes in
+/+ and mutant TA muscle. Feeding decreased expression of
PEPCK, G6Pase, and lipoprotein lipase (LPL), and increased
expression of the lipogenic transcription factor SREBP1c
(Figure 9C). This regulation was lost in Vapb 2/2 muscles, as
feeding did not modify expression of these four genes. Vapb
genotype did not affect levels of PDK4 mRNA. FoxO1 and
FoxO3 expression was down-regulated upon feeding in control
TA muscles, but FoxO3 regulation was lost in 2/2 muscles
(Figure 9C). The expression of muscle FoxO3 targets LC3 and
Atrogin1 was up-regulated in fed 2/2 mice, while another
FoxO3 target, ATG12, was unchanged. These results indicate that
muscles of Vapb 2/2 mice are partially insensitive to fasting/
feeding alterations in lipid mobilization and FoxO target gene
expression. Hence, Vapb mutant worms and mice appear to have
muscle energy metabolism alterations, at least in part involving
FoxO targets. Whether the putative metabolic changes in mouse
muscle are due to secreted vMSPs is not yet clear.
Discussion
Results from Drosophila and C. elegans support the model that
VAP MSP domains are secreted neurogenic factors that promote
striated muscle oxidative metabolism [15]. In C. elegans, neurons
cleave the vMSP and secrete it into the surrounding environment.
Secreted vMSPs signal through SAX-3 Roundabout and CLR-1
Lar-like receptors expressed in muscle, down-regulating Lar
signaling to the Arp2/3 complex. This signaling pathway restricts
actin filament formation to I-bands of the myofilaments, thereby
localizing mitochondria to I-bands and promoting mitochondrial
function [13,15]. Here we show that impaired vMSP signaling to
muscle triggers increased DAF-16/FoxO transcription factor
activity. FoxO promotes TAG accumulation in muscle, helps
maintain ATP levels during aging, and extends lifespan. We
propose that reduced vMSP signaling puts animals in an energy
deficit, which triggers an altered metabolic response involving
FoxO. Evidence for this model and implications for ALS are
discussed below.
A VAPB cell nonautonomous mechanism for regulating
muscle TAGs
VAPs physically interact with multiple proteins involved in lipid
binding and transport, such as oxysterol binding protein and
ceramide-transfer protein [10,11,30,46]. Although the biological
role of these interactions is not well understood, VAPs have been
proposed to act in macromolecular complexes for transporting
lipids between organelles at membrane contact sites. This
mechanism depends on VAP function in the same cell in which
lipid dynamics occur (i.e. a cell autonomous function). Here we
show in C. elegans that vpr-1/vap loss triggers a robust increase in
striated muscle TAG levels. Unexpectedly, this function does not
require VPR-1 in muscle. Genetic mosaic and cell-type specific
expression studies demonstrate that VPR-1 acts in neurons,
Figure 6. DAF-16 localization and activity in wild-type and mutant worms. (A) Transgenic strains expressing DAF-16::GFP under its
endogenous promoter. Transgenic controls raised at 20uC are similar to those raised at 20uC then shifted to 35uC for 30 minutes (see panel B for
quantification). Close up images of boxed areas are shown. Anterior is to the left in all panels. Low magnification bar, 50 mm; high magnification bar,
25 mm. (B) Quantification of DAF-16::GFP localization in control (n = 157) and vpr-1(tm1411) mutants (n = 49). (2), incubation under normal growth
condition; (+), incubation at 35uC for 30 minutes. (C) Magnified images showing transgenic lines expressing GFP under the sod-3 promoter. arx-2
encodes Arp2. Arrows indicate vulva muscle region. Anterior is to the left in all panels. Bar, 50 mm.
doi:10.1371/journal.pgen.1003738.g006
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consistent with the signaling function. Indeed, muscle vMSP
receptors and the downstream Arp2/3 complex mediate this
lipid metabolism response. We also found that sperm presence
can modulate striated muscle TAG metabolism. Neurons and
sperm are two cell types capable of secreting MSP domains
[15,47]. Our data do not exclude cell autonomous roles for
VPR-1 in regulating lipid dynamics. Nevertheless, they highlight
the importance of testing VAP autonomy when evaluating
biological mechanism.
The connection between VAPB and FoxO
We show that vpr-1/vap loss triggers elevated DAF-16/FoxO
activity, resulting in muscle TAG accumulation. Inactivating the
Arp2/3 complex largely suppresses these metabolic alterations, as
well as the muscle mitochondrial defects. These data support the
model that impaired vMSP signaling to muscle triggers elevated
FoxO activity. Consistent with this model, over-expressing Arp2
specifically in wild-type muscle causes TAG accumulation and
mitochondrial defects. Although we cannot eliminate the possibil-
ity that Arp2/3 acts in other tissues, it appears to be a muscle-
specific suppressor of vpr-1 mutants. How might the Arp2/3
complex regulate FoxO? One possibility is that vpr-1 mutants go
into energy deficit as they age, as mitochondrial dysfunction is
thought to increase FoxO activity [48–51]. An alternative
possibility is that FoxO acts downstream of Arp2/3, but in
parallel to mitochondria. In either case, reduced insulin signaling
could be involved. A strong reduction in insulin causes increased
FoxO nuclear translocation, which is not observed in vpr-1
mutants under standard conditions. However, subtle changes can
be more difficult to detect.
Additional mechanisms could also modulate FoxO in vpr-1
mutants. The vMSP/ephrin receptor VAB-1 directly interacts
with DAF-18/PTEN (phosphatase and tensin homolog deleted on
chromosome ten), which regulates FoxO activity [52]. VAB-1 is
expressed throughout the adult nervous system and in the gonad
[53,54]. Previous studies have shown that sperm presence can
modulate DAF-16/FoxO translocation and transcriptional activity
[55], perhaps through secreted MSPs. Whether sperm act via the
Arp2/3 complex is not clear. An interesting possibility is that
global MSP signals from neurons and sperm are sensed through
distinct mechanisms. These mechanisms might converge on
muscle metabolic output to meet changes in energy requirements.
In mammals, FoxO transcription factors are critical regulators
of energy metabolism, particularly under fasting conditions. We
show that Vapb ablation in mice renders muscle lipid stores
resistant to fasting, a situation analogous to lipid accumulation in
vpr-1 mutant worm muscles. Dysregulated lipid stores in mutant
mice is associated with alterations in muscle gene expression
consistent with abnormal FoxO1 and FoxO3 activity [56]. For
instance, FoxO1 target gene mRNAs for PEPCK and G6Pase are
clearly up-regulated in muscle of young Vapb 2/2 mice in the fed
state (i.e. in the presence of insulin that decreases FoxO1 activity).
Similar results are observed for FoxO3 target genes LC3 and
Atrogin-1. These data suggest that FoxO1/3 are less sensitive to
insulin inhibition in Vapb 2/2 mice.
Figure 7. Effect of DAF-16 inactivation on muscle mitochon-
dria. (A) Muscle mitochondrial tubules in indicated genotypes
visualized using mitoGFP. Arrowheads indicate fat droplets. Asterisks
indicate nucleus. Bar, 5 mm. (B) MitoTracker CMXRos staining of wild-
type and mutant muscle. Asterisks indicate nucleus. Bar, 5 mm. (C and
D) Oxygen consumption rates of wild-type and mutant hermaphrodites.
Measured consumption rates were normalized by protein content (C) or
number of worms (D). Error bars represent SD. *, P,0.001 compared to
wild type. Oxygen consumption rate of wild-type and vpr-1(tm1411)
mutants includes published data [15] measured together with vpr-
1(tm1411) daf-16(mu86) mutants.
doi:10.1371/journal.pgen.1003738.g007
Figure 8. Effect of DAF-16 inactivation on ATP level and lifespan. (A) ATP concentration in wild-type and vpr-1(tm1411) mutant adult
extracts. *, P,0.001 compared to wild type. Error bars represent SD. ATP concentration of wild-type and vpr-1(tm1411) mutants at 1-day-old adults
include published data [15] measured together with vpr-1(tm1411) daf-16(mu86) mutants. (B) Lifespan measurements of indicated genotypes. The
lifespan of daf-16(mu86) mutants (not shown) was similar to the wild type, as previously shown.
doi:10.1371/journal.pgen.1003738.g008
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Not all FoxO target genes studied are sensitive to Vapb ablation.
For instance, VAPB does not appear to influence PDK4 and
ATG12 mRNAs. Additionally, some of the mRNAs studied
showed uncoupling from circulating insulin levels, consistent with
an insensitivity of FoxO1 to insulin. SREBP1c mRNA, which is
negatively regulated by FoxO1 [57], was increased by feeding in
+/+ mice, but not in 2/2 mice. A similar, albeit mirror situation
was observed for LPL, a gene positively regulated by FoxO1 [58].
Hence, FoxO1/3 might participate in the abnormal lipid
mobilization in Vapb 2/2 mice, but other mechanisms are likely
at work to avoid the major consequences of chronic muscle FoxO
activation, such as muscle atrophy [59]. In summary, our findings
show that VAPB is involved in modulating mouse muscle energy
metabolism upon fasting and refeeding, possibly via altered FoxO
activity. Whether this occurs through a cell autonomous or a cell
nonautonomous mechanism, like in C. elegans and Drosophila,
remains to be determined.
FoxO is protective in vap mutants
A key finding in worms is that DAF-16/FoxO activity prolongs
the adult lifespan of vpr-1 mutants from 6.962.5 to 12.964.4 days.
This lifespan increase may be due to metabolic alterations that
compensate for mitochondrial dysfunction. Consistent with this
idea, FoxO extends the lifespan of C. elegans with reduced
mitochondrial function [48,49,60]. The FoxO-dependent fat
accumulation in vpr-1 mutant muscle may reflect an effort to
increase energy production. We show that DAF-16 helps vpr-1
mutants maintain ATP levels in 3-day old adults. Among the
numerous DAF-16 metabolic genes are those involved in fat
synthesis and transport, b-oxidation, the glyoxylate cycle, and
gluconeogenesis [37]. However, additional DAF-16 targets may
also be involved, such as stress resistance enzymes [37,38,61]. vpr-1
mutants are more resistant than the wild type to reactive oxygen
species and ER stress. Based on identified DAF-16 targets and vpr-
1 mutant phenotypes, DAF-16 might increase energy substrate
availability in muscle, stimulate anaerobic metabolism, increase
oxidative metabolism in non-muscle cells, or decrease ATP
consumption. Further studies are necessary to distinguish among
these possibilities, as well as other models.
Implications for ALS
Metabolic alterations in ALS patients and mouse models are
hypothesized to compensate for mitochondrial dysfunction,
particularly in skeletal muscle [17,19,62,63]. Differentially ex-
pressed gene networks involved in oxidative metabolism and the
cytoskeleton, including up-regulated FoxO1 and FoxO3 mRNAs
have been found in ALS patient skeletal muscles [64,65]. Our
studies of VAPB in worms, flies, and mice are consistent with
impaired vMSP signaling to muscle causing some of these
alterations. Importantly, vpr-1 loss in worms, Vapb depletion in
zebrafish, or Vapb loss in mice does not cause motor neuron
degeneration [4,15], providing strong evidence that mitochondrial
and metabolic defects are not secondary consequences of
neurodegeneration. These data contrast with a recent Drosophila
study suggesting that Vapb loss causes neurodegeneration via
increased phosphoinositides [66]. In humans, metabolic alter-
ations caused by reduced VAPB function may not be sufficient to
induce motor neuron degeneration, although they could strongly
predispose to ALS. Redundancy could be an important consid-
eration in the different models. The worm genome encodes a
single vap homolog, but many genes with MSP domains.
Vertebrate genomes typically encode VAPA and VAPB, which
are approximately 60% identical. Vap mutant flies have the most
severe developmental defects and the fewest MSP genes in the
genome.
In summary, our results support the model that striated muscle
mitochondrial dysfunction alters FoxO activity, which in turn
affects energy metabolism and promotes survival. It is possible that
reduced vMSP signaling causes some of the mitochondrial and
metabolic alterations in ALS patients. Perhaps vMSPs might
protect against ALS via effects on skeletal muscle energy
metabolism.
Materials and Methods
C. elegans genetics, strains, and RNA-mediated
interference
C. elegans Bristol N2 is the wild-type strain. Worms were grown
on NGM plates with NA22 bacteria as the food source [67]. Strain
construction and marker scoring were done as previously
described [15,54]. The strains and genetic markers used or
generated were as follows: CF1553 muIs84[pAD76(sod-3::GFP)],
CF1038 daf-16(mu86) I, vpr-1(tm1411)/hT2[bli-4(e937) let-?(q782)
qIs48] I;III, SJ4005 zcIs4[hsp-4::GFP], TJ356 zIs356[daf-16p::daf-
16::GFP; rol-6] IV, fog-3(q443) I/hT2[bli-4(e937) let-?(q782) qIs48]
I;III, CX3198 sax-3(ky123) X, and XM1004 vpr-1(tm1411) daf-
16(mu86)/hT2[bli-4(e937) let-?(q782) qIs48] I;III. Transgenics
expressing vit-2p::vit-2::gfp were generated by crossing into the
pwIs23 integrated line. RNAi was performed using the feeding
method starting at the L1 stage, as previously described [15]. arx-2,
clr-1, and xbp-1 RNAi clones are from the genome-wide library
[68]. Each clone was sequenced for confirmation.
Transgenics
To generate transgenic C. elegans, the marker plasmids pRF4
[rol-6] (60 ng/ml) or myo-3p::mito::GFP (30–60 ng/ml) were mixed
with myo-3p::vpr-1 (60 ng/ml), ges-1p::vpr-1(60 ng/ml), unc-119p::vpr-
1(60 ng/ml), unc-119p::vpr-1 P56S (60 ng/ml), or myo-3p::arx-
2::mCherry (60 ng/ml) and microinjected into the gonads of young
adult hermaphrodites. Injected worms were incubated for
24 hours, transferred to new NGM plates, and screened for
transgenic progeny. Transgenic lines were selected based on the
roller phenotype or GFP expression. Multiple independent
transgenic lines were generated for all strains. To conduct genetic
mosaic analysis, 10 ng/ml WRM06B28 fosmid DNA containing
the vpr-1 genomic locus was mixed with 10 ng/ml pTG96 (sur-
5p::GFP) plasmid and microinjected into the gonads of vpr-
1(tm1411)/hT2 hermaphrodites. Transgenic lines were selected
based on GFP expression. Transgenic lines were maintained as
vpr-1(tm1411) homozygotes, as the fosmid rescued the sterility,
mitochondria, fat metabolism, slow growth, and embryonic
defects. For lineage scoring, approximately 15,000 worms were
screened. Transgene loss in the AB lineage was scored by GFP loss
in head and tail neurons, the nerve cords, and the excretory gland.
Figure 9. Effect of Vapb ablation on fasting/refeeding energy metabolism in mice. (A) TAG concentration in GA muscle and liver of wild-
type (+/+) and Vapb knock-out (2/2) mice after 24-hour fasting (red) or 24 hours fasting followed by 6 hours of refeeding (blue). (B and C)
Quantitative RT-PCR of indicated genes in liver (B) and TA muscle (C) of wild-type (+/+) and Vapb knock-out (2/2) mice after 24-hour fasting (red) or
24 hours fasting followed by 6 hours of refeeding (blue). Relative mRNA levels are shown on the Y-axis.#, P,0.05 compared to fed mice of the same
genotype. *, P,0.05 compared to +/+ under the same condition.
doi:10.1371/journal.pgen.1003738.g009
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Transgene loss in the P1 lineage was scored by GFP loss in the
intestine, muscle, somatic gonad, and hyp11. The P2 lineage was
scored by GFP loss in numerous body wall muscle cells and hyp11,
the P3 lineage was scored by GFP loss in body wall muscle, and
the P4 lineage was inferred by a sterile phenotype without GFP
loss. Transgene loss in the EMS lineage was scored by GFP loss in
the intestine and somatic gonad, while loss in the E lineage was
score by exclusive GFP loss in the intestine.
Transmission electron microscopy
TEM was performed as previously described [15].
Bodipy-FA and Sudan Black B staining
For the Bodipy-FA experiments, a 5 mM Bodipy-FA (Molecular
probe, U.S.A) stock solution was prepared in DMSO and kept at
220uC. A 200 mM working solution diluted in distilled water was
dropped onto seeded plates and allowed to dry. L4 stage worms
were placed on the plates and incubated in the dark for 24 hours
at 20uC. Bodipy-FAs can get trapped in intestinal gut granules that
are not present in muscle.
Sudan Black B staining was conducted as described in previous
studies [15]. Briefly, synchronized 1-day-old adult worms were
collected into microfuge tubes containing M9 solution. Worms
were washed five times, incubated for 40 minutes at 20uC to
remove intestinal bacteria, and fixed in 1% paraformaldehyde.
The fixed worms were washed three times in cold M9 solution and
dehydrated through a 25%, 50%, and 70% ethanol series. Sudan
Black B solution was added to the worms and incubated for
1 hour. To remove excess stain, worms were washed five times
with 70% ethanol. To normalize for staining variability among
experiments, wild type and vpr-1(tm1411) mutants were processed
in the same tube and identified based on gonad morphology.
Lipid analysis by ESI-MS/MS
For the lipid analysis by ESI-MS/MS, lipids from equal masses
of wild type and vpr-1(tm1411) mutant adults were extracted by
chloroform-methanol following a modified Bligh/Dyer extraction
[69]. A mixture of internal standards including T17:1 TAG was
added to the chloroform-methanol phase before extraction. The
extracted samples were concentrated to dryness under a nitrogen
stream, reconstituted with methanol:chloroform (1:1 v/v) and
transferred to HPLC auto samplers. Lipids were analyzed by ESI-
MS/MS using an API 4000 (Applied Biosystems/MDS Sciex,
Concord, Ontario, Canada) triple quadrupole mass spectrometer.
Extracted lipid samples (5 ml) were infused into the mass
spectrometer with a solvent mixture of chloroform-methanol
(1:2, v/v) containing 0.1% formic acid using a Shimadzu
Prominence HPLC with a refrigerated auto sampler (Shimadzu
Scientific Instruments, Inc. Columbia, MD). Lipids were analyzed
in positive ion mode using an API 4000 (Applied Biosystems/
MDS Sciex, Concord, Ontario, Canada) triple quadruple mass
spectrometer. Samples (5 ml) were directly infused into the
electrospray source using a Shimadzu Prominence HPLC with a
refrigerated auto sampler (Shimadzu Scientific Instruments, Inc.
Columbia, MD). Neutral loss (NL) scanning (228, 254, 256, 268,
278, 280, 284, and 304) of naturally occurring aliphatic chains (i.e.
building block of TAG molecular species) were utilized to
determine the identities of each molecular species. NL scanning
of 141 was used for profiling phosphatidylethanolamine. The
following analysis parameters were used: ion spray voltage
5000 V, de-clustering potential 40 V, temperature 300uC (for
TAG), collision energy 35 V, and collisionally activated dissoci-
ation 5.
Mitochondrial staining
To assess mitochondrial transmembrane potential, worms
were stained using the MitoTracker CMXRos dye (Molecular
Probes, U.S.A), as previously described [15]. This lipophilic
cationic fluorescent dye accumulates in mitochondria in a
membrane potential-dependent manner [70]. L4 larval stage
worms were placed on dried plates containing a 100 mM
MitoTracker CMXRos dye solution (dropped on bacteria).
After 24 hours incubation in the dark, worms were transferred
to a new NGM plate and incubated in the dark for 20 minutes
to remove intestinal background. Worms were mounted on
dried 2% agarose pads without anesthetic. Wild-type and vpr-
1(tm1411) mutant hermaphrodites were cultured on the same
plates.
ATP concentration measurement
ATP concentration was measured as described previously, with
slight modification [15]. Briefly, 150 worms were individually
picked and placed into tubes containing M9 buffer, washed four
times, and incubated at 20uC for 40 minutes to remove intestinal
bacteria. These worms were then washed four times with TE
solution (100 mM Tris–Cl, pH 7.6, 4 mM EDTA) and placed into
microfuge tubes containing 300 ml TE solution. Worm extracts
were prepared by a series of cycles including freezing, thawing,
and sonicating. These extracts were boiled for 10 minutes to
release ATP and block ATPase activity. Carcasses and insoluble
material were pelleted in a microcentrifuge at 20,0006g for
10 minutes. The soluble extracts were diluted in a 1:10 ratio using
TE solution. ATP concentration in 60 ml of diluted extracts was
measured using the ENLITEN ATP Assay System (Promega,
U.S.A), according to the manufacturer’s instructions. A luminom-
eter (Berthold, Germany) was used for quantification. Protein
concentration was determined using the BCA protein assay
(Pierce, U.S.A). ATP measurements were repeated at least three
times for each strain.
Oxygen consumption
Oxygen consumption rates were measured as previously
described using the oxygraph system (Hansatech, UK) with
minor modifications [15]. Worms were cultured at 20uC and
synchronized to the 1-day-old adult stage. For each test, 1000
worms were individually picked and placed into a glass tube
with 1 ml M9 buffer at 20uC. Collected worms were incubated
for 40 min at 20uC to remove intestinal bacteria, carefully
washed five times, and placed into 1 ml M9 buffer. The worm
solution was loaded into the chamber equipped with a S1 Clark
type polarographic oxygen electrode disc maintained at 20uC.
Oxygen concentration was measured for 10 minutes. For
normalization, worms were carefully collected from the cham-
ber and protein content was measured using the BCA test kit
(Pierce, U.S.A.). Rates were normalized to either total protein
content or number of worms. We performed at least three
independent measurements per strain.
Feeding rate and lifespan assays
To measure feeding rates, worms were cultured at 20uC and 1-
day-old adult worms were placed on new NGM plates. Feeding
behavior was recorded using a Zeiss Lumar stereomicroscope with
AxioCam MRM digital camera. Measurements were conducted
during a 30 second period at room temperature (22uC). The
rhythmic contractions of the pharyngeal bulb were counted. For
each strain, over 20 worms were counted. To determine lifespan of
worms, L4 larval stage worms were placed on new NGM plates
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seeded with NA22 bacteria and cultured at 20uC. The L4 stage
was used because a small percentage of vpr-1 mutants die during
L1–L4 stages and vpr-1 mutants develop slowly. Worms were
monitored every day and transferred to flesh NGM plates. Death
was scored by failure to respond to touching with a platinum wire.
Wild-type worms fed NA22 bacteria have slightly shorter lifespan
than worms fed OP50 bacteria.
Tunicamycin resistance
To analyze ER homeostasis, worms were cultured on plates
with tunicamycin (Sigma, U.S.A) from the embryonic stage to
adulthood. NGM plates with 0.1% DMSO and 0 or 5.0 mg/ml
tunicamycin were prepared. About 30 adult worms were placed on
each tunicamycin plate and allowed to lay embryos for 30 min-
utes. Adult worms were then removed. Twelve hours later the
number of hatched embryos was counted and compared with the
number of worms that reached the adult stage within 96 hours.
We performed at least three independent measurements for each
strain.
Mouse experiments
Mouse experiments were performed using the Institutional
European Guidelines, under the supervision of an authorized
investigator (LD), and approved by the local ethical committee for
animal experiments (CREMEAS, agreement Nu AL/01/08/02/
13). Vapb 2/2 mice were used and genotyped as described [4].
Mice (8–10 per group) were either fasted for 24 hours from 5PM
(fasted group), or fasted from 5PM to 9AM and refed until sacrifice
at 5PM. GA and TA muscle and liver tissues were collected, and
rapidly frozen in liquid nitrogen for subsequent analyses of gene
expression and TAG levels. The tissues were stored at280uC until
the time of analysis.
For RT-qPCR, frozen liver and muscle tissues were placed
into tubes containing 5 mm stainless steel beads (Qiagen,
Courtaboeuf, France) and 1 ml of Trizol reagent (Invitrogen,
Paisley, UK) and homogenized using a TissueLyser (Qiagen).
RNA was prepared from tissue homogenates following Trizol
manufacturer’s instructions. RNA reverse transcription and
SYBR Green real-time PCR assays were performed using the
Bio-Rad (Biorad, Marnes la Coquette, France) iCycler kits and
protocols. PCR conditions were 3 min at 94uC, followed by 40
cycles of 45 s at 94uC and 10 s at 60uC. Primers are shown in
Table S1. For western blotting, liver and TA muscles were
incubated in Lysis buffer containing complete protease and
phosphatase inhibitor cocktails. Protein concentration was
measured using BCA Protein Assay. Equal amount of protein
(50 mg) were separated by SDS-PAGE 10% and blotted onto
nitrocellulose membrane. Membranes were saturated with 10%
milk and then incubated with the primary antibodies FoxO1
(Proteintech; 18592-1-AP), FoxO3a (Cell signaling; #2497),
VAPB [4] and Histone H3 (Cell signaling; #9715), all diluted
(1:1000) followed by anti-rabbit secondary antibody, diluted
1:5000.
For TAG analysis, tissue powder was homogenized in lysis
buffer (250 mM Sucrose solution, 1 mM EDTA, 2% SDT, 1 mM
DTT, 10 mM Tris HCl pH 7.4) containing protease inhibitors
(Sigma P8340) and phosphatase inhibitors (Sigma 8345), centri-
fuged at 120006rpm for 15 minutes at room temperature. TAG
concentration was determined in duplicate for each sample in 5 ml
of supernatant, using the enzymatic method of analysis (Randox
Triglyceride Colorimetric Assay Kit, Randox Laboratories Limited, UK) as
described by the manufacturer. Lipid values were normalized to
protein concentration.
Supporting Information
Figure S1 Lipid-like droplets and mitochondria in vpr-1 mutant
striated muscle. (A) Close-up image of a live transgenic vpr-
1(tm1441) mutant hermaphrodite expressing mitoGFP in body wall
muscle. mitoGFP labels muscle mitochondrial tubules. (B) Image of
a single body wall muscle in a transgenic vpr-1(tm1441) mutant
hermaphrodite expressing mitoGFP. (C) Close-up image of the
boxed region from panel B showing horizontal and vertical cross-
sections. Arrowheads indicate lipid-like droplets. Asterisks indicate
nucleus. Bar in A, 1 mm; Bars in B and C, 10 mm.
(TIF)
Figure S2 Transmission electron micrographs of wild-type and
mutant adults. Micrographs are transverse sections showing the
cuticle (C) and body wall muscle sarcomeres (S) with hypodermis
sandwiched in between. A lipid droplet within the hypodermis (HL)
is seen in the wild-type panel. The intestine is filled with electron
dense and opaque lipid droplets (IL). Yolk lipoprotein complexes (Y)
are found between muscle and intestinal tissues (also see Figure S4).
Notice that yolk is electron dense, whereas muscle lipid droplets
(ML) are opaque. N, muscle nucleus. Bars, 1 mm.
(TIF)
Figure S3 Sudan Black B staining in wild type and vpr-1
mutants. 1-day-old adult wild-type and vpr-1(tm1411) hermaphro-
dites were stained using Sudan Black B. Arrowheads indicate fat
droplets in body wall muscle. Anterior is to the left in all panels.
Boxed regions are magnified 56 below. Low magnification bars,
50 mm; high magnification bars, 10 mm.
(TIF)
Figure S4 Yolk lipoprotein complex distribution in wild-type
and vpr-1 mutants. (A) Yolk distribution visualized with the vit-
2p::vit-2::gfp transgene. vpr-1 mutants accumulate yolk in the
pseudocoelom due to failure of oocyte differentiation. GFP uptake
is not observed in peripheral tissues. (B) Close-up image showing
muscle fat droplets (arrows) in vpr-1 mutants. Bar, 5 mm.
(TIF)
Figure S5 ER stress assays in wild-type and vpr-1 mutant worms.
(A) Integrated transgenic lines expressing GFP under the hsp-4
promoter (hsp-4p::GFP) with and without tunicamycin treatment,
which induces ER stress. Anterior is to the left in all panels. Bar,
5 mm. (B) Tunicamycin sensitivity in wild-type and vpr-1(tm1411)
mutants hermaphrodites. Y-axis indicates the percentage of worms
that developed to the adult stage in the presence of 5 mg/ml
tunicamycin. Error bars represent SD. Three independent
measurements were performed.
(TIF)
Figure S6 Effect of sperm presence on muscle fat droplets and
mitochondria. (A) DIC and fluorescent images of muscle in live 3-
day-old vpr-1 mutant hermaphrodite worms fed Bodipy-FAs.
Mating with wild type (WT) males provides sperm into the uterus.
Sperm presence did not affect the sterility or muscle mitochondrial
morphology of vpr-1 mutants (data not shown). Anterior is to the
left in all panels. Arrowheads indicate lipid-like droplets. Bar,
5 mm. (B) DIC and fluorescent images of muscle in live transgenic
fog-3(q443)/hT2 hermaphrodites containing sperm and unmated
fog-3(q443) mutants without sperm. Muscle mitochondrial tubules
were visualized using mitoGFP. Arrowheads indicate lipid-like
droplets. Asterisks indicate nucleus. Bar, 5 mm.
(TIF)
Figure S7 Effect of ARX-2/Arp2 overexpression on muscle fat
droplets and mitochondria. DIC and fluorescent images of muscle
in live transgenic wild-type hermaphrodites expressing arx-2 under
VAPB/ALS8 in Muscle Energy Metabolism
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control of the muscle specific myo-3 promoter. Muscle mitochon-
drial tubules were visualized using mitoGFP. Notice that muscle
mitochondrial morphology closely resembles the morphology seen
in vpr-1 mutants [15]. See Figures 7A, S6B and [15] for controls.
Arrows indicate lipid-like droplets. Asterisks indicate nucleus. Bar,
5 mm.
(TIF)
Table S1 Primers used for RT-qPCR in mice.
(TIF)
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Abstract  
Amyotrophic Lateral Sclerosis (ALS), the most common adult-onset motor neuron disease, 
leads to death within 3 to 5 years after onset. Beyond progressive motor impairment, ALS patients 
suffer from major defects in energy metabolism, such as weight loss, which are well correlated with 
survival. Indeed, nutritional intervention targeting weight loss might be improving survival of 
patients. However, the neural mechanisms underlying metabolic impairment in ALS patients remain 
elusive, in particular due to the lack of longitudinal studies. Here we took advantage of samples 
collected during the clinical trial of pioglitazone (GERP-ALS), and characterized longitudinally 
energy metabolism of ALS patients in response to pioglitazone, a drug with well characterized 
metabolic effects. As expected, pioglitazone decreased glycemia, decreased liver enzymes and 
increased circulating adiponectin in ALS patients, showing its efficacy in the periphery. However, 
pioglitazone did not increase body weight of ALS patients independently of bulbar involvement. 
Since pioglitazone increases body weight through a direct inhibition of hypothalamic neurons 
producing pro-opiomelanocortin (POMC), we studied POMC neurons in mice expressing ALS-
linked mutant SOD1(G86R). We observed presymptomatically decreased hypothalamic levels of 
POMC mRNA, decreased numbers of POMC positive neurons in the hypothalamic arcuate nucleus 
of SOD1(G86R) mice, and increased food intake after short term fasting, consistent with a defect in 
the hypothalamic melanocortin system. Importantly, these findings were replicated in two other 
ALS mouse models based on TDP-43 and FUS mutations. Last, we demonstrate that the 
melanocortin defect is primarily caused by serotonin loss in mutant SOD1(G86R) mice. In all, the 
current study combined clinical evidence and experimental studies in rodents to provide a 
mechanistic explanation for abnormalities in food intake and weight control observed in ALS 
patients. Importantly, these results also show that ALS progression impairs responsiveness to 
classical drugs leading to weight gain. This has important implications for pharmacological 
management of weight loss in ALS. 
 
Keywords: amyotrophic lateral sclerosis, calorie intake, hypothalamus, thiazolinediones, weight 
loss 
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Introduction 
Amyotrophic Lateral Sclerosis (ALS), the most common adult-onset motor neuron disease, is 
characterized by the simultaneous degeneration of upper and lower motor neurons, leading to 
muscle atrophy and paralysis, and death within 3 to 5 years after onset. A subset of ALS cases are 
of familial origin and five major genes are currently associated with familial ALS (C9ORF72, 
SOD1, FUS, TARDBP and TBK1) (Leblond et al., 2014, Cirulli et al., 2015, Freischmidt et al., 
2015, Lattante et al., 2015). The SOD1 gene was the first associated with ALS and most ALS 
mouse models currently used are based upon overexpression of mutant forms of SOD1 (Gurney et 
al., 1994, Ripps et al., 1995). 
Beyond progressive motor impairment, ALS patients suffer from major, yet incompletely 
characterized, defects in energy metabolism (Dupuis et al., 2011). First, ALS is more likely to occur 
with lower premorbid body fat (Gallo et al., 2013, O'Reilly et al., 2013) or better cardiovascular or 
physical fitness (Turner et al., 2012, Huisman et al., 2013). Second, weight loss is negatively 
correlated with survival (Desport et al., 1999, Marin et al., 2011, Paganoni et al., 2011). This 
weight loss is associated with, and likely caused by, intrinsic hypermetabolism (Desport et al., 
2001, Bouteloup et al., 2009), and is exacerbated by dysphagia occuring with bulbar involvement. 
Third, ALS patients develop abnormalities in lipid (Dupuis et al., 2008, Dorst et al., 2011, Lindauer 
et al., 2013) and glucose (Pradat et al., 2010) metabolisms. Interestingly, these metabolic alterations 
are largely replicated in transgenic mice expressing mutant SOD1 (Dupuis et al., 2004, Fergani et 
al., 2007, Palamiuc et al., 2015). Not much is known on the underlying mechanisms of energy 
metabolism impairment despite the elucidation of such mechanisms would offer therapeutic 
strategies to treat weight loss pharmacologically. Furthermore, deciphering the mechanisms of 
energy metabolism impairment could identify disease-modifying interventions since hypercaloric 
diet was recently found to increase survival of ALS patients under gastrostomy (Wills et al., 2014, 
Dorst et al., 2015).  
Most of the studies to date have characterized energy metabolism in ALS patients in steady 
state, at one single time point. The dynamic nature of energy metabolism and its homeostatic 
regulation thus severely limit the interpretation of these studies. Interventions performed during 
randomized clinical trials often have metabolic effects, and such studies include long term follow 
up of patients for many months. These clinical studies thus provide high-quality information useful 
to understand the metabolic defects of ALS patients.  
Here, we performed a post hoc analysis of samples obtained during the clinical trial of 
pioglitazone (Dupuis et al., 2012) to characterize energy metabolism of ALS patients upon a 
metabolic challenge. Indeed, pioglitazone, like other thiazolinediones (TZDs), has pleiotropic 
effects on energy metabolism that have been extremely well characterized in both mouse models, 
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and human patients. In the periphery, pioglitazone sensitizes to insulin, leading to decreased 
glycaemia, and decreases circulating levels of liver enzymes (Promrat et al., 2004, Belfort et al., 
2006, Sanyal et al., 2010, DeFronzo et al., 2011). In the central nervous system, pioglitazone 
inhibits the hypothalamic melanocortin system to increase food intake (Diano et al., 2011, Lu et al., 
2011, Ryan et al., 2011, Long et al., 2014). Specifically, pioglitazone decreases activity of the 
hypothalamic neurons producing pro-opiomelanocortin (POMC), the precursor of a number of 
anorexigenic peptides such as α-MSH (melanocyte stimulating hormone) (Diano et al., 2011, Lu et 
al., 2011, Ryan et al., 2011, Long et al., 2014). In humans, this leads to a robust (3-5 kg) weight 
gain that was repeatedly observed in multiple clinical trials (Promrat et al., 2004, Belfort et al., 
2006, Sanyal et al., 2010, DeFronzo et al., 2011). Here, we show that ALS patients display normal 
peripheral action of pioglitazone, while they lack weight gain. In transgenic mice expressing mutant 
SOD1, pioglitazone failed to increase food intake. This was associated with prominent involvement 
of the hypothalamic melanocortin system, also observed in other mouse models of ALS, 
independent of mutant SOD1 overexpression. Last, we show that the melanocortin defect occurs 
downstream of the previously documented serotonin loss (Dentel et al., 2013). Altogether, our 
analysis of the data from the pioglitazone trial disclosed a previously unanticipated defect in ALS 
patients that could account for a subset of ALS-related metabolic defects. 
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Materials and methods 
Patients and treatments 
All the biological materials from human ALS patients were sampled as part of the GERP-ALS trial 
(clinicaltrials.gov reference: NCT00690118) (Dupuis et al., 2012). Briefly, patients with possible, 
probable (clinically or laboratory-supported) or definite ALS according to the revised version of the 
El Escorial criteria were considered for enrolment into the study. Included patients displayed onset 
of progressive weakness within 36 months prior to study and had a disease duration of more than 
six months and less than three years (inclusive) with disease onset defined as date of first muscle 
weakness, excluding fasciculation and cramps. They reached a best-sitting slow vital capacity 
between 50 % and 95 % of predicted normal. They were capable of thoroughly understanding the 
information provided and giving full informed consent. All included patients had been treated with 
100 mg riluzole daily for at least three months prior to inclusion. Detailed exclusion and inclusion 
criteria have been described earlier (Dupuis et al., 2012). All patients gave written informed 
consent. The study protocol was approved by the ethics committee of the university of Ulm and all 
other participating centres. 
The two treatment groups were 100 mg riluzole plus 45 mg pioglitazone (pioglitazone group) and 
100 mg riluzole plus placebo (placebo group). Patients were randomly assigned to one of the two 
treatment groups and both groups were matched for age, gender and site of onset (Dupuis et al., 
2012). 
 
Procedures and biochemical analysis of human samples 
After inclusion, patients underwent a screening phase and a treatment phase (18 months), with 
stepwise increase in dosage (Dupuis et al., 2012). Clinical and physical examinations, blood 
sampling, and drug compliance were recorded at on-site visits (1, 2, 6, 12 and 18 months after 
baseline visit). Body weight was also recorded at 9 and 15 months after baseline visit through 
telephone contacts. Routine clinical laboratory tests were performed at each on-site visit (baseline 
and 1, 2, 6, 12 and 18months after baseline). All tests were carried out according to standard 
laboratory procedures at each study centre's locally accredited laboratory, which defined the normal 
reference range for each analyte. The following laboratory tests were performed using standard 
methods: Alanine Aminotransferase (ALAT), Aspartate Aminotransferase (ASAT), fasting blood 
glucose. Adiponectin measurements were done in the neurochemical laboratory in Ulm (MSD 
assay). 
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Animals 
Transgenic mice were housed in the animal facility of the medicine faculty of Strasbourg 
University, with 12 h/12 h of light/dark and unrestricted access to food and water. In all 
experiments, littermates were used for comparison. Transgenic SOD1(G86R) were maintained in 
their initial FVB/N genetic background according to previous studies (Dentel et al, 2013). 
Transgenic mice expressing TDP43(A315T) were previously described and were maintained as 
heterozygous in their initial C57Bl6/J background (Wegorzewska et al, 2009). Heterozygous 
Fus
∆NLS/+
 are knock-in mice expressing FUS protein deleted from its C-terminal NLS from one of 
the endogenous Fus gene. These mice were generated and maintained in C57Bl6/J background. The 
motor phenotype of these mice will be described elsewhere (Scekic-Zahirovic, submitted). Tph2-
YFP mice were purchased from Jackson laboratories (Bar Harbor, ME, USA; strain 014555) and 
maintained in their initial genetic background. Female Tph2-YFP mice were crossed with male 
SOD1(G86R) to generate compound transgenic mice.  
For biochemical analysis, animals were sacrificed at the ages indicated at 2PM, and tissues were 
quickly dissected, frozen in liquid nitrogen, and stored at −80 °C until use. For histological analysis, 
animals were anesthetized by intraperitoneal injection of ketamine (Imalgène 1000®, Merial, Lyon 
France; 90 mg/kg body weight) and xylazine (Rompun 2% ®, Bayer, Leverkusen, Germany; 10 
mg/kg body weight) at the ages indicated at 2PM. After perfusion of 4% paraformaldehyde (PFA, 
Sigma, St Louis, MO, USA), brains were removed, stored in the same fixative overnight at 4°C and 
stored in phosphate buffered saline (PBS) until used. These experiments were authorized by the 
local ethical committee of Strasbourg University (CREMEAS). 
 
Drugs and treatments 
Pioglitazone (Actos®, Takeda, London, UK) was dissolved in 10% dimethyl sulfoxide (DMSO, 
Fisher Scientific, Illkirch, France) and a single oral administration was given by gavage at a dose of 
40 mg/kg body weight. Fluoxetine (Sigma, St Louis, MO, USA) was dissolved in 0,9% sodium 
chloride (NaCl, Sigma, St Louis, MO, USA) and administrated intraperitoneally (i.p.) at a dose of 
20 mg/kg body weight. 
 
Measurements of food intake 
For the pioglitazone experiment, mice were fasted from 9AM to 3PM, and pioglitazone was 
administrated at 3PM. Food was reintroduced 1 hour after gavage and food intake was recorded 
during 24h.  
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For short term fasting experiments, mice were fasted from 8AM to 3PM (7 hours fasting conditions) 
or from 2PM to 3PM (1 hour fasting conditions) and food was reintroduced after 7 hours or 1 hour 
of fasting. Food intake was measured one hour and 24 hours after refeeding.  
For fluoxetine experiment, mice were fasted from 1PM to 2PM, and fluoxetine was injected at 
2PM. Food was reintroduced 30 minutes after fluoxetine injection and food intake was measured 
during one hour. For biochemical analysis, a second injection of fluoxetine was done after 1 hour of 
feeding and mice were sacrificed 30 minutes later.  
 
Histology  
Fixed brains were include in 6% agar (Sigma, St Louis, MO, USA) and cut from Bregma 0.02mm 
to Bregma -2.90mm into 40µm coronal sections on a vibratome. Arcuate nucleus was identified 
according to Paxinos Brain Atlas. POMC immunohistochemistry was performed on half of selected 
brain sections. YFP immunohistochemistry was performed on 1 section per animal. 
Immunohistochemistry was performed on floating sections using standard histological techniques. 
Endogenous peroxidases were inactivated using 3% H2O2. For POMC immunohistochemistry, 
permeabilization and saturation of nonspecific sites were done with 0.25%(v/v) Triton (Sigma, St 
Louis, MO, USA) and 50mg/ml Bovine Albumin Serum (BSA, Sigma, St Louis, MO, USA). For 
GFP immunohistochemistry, permeabilization and saturation of nonspecific sites were done with 
0.5%(v/v) Triton (Sigma, St Louis, MO, USA) and 5%(v/v) Horse serum (Gibco, Life 
Technologies, Carlsbad, CA, USA). Rabbit anti-POMC primary antibody (Phoenix Peptide, 
Burlingame, CA, USA; 1:2000) or rabbit anti-GFP primary antibody (Invitrogen, Life 
Technologies, Carlsbad, CA, USA, 1:1000) were incubated for overnight at room temperature. 
Biotinilated donkey anti-Rabbit secondary antibody (Jackson, West Grove, PA, USA; 1:500) was 
incubated during 90 minutes. Staining was performed using Vectastain Elite ABC kit (Vector, 
Burlingame, CA, USA). After revelation with 3,3'-Diaminobenzidine (DAB, Sigma, St Louis, MO, 
USA; 0.5mg/ml), sections were mounted and images of all sections were taken. Total numbers of 
POMC positive cell bodies in the arcuate nucleus were determined by animal by an operator in a 
blinded manner. The number of POMC positif cell bodies were normalised by the number of 
selected brain sections for each animal. Innervation score of YFP staining were determined by 
animal by an operator in a blinded manner.  
 
RNA extraction and quantitative RT-PCR 
RNA was extracted from mouse hypothalami using TRIZOL reagent (Life Technologies, Carlsbad, 
CA, USA). After reverse transcription with iScript reverse transcription Supermix for RT-qPCR 
(BioRAD, Hercules, CA, USA), cDNA was obtained from 1 µg of RNA. POMC and AgRP mRNA 
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level were obtained by quantitative PCR using Sso Advanced Universal SYBR Green Supermix 
(BioRAD, Hercules, CA, USA) with Agrp and POMC sense and antisense primers. Standard curves 
were constructed by amplifying serial dilutions of cDNA. Starting quantities of samples were 
calculated with Biorad software. mRNA levels of Agrp and Pomc were normalized to expression 
levels of the 18S ribosomal, TBP and pol2 RNA housekeeping genes using GeNorm 
(Vandesompele et al., 2002). Primer sequences were the following: 
 POMC: F-AGTGCCAGGACCTCACCA, R-CAGCGAGAGGTCGAGTTTG 
AgRP: F-CAGGCTCTGTTCCCAGAGTT, R-TCTAGCACCTCCGCCAAA 
18S: F-TCTGATAAATGCACGCATCC, R-GCCATGCATGTCTAAGTACGC 
TBP: F-CCAATGACTCCTATGACCCCTA, R-CAGCCAAGATTCACGGTAGAT 
POL2: F-GCTGGGAGACATAGCACCA, R-TTACTCCCCTGCATGGTCTC 
 
Serotonin levels 
Hypothalamic serotonin levels were measured using HPLC, as previously described (Dentel et al., 
2013). 
 
Statistical analysis 
For statistical analyses in ALS patients, group comparisons were performed using mixed effects 
regression model analysis by the Institute of Epidemiology and Medical Biometrics at the 
University of Ulm using the statistical software package SAS Version 9.2 under Windows. 
For animal experiments, comparison of two groups was performed using unpaired Student’s t-test, 
except for experiments with pioglitazone in which paired t-test was used. Comparison of three or 
four groups was performed using One-way ANOVA and Tukey post-hoc test. Statistics in animal 
experiments were performed using Prism version 6.0. 
All results from analysis were regarded as hypothesis generating only. All statistical tests were 
carried out two-sided at a significance level of 5%. 
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Results 
 
Normal peripheral response to pioglitazone in ALS patients 
We took advantage of data collected during the pioglitazone GERP-ALS trial to investigate energy 
metabolism in ALS patients in response to pioglitazone. The metabolic effects of thiazolinediones 
(TZDs), including pioglitazone are well understood in models and their effects are largely described 
in patients (Fig. 1A). Pioglitazone treatment is known to increase levels of adiponectin, an adipose-
derived hormone through direct transcriptional activation of the adiponectin gene in adipocytes 
(Maeda et al., 2001). Consistently, pioglitazone treatment multiplied by four the levels of 
circulating adiponectin in ALS patients after six months of treatment, and this was maintained after 
12 months of treatment (Fig. 1B). Pioglitazone decreases glycemia through hepatic and skeletal 
muscle PPARγ. In ALS patients, pioglitazone decreased glycaemia (Fig. 1C), although this effect 
was milder than observed in other populations, including non-diabetic patients (Belfort et al., 2006, 
Sanyal et al., 2010, DeFronzo et al., 2011). Consistent with a direct action on liver, pioglitazone 
decreased levels of ASAT and more robustly levels of ALAT (Fig. 1D-E). In all, pioglitazone 
displayed the expected metabolic effects on adipocytic, muscular, and hepatic biomarkers, and was 
likely able to activate PPARγ in these tissues.  
 
Pioglitazone does not lead to weight gain in ALS patients 
TZDs are also known to act in hypothalamic melanocortin neurons to promote feeding (Diano et al., 
2011, Long et al., 2014), and this activation of PPARγ in melanocortin neurons is responsible for 
the robust weight gain associated with TZDs treatment (Lu et al., 2011, Ryan et al., 2011, Long et 
al., 2014). Thus, the evolution of body weight upon pioglitazone treatment represents a reliable 
proximal marker of PPARγ action in hypothalamic melanocortin neurons. In ALS patients, 
pioglitazone had no effect on weight loss (Fig. 2A), or BMI (Fig. 2B). Increased weight in response 
to pioglitazone is due to increased food intake, and a subset of ALS patients experience dysphagia. 
However, pioglitazone had also no effect on BMI and weight loss when considering spinal onset 
patients (Fig. 2C-D), or patients with preserved everyday life during at least 6 months (results from 
EuroQoL EQ-5D questionnaire, Fig. 2E-F). Last, patients with preserved bulbar function during at 
least 6 months after inclusion (as assessed using ALS-FRS R bulbar subscale) did not lose weight, 
yet pioglitazone had no effect on their BMI (Fig. 2G-H). Thus, pioglitazone did not increase weight 
in ALS patients, and this appeared unrelated with dysphagia.  
Page 11 of 31
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Vercruysse et al.  11 
Pioglitazone does not increase food intake in mutant SOD1 mice 
We hypothesized that the lack of weight gain for ALS patients under pioglitazone was due to 
defects in stimulating food intake. To test this hypothesis, we turned to transgenic mice expressing 
mutant SOD1(G86R) (SOD1m mice) as a model of ALS and set up an experimental protocol to 
study food intake in response to pioglitazone. In rodents, pioglitazone has various effects on food 
intake depending on genetic background, dose, route and associated diet (Diano et al., 2011, Ryan 
et al., 2011, Long et al., 2014). Using a protocol (Fig. 3A) adapted from Ryan and collaborators 
(Ryan et al., 2011), we observed that a single oral dose of pioglitazone (40mg/kg) increased food 
intake by 10-15% in wild type FVB/N mice (Fig. 3 B-C). However, food intake was not increased 
in littermate SOD1m mice either one month before motor symptoms (Fig. 3B) or at disease onset 
(Fig. 3C). Thus, pioglitazone was not able to increase food intake in SOD1m mice. 
 
Defects in melanocortin neurons in mutant SOD1 mice 
Hypothalamic melanocortin neurons constitute the primary target of TZDs to promote food intake 
(Diano et al., 2011, Long et al., 2014). The melanocortin system is mainly constituted of two 
antagonistic neuronal types located in the arcuate nucleus: pro-opiomelanocortin (POMC) neurons, 
that secrete the anorexigenic peptide αMSH, and AgRP neurons, that promote food intake, mostly 
through production of AgRP, an endogenous αMSH antagonist. POMC mRNA levels were two-
fold lower in SOD1m mice, either at 75 days of age (Fig. 4A) or at onset (Fig. 4B), while AgRP 
mRNA levels were higher in non-symptomatic mice (Fig. 4A). Consistent with decreased POMC 
expression, we observed about 30% less POMC-positive neurons in the arcuate nucleus of SOD1m 
mice as compared with their wild type littermates at 75 days of age and almost 50% less at onset 
(Fig. 4C).  
 
Multiple ALS mouse models display functional and molecular alterations in 
hypothalamic melanocortin system 
We then asked whether the observed melanocortin defects translated into functional abnormalities. 
Indeed, the combination of decreased POMC mRNA levels with increased AgRP mRNA is usually 
found in situations of promotion of food intake, such as during fasting or in case of leptin deficiency 
(Mizuno et al., 1998, Mizuno et al., 1999, Ziotopoulou et al., 2000), and compromised 
melanocortin system is likely to affect food intake behaviour, in particular during refeeding (Perez-
Tilve et al., 2010). Thus, we measured food intake after short term fasting in SOD1m mice. 
Consistent with decreased POMC levels, one hour food intake of SOD1m mice was two fold higher 
after seven hours (Fig. 5A) or one hour (Fig. 5B) of fasting. Mutations in SOD1 only account for 
Page 12 of 31
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Vercruysse et al.  12 
20% of familial ALS cases, and alterations in hypothalamic melanocortin pathways could be SOD1-
specific. However, POMC mRNA levels were decreased in transgenic mice expressing A315T 
mutant TDP-43 (Wegorzewska et al., 2009) (Fig. 6A), and these mice also displayed transient 
hyperphagia in response to fasting (Fig. 6B). Last, POMC mRNA levels tended to be lower in 10 
months old knock-in mice expressing a truncated FUS protein retained in the cytoplasm (Fus
∆NLS/+
 
mice) (Fig. 6C) (Scekic-Zahirovic, in preparation), and Fus
∆NLS/+
 mice displayed increased food 
intake after short term fasting as compared with their littermates (Fig. 6D). Thus, abnormal food 
intake behaviour and defects in the melanocortin system is a hallmark of ALS mouse models. 
 
Involvement of serotonin loss in melanocortin defects associated with ALS 
We then sought to understand the mechanisms underlying melanocortin defects in ALS. POMC 
neurons are affected by multiple stressors that could ultimately underlie the observed defects. We 
did not observe changes in expression of a series of genes related with oxidative or endoplasmic 
reticulum stress (eg gp47, splicing of XBP1 mRNA), peroxisome biogenesis (Gpx1, catalase) or 
mitochondrial function (Mfn2)  (not shown) indirectly suggesting that neither overt oxidative stress, 
nor ER stress nor defective peroxisomal biogenesis nor mitochondrial abnormalities might account 
for decreased POMC neuronal counts. We hypothesized that the previously observed serotonin 
neuron degeneration (Turner et al., 2005, Dentel et al., 2013) could contribute to the observed 
melanocortin defects. Indeed, serotonin is known to promote POMC expression in arcuate nucleus 
through the 5-HT2C receptor (Heisler et al., 2006, Lam et al., 2008). Interestingly, serotonin levels 
tended to decrease at onset in the hypothalamus of SOD1m mice (Fig. 7A). To determine whether 
loss of serotonin axons occurred earlier in the arcuate nucleus, we crossed SOD1m mice with Tph2-
YFP mice, expressing YFP under the control of the Tph2 promoter targeting expression only in 
central serotonin neurons (Zhao et al., 2011). We observed a sharp and profound decrease in the 
density of YFP positive fibers in the arcuate nucleus of SOD1m mice, as compared with their 
littermates (Fig. 7B). Hypothalamic 5-HT2C expression was increased suggesting that the 
hypothalamus sought to compensate for loss of serotonergic innervation (Fig. 7C). To probe for 
serotonergic involvement in defects of the melanocortin system, we used fluoxetine, a selective 
serotonin reuptake inhibitor to rescue serotonin signaling, using previously published doses and 
protocols (Kaur and Kulkarni, 2002, Liou et al., 2012). Interestingly fluoxetine pre-treatment 
completely abrogated the increased food intake in response to short term fasting (Fig. 7D) and 
increased POMC mRNA levels back to normal in SOD1m mice (Fig. 7E). Fluoxetine had no effect 
on AgRP upregulation (Fig. 7E). Thus, loss of serotonin innervation is contributing to the 
melanocortin defects observed in SOD1m mice. 
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Discussion 
In this combined mouse and man study we showed that ALS is associated with defects in the 
melanocortin system, the major hypothalamic circuit controlling food intake and energy 
expenditure. Pioglitazone did not increase weight in ALS patients, thus providing indirect evidence 
of altered hypothalamic melanocortin pathway, and pathological and functional deficits of 
melanocortin system were found in ALS mouse models directly demonstrating these defects. These 
findings further extend the spectrum of defects in ALS and provide a mechanistic explanation for a 
subset of metabolic signs observed in these patients. Our study has also important implications for 
the design of therapies to target weight loss in this disease. 
 
We first observed that pioglitazone did not increase body weight nor slowed down weight loss in 
ALS patients. This was a surprising observation since progressive weight gain has been repeatedly 
observed in all clinical trials of pioglitazone in multiple non-neurological diseases (Promrat et al., 
2004, Belfort et al., 2006, Sanyal et al., 2010, DeFronzo et al., 2011). Despite this lack of weight 
gain, ALS patients under pioglitazone displayed all other biomarkers of efficacy, including 
decreased glycemia, decreased circulating liver enzymes or increased adiponectin, thus ruling out 
that ALS patients simply did not respond to the drug. Interestingly, a series of recent studies 
dissected out how TZDs lead to weight gain through activation of PPARγ in hypothalamic POMC 
neurons leading to increased food intake (Diano et al., 2011, Lu et al., 2011, Ryan et al., 2011, 
Long et al., 2014). Consistent with the notion that pioglitazone hypothalamic response was blunted 
in ALS patients, pioglitazone was not able to promote food intake in SOD1m mice. Indeed, the 
melanocortin system is dramatically affected in these mice with decreased POMC expression and 
loss of POMC positive neurons; similar alterations were observed in TDP43 and FUS based mouse 
models pointing out that such defects are a general feature in ALS. Since pioglitazone decreases the 
activity of POMC neurons thus increasing food intake (Diano et al., 2011), we propose that the 
already decreased melanocortin tone in ALS prevents the silencing of POMC neurons by 
pioglitazone. Consistent with this, SOD1 mice displayed hyperphagia in response to short term 
fasting, an orexigenic stimulus that also leads to decreased POMC neuronal activity (Perez-Tilve et 
al., 2010, Diano et al., 2011). Thus, our results point to a general decrease in melanocortin tone in 
ALS, leading to both a lack of response to TZDs, and abnormal food intake behaviour in response 
to fasting. 
 
What is the contribution of impaired melanocortin system to the metabolic phenotypes associated 
with ALS? The melanocortin system exerts multiple actions on energy metabolism, either 
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dependent on or independent on food intake. First, an expected consequence of decreased 
melanocortin tone is increased energy intake, especially in response to an orexigenic stimulus such 
as food deprivation. This is indeed what has been observed in multiple transgenic mouse models of 
ALS, suggesting that the defect in melanocortin system translates into a functional deficit. 
Furthermore, consistent with the observed melanocortin defect, we previously observed slightly 
increased cumulative food intake in SOD1m mice (Dupuis et al., 2004). The situation in ALS 
patients is less clear with respect to energy intake due to a relative lack of studies reporting dietary 
intake accurately and to confounding effects of dysphagia in advanced ALS patients. However, two 
case-control studies reported that increased dietary fat intake was associated with ALS (Nelson et 
al., 2000, Huisman et al., 2015). Moreover, Huisman and collaborators observed that 
presymptomatic daily energy intake was increased in ALS patients as compared with controls 
(Huisman et al., 2015), and this would be consistent with both melanocortin impairment and lack of 
weight gain under pioglitazone. Second, the melanocortin defect could be responsible for alterations 
in peripheral metabolic pathways. Indeed, the melanocortin system regulates peripheral lipid 
metabolism in rodents, by activating cholesterol re-uptake by the liver (Perez-Tilve et al., 2010) and 
reduces hepatic lipogenesis (Leckstrom et al., 2011) independently of food intake. In the same line, 
the melanocortin system is controlling glucose metabolism and insulin response (Obici et al., 2001). 
Interestingly, ALS patients have been reported to display increased circulating cholesterol levels 
(Dupuis et al., 2008), and glucose intolerance (Pradat et al., 2010). Third, the melanocortin defect 
could impair regulation of the autonomic nervous system (Sohn et al., 2013), and autonomic 
abnormalities have been sometimes found in ALS patients (Baltadzhieva et al., 2005). The 
relationships between these different phenotypes and melanocortin defects are unclear and will have 
to be clarified in further studies. Importantly, the observed melanocortin defect is unable to explain 
the weight loss associated with ALS, as, on the contrary, the increased orexigenic drive triggered by 
POMC deficiency likely compensates for weight loss by increasing food intake. Other mechanisms, 
either peripheral or central have still to be identified to explain weight loss. 
 
What causes the melanocortin defect in ALS? A first obvious potential mechanism is energy deficit. 
Indeed, SOD1m mice display weight loss due to hypermetabolism, leading to decreased fat mass 
and decreased circulating leptin levels (Dupuis et al., 2004). Ablation of leptin in ob/ob mice or 
fasting is indeed sufficient to cause decreased POMC mRNA (Mizuno et al., 1998, Mizuno et al., 
1999, Ziotopoulou et al., 2000). However, leptin levels are only decreased by 30% in 75 days old 
mice (Dupuis et al., 2004), an age at which we already observe strong POMC mRNA decreases. We 
and others had previously observed serotonin loss in ALS (Turner et al., 2005, Dentel et al., 2013), 
and we hypothesized that this contributed to melanocortin impairment in SOD1m mice. Indeed, 
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serotonin is a major activator of POMC neurons through the 5-HT2C receptor, and this occurs 
through direct electrical stimulation (Heisler et al., 2002) but also trough transcriptional activation 
(Zhou et al., 2007, Lam et al., 2008, Xu et al., 2008). Consistently, loss of 5-HT2C receptor leads to 
decreased POMC mRNA in the hypothalamus (Wang and Chehab, 2006). Our observation of 
restoration of POMC mRNA levels, as well as reversal of transient hyperphagia in SOD1m mice by 
fluoxetine argues for serotonin loss being a primary cause of melanocortin defect. This however 
does not exclude that direct modulation of electrical activity by either decreased leptin or other cues 
either extrinsic or intrinsic further exacerbate the observed defect. Consistent with this notion, 
decreasing leptin, whose major action is on the melanocortin system, was able to revert partially 
weight loss and increased energy expenditure in SOD1m mice (Lim et al., 2014), suggesting that 
the melanocortin system can be further inhibited by leptin ablation. 
 
What are the consequences of our current findings in ALS? There are at least two consequences of 
our finding for ALS research. First, the observation of melanocortin impairment further extends the 
notion of systemic involvement in ALS. That melanocortin impairment appears downstream of 
serotonin loss, also brings about the notion that circuitry dysfunction might contribute to aspects of 
ALS phenotype. How these serotonin and melanocortin defects might be related with the spreading 
of TDP-43 aggregates (Brettschneider et al., 2013) remain to be resolved. Second, these results 
have consequences for the design of pharmacological strategies to combat weight loss in ALS. 
Indeed, many drugs that could be used to prevent weight loss, including atypical anti-psychotics (eg 
olanzapine) inhibit POMC neurons (Kirk et al., 2009, Weston-Green et al., 2012, Lian et al., 2014). 
Drugs targeting the cannabinoid system increase body weight by increasing beta-endorphin release 
from POMC neurons (Koch et al., 2015). Since beta-endorphin is derived from POMC which is 
decreased in ALS mice, it appears likely that cannabinoids might not be able to promote food intake 
through this mechanism in ALS. Thus, our current study provides a note of caution for the use of 
these drugs to counteract weight loss in the specific context of ALS patients, and suggest that 
disease progression might impair responsiveness of ALS patients to classical drugs leading to 
weight gain.  
In all, our post-hoc analysis of the pioglitazone trial revealed that the melanocortin system is 
profoundly altered in ALS, and that this might be important for understanding and preventing 
impairment of energy metabolism in ALS patients. 
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Figures legends 
 
Figure 1: effects of pioglitazone on peripheral biomarkers in ALS patients 
A: summary of metabolic effects of pioglitazone (and TZDs) in humans 
B-E: Changes in plasma adiponectin (% from the baseline) (B), glycaemia (% from the baseline, C), 
circulating aspartate amino-transferase (ASAT, changes in U/L from the baseline, D), and alanine 
amino-transferase (ALAT, changes in U/L from the baseline, E). Number of patients per time point 
is indicated in the table. Pioglitazone treated patients are significantly different from placebo treated 
patients for these items as assessed using a mixed effects regression model analysis. Data are 
presented as mean and standard error. 
 
Figure 2: effects of pioglitazone on weight loss in ALS patients 
Weight loss (kg loss per month, A, C, E, G) and changes in BMI from the baseline (B, D, F, H) in 
in the whole ALS population (A, B), spinal onset patients (C, D), in patients with relatively 
preserved quality of life (E, F) and in patients with preserved bulbar function (G, H). To select the 
patients with preserved quality of life, we used the results from the EuroQoL questionnaire to 
identify patients that had no or only few problems with their everyday-life. Selected patients 
answered that they had either no or few problems in their everyday life during at least 6 months 
after their allocation to a group. To select the patients with preserved bulbar function, we used the 
results from ALS-FRS-R bulbar subscale and selected patients with a score equal or superior to 10 
(maximum: 12) six months after inclusion. The number of patients per time point is indicated on 
each panel. No significant difference is noted for these items. Data are presented as mean and 
standard error. 
 
Figure 3 : No effect of piogliotazone on SOD1m mice food intake.  
A: Experimental scheme: pioglitazone was provided per os after 6 hours of fasting. Food was 
reintroduced 1 hour after gavage, and food intake recorded for the next 24 hours. 
B,C: food intake after pioglitazone treatment in SOD1(G86R) mice (SOD1m) and control 
littermates (wt) at 75 days of age (n=12, left panel) and symptom onset (n=13, right panel), either 
treated with vehicle (blue columns) or pioglitazone 40mg/kg body weight (red columns).*p< 0.05, 
Paired Student’s t-test for the drug. Data are presented as mean and standard error. 
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Figure 4: Defect in melanocortin neurons in SOD1m mice.  
A: mRNA levels of POMC and AgRP in the hypothalamus of SOD1(G86R) mice (black columns, 
SOD1m) and control littermates (white columns, wt) at 75 days of age (n= 15, left panel) and 
symptom onset (n=11, right panel). *p<0.05. **p<0.005. ***p<0.0005, Student’s t-test.  
B:  Quantification of POMC neurons in the arcuate nucleus. POMC immunohistochemistry was 
performed on whole brain sections, and arcuate nucleus was identified according to Paxinos Brain 
Atlas (scheme of identified regions, in red, a). The whole region was sectioned and half of these 
sections were stained for POMC immunohistochemistry. Representative images are shown for 
SOD1(G86R) mice and control littermates at 75 days of age at two magnifications (scale bar 200 
µm (middle row), 20µm (lower row)). Total numbers of POMC positive cell bodies in the arcuate 
nucleus were determined in SOD1m mice at 75 days of age (n=8, b-f) and at symptom onset (n=7, 
b) as compared with their wt littermates. **p<0.005, ****p<0.0001, One-way ANOVA followed by 
Tukey post-hoc test. Data are presented as mean and standard error. 
 
Figure 5: Transient hyperphagia after fasting in SOD1m mice.  
A-B: Food intake was measured during one hour, after either seven hours (A) or one hour (B) of 
fasting in SOD1(G86R) mice (black columns, SOD1m) and control littermates (white columns, wt) 
at 75 days of age (n= 10 and n=14 respectively for A and B). *p<0.05, Student’s t-test. Data are 
presented as mean and standard error. 
 
Figure 6:. Multiple ALS mouse models display functional and molecular alterations in 
hypothalamic melanocortin system 
A: mRNA levels of POMC and AgRP in the hypothalamus of transgenic mice expressing A315T 
TDP-43 mutation (black columns, TDP43m) and control littermates (white columns, wt) at non 
symptomatic stage (n=6). Unpaired t-test. *p<0.05. -B: Food intake was measured one hour after 
refeeding in TDP43m mice (n=8). *p<0.05, **p<0.01, Multiple t-test. 
C: mRNA levels of POMC and AgRP in the hypothalamus of transgenic mice Fus ∆NLS/+ knock-
in mice) (black columns, ∆NLS/+) and control littermates (white columns, +/+) at 10 months of age 
(n=4).  
D: Food intake was measured one hour after refeeding in ∆NLS/+ mice (n=10) at 10 months of age. 
*p<0.05, Student’s t-test. Data are presented as mean and standard error. 
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Figure 7:. Involvement of serotonin loss in melanocortin defects of mutant SOD1 mice 
A: Serotonin levels in the hypothalamus of SOD1(G86R) mice (black columns, SOD1m) and 
control littermates (white columns, wt) (n=5 at 75 days and n=5 at onset). One- way ANOVA 
followed by Tukey post hoc test. 
B: Serotonergic innervation in the arcuate nucleus. GFP immunohistochemistry was performed on 
Tph2-YFP mice on arcuate nucleus cuts after identification on Paxinos Brain Atlas (scheme of 
identified regions, in red, in the upper left column, a). Representative images are shown for 
SOD1(G86R) Tph2-YFP mice and control littermates at onset at two magnifications (scale bar 200 
µm (middle row), 20µm (lower row)) Serotonergic innervation in the arcuate nucleus were scored 
by a blind observer in SOD1m mice at symptom onset (b-f, n=4) as compared with their wt 
littermates. **p<0.005, Student’s t-test. 
C: mRNA levels of 5HT2C receptor in the hypothalamus of SOD1(G86R) mice (black columns, 
SOD1m) at 75 days of age and onset and in control littermates (white column, wt) (n=8). **p<0.01, 
One-way ANOVA 
D: Food intake was measured one hour after refeeding in SOD1(G86R) mice (SOD1m) at 80 days 
of age and control littermates (wt) after fluoxetine 20mg/kg body weight (red columns) or vehicle 
(blue columns) injection (n=38). **p<0.005, Multiple t-test. 
E: mRNA levels of POMC and AgRP in the hypothalamus of SOD1(G86R) mice (SOD1m) and 
control littermates (wt) at 85 days of age after fluoxetine 20mg/kg body weight (red columns) or 
vehicle (blue columns) injection (n=20). *p<0.05, One-way ANOVA. 
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Figure 1: effects of pioglitazone on peripheral biomarkers in ALS patients  
A: summary of metabolic effects of pioglitazone (and TZDs) in humans  
B-E: Changes in plasma adiponectin (% from the baseline) (B), glycaemia (% from the baseline, C), 
circulating aspartate amino-transferase (ASAT, changes in U/L from the baseline, D), and alanine amino-
transferase (ALAT, changes in U/L from the baseline, E). Number of patients per time point is indicated in 
the table. Pioglitazone treated patients are significantly different from placebo treated patients for these 
items as assessed using a mixed effects regression model analysis. Data are presented as mean and 
standard error.  
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Figure 2: effects of pioglitazone on weight loss in ALS patients  
Weight loss (kg loss per month, A, C, E, G) and changes in BMI from the baseline (B, D, F, H) in in the 
whole ALS population (A, B), spinal onset patients (C, D), in patients with relatively preserved quality of life 
(E, F) and in patients with preserved bulbar function (G, H). To select the patients with preserved quality of 
life, we used the results from the EuroQoL questionnaire to identify patients that had no or only few 
problems with their everyday-life. Selected patients answered that they had either no or few problems in 
their everyday life during at least 6 months after their allocation to a group. To select the patients with 
preserved bulbar function, we used the results from ALS-FRS-R bulbar subscale and selected patients with a 
score equal or superior to 10 (maximum: 12) six months after inclusion. The number of patients per time 
point is indicated on each panel. No significant difference is noted for these items. Data are presented as 
mean and standard error.  
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Figure 3 : No effect of piogliotazone on SOD1m mice food intake.  
A: Experimental scheme: pioglitazone was provided per os after 6 hours of fasting. Food was reintroduced 1 
hour after gavage, and food intake recorded for the next 24 hours.  
B,C: food intake after pioglitazone treatment in SOD1(G86R) mice (SOD1m) and control littermates (wt) at 
75 days of age (n=12, left panel) and symptom onset (n=13, right panel), either treated with vehicle (blue 
columns) or pioglitazone 40mg/kg body weight (red columns).*p< 0.05, Paired Student’s t-test for the drug. 
Data are presented as mean and standard error.  
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Figure 4: Defect in melanocortin neurons in SOD1m mice.  
A: mRNA levels of POMC and AgRP in the hypothalamus of SOD1(G86R) mice (black columns, SOD1m) and 
control littermates (white columns, wt) at 75 days of age (n= 15, left panel) and symptom onset (n=11, 
right panel). *p<0.05. **p<0.005. ***p<0.0005, Student’s t-test.  
B:  Quantification of POMC neurons in the arcuate nucleus. POMC immunohistochemistry was performed on 
whole brain sections, and arcuate nucleus was identified according to Paxinos Brain Atlas (scheme of 
identified regions, in red, a). The whole region was sectioned and half of these sections were stained for 
POMC immunohistochemistry. Representative images are shown for SOD1(G86R) mice and control 
littermates at 75 days of age at two magnifications (scale bar 200 µm (middle row), 20µm (lower row)). 
Total numbers of POMC positive cell bodies in the arcuate nucleus were determined in SOD1m mice at 75 
days of age (n=8, b-f) and at symptom onset (n=7, b) as compared with their wt littermates. **p<0.005, 
****p<0.0001, One-way ANOVA followed by Tukey post-hoc test. Data are presented as mean and 
standard error.  
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Figure 5: Transient hyperphagia after fasting in SOD1m mice.  
A-B: Food intake was measured during one hour, after either seven hours (A) or one hour (B) of fasting in 
SOD1(G86R) mice (black columns, SOD1m) and control littermates (white columns, wt) at 75 days of age 
(n= 10 and n=14 respectively for A and B). *p<0.05, Student’s t-test. Data are presented as mean and 
standard error.  
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Figure 6:. Multiple ALS mouse models display functional and molecular alterations in hypothalamic 
melanocortin system  
A: mRNA levels of POMC and AgRP in the hypothalamus of transgenic mice expressing A315T TDP-43 
mutation (black columns, TDP43m) and control littermates (white columns, wt) at non symptomatic stage 
(n=6). Unpaired t-test. *p<0.05. -B: Food intake was measured one hour after refeeding in TDP43m mice 
(n=8). *p<0.05, **p<0.01, Multiple t-test.  
C: mRNA levels of POMC and AgRP in the hypothalamus of transgenic mice Fus ∆NLS/+ knock-in mice) 
(black columns, ∆NLS/+) and control littermates (white columns, +/+) at 10 months of age (n=4).  
D: Food intake was measured one hour after refeeding in ∆NLS/+ mice (n=10) at 10 months of age. 
*p<0.05, Student’s t-test. Data are presented as mean and standard error.  
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Figure 7:. Involvement of serotonin loss in melanocortin defects of mutant SOD1 mice  
A: Serotonin levels in the hypothalamus of SOD1(G86R) mice (black columns, SOD1m) and control 
littermates (white columns, wt) (n=5 at 75 days and n=5 at onset). One- way ANOVA followed by Tukey 
post hoc test.  
B: Serotonergic innervation in the arcuate nucleus. GFP immunohistochemistry was performed on Tph2-YFP 
mice on arcuate nucleus cuts after identification on Paxinos Brain Atlas (scheme of identified regions, in red, 
in the upper left column, a). Representative images are shown for SOD1(G86R) Tph2-YFP mice and control 
littermates at onset at two magnifications (scale bar 200 µm (middle row), 20µm (lower row)) Serotonergic 
innervation in the arcuate nucleus were scored by a blind observer in SOD1m mice at symptom onset (b-f, 
n=4) as compared with their wt littermates. **p<0.005, Student’s t-test.  
C: mRNA levels of 5HT2C receptor in the hypothalamus of SOD1(G86R) mice (black columns, SOD1m) at 75 
days of age and onset and in control littermates (white column, wt) (n=8). **p<0.01, One-way ANOVA  
D: Food intake was measured one hour after refeeding in SOD1(G86R) mice (SOD1m) at 80 days of age and 
control littermates (wt) after fluoxetine 20mg/kg body weight (red columns) or vehicle (blue columns) 
injection (n=38). **p<0.005, Multiple t-test.  
E: mRNA levels of POMC and AgRP in the hypothalamus of SOD1(G86R) mice (SOD1m) and control 
littermates (wt) at 85 days of age after fluoxetine 20mg/kg body weight (red columns) or vehicle (blue 
columns) injection (n=20). *p<0.05, One-way ANOVA.  
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Table 4. FUS knockout and knockdown  models 
 
 
 
  
 
 
 
 
Table 5. Models with overexpression of wild type or mutant FUS 
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